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Rheumatoid arthritis (RA) is a chronic joint disease of unknown aetiology. The 
autoimmune nature of RA is underlined by abundant generation of rheumatoid factor 
(RF) autoantibodies to IgG1 Fc, and anti-citrullinated protein antibodies (ACPA) to 
citrullinated autoantigens such as fibrinogen. Although RA pathogenesis has not been 
elucidated, genetic predisposition, environmental insults and viral pathogens are 
considered contributory factors. Human endogenous retrovirus K10 (HERV-K10) is 
one such virus as it retained the capacity to produce viral particles in RA synovium. 
This study set out to explore how HERV-K10 Gag matrix region could contribute to RA 
pathogenesis and perpetuation, with particular emphasis on its ability to mimic host 
autoantigens. We showed that Gag region exhibits high levels of sequence and 
structural homology to IgG1 Fc and it could provide a key epitope important for auto-
reactivity in RA.  
Analysis of how HERV-K10 may evoke immune responses in RA was broadened by 
investigation of serological cross-reactivity of novel anti-K10 polyclonal antibody 
(PAbMAG) with IgG1 Fc. We showed that PAbMAG cross-reacted with linear and 
conformational epitopes on IgG1 Fc. In a further development, we showed a 
significantly elevated mean IgG response to HERV-K10 epitopes in serum samples 
from RA patients when compared to other arthritides. These data suggest that 
molecular mimicry between viral and host proteins has the potential to lead to antigen-
driven high-affinity RF IgG immunological reactivity in RA.    
Finally, we broadened our study of mimicry in RA by the investigation of citrullinated 
autoantigens. Structural studies demonstrated high levels of homology between 
citrullinated fibrinogen, IgG1 Fc and HERV. We further explored how protein 
citrullination affects the cross-reactivity of autoantibody responses in RA. These 
experiments revealed that generation of neoepitopes through citrullination of HERV-
K10 and autoantigens IgG1 Fc and fibrinogen enhanced the reactivity of RA sera to 
these targets. Moreover, we showed that RF autoantibodies could mediate responses 
to a classical ACPA target fibrinogen, only when it is citrullinated, in the absence of 
ACPAs. These data provide a new insight into the initiation and propagation of 
immunological responses in RA and how viral/host molecular mimics and citrullination 






LIST OF FIGURES …………………………………………………………………………..1 
LIST OF TABLES ……………………………………………………………………...........6 
LIST OF ABBREVIATIONS ………………………………………………………………..8 
 
1. INTRODUCTION  ………………………………………………………………………..12 
1.1. Overview of the immune system ……………………………………........12 
1.1.1. Innate immunity ……………………………………………………..12 
1.1.2. Adaptive immunity …………………………………………………..14 
1.1.3. B  Lymphocytes ……………………………………………………..15 
1.1.4. Antigen and antibody interactions …………………………………17 
1.1.5. T Lymphocytes ………………………………………………………21 
1.2. Immunological tolerance and autoimmunity ……………………….......23 
1.2.1. Central tolerance ……………………………………………………23 
1.2.2. Peripheral tolerance ……………………………………………......25 
1.2.3. Autoimmunity ……………………………………………….............26 
1.3. Rheumatoid Arthritis ………………………………………………………..28 
1.3.1. General Introduction ………………………………………………..28 
1.3.2. Inflammation …………………………………………………………30 
1.3.3. Clinical manifestations of RA ………………………………….......31 
1.3.4. Rheumatoid Arthritis (RA) ………………………………………….34 
1.3.5. Pathogenesis of RA …………………………………………..........35 
1.3.6. Post-Translational Modifications (PTMs) of proteins in RA ……..40 
1.3.6.1. Citrullination ……………………………………………….40 
1.3.6.2. Carbamylation …………………………………………….41 
1.3.6.3. Glycosylation ……………………………………………...42 
1.3.7. The immunology of RA ……………………………………………..43 
1.3.7.1. The role of B Lymphocytes in RA ……………………….43 
1.3.7.2. The role of T Lymphocytes in RA ……………………….45 
1.3.7.3. The role of Rheumatoid Factor (RF) autoantibody in 




1.3.7.4. The role of Anti-Citrullinated Protein Antibody 
             (ACPA) in RA ...……………………………………………49 
1.3.8. Treatment strategies in RA …………………………………………50 
1.3.9. Animal models of RA ………………………………………............52 
1.4. Human Endogenous Retroviruses (HERVs) …………………………….55 
1.4.1. Introduction …………………………………………………............55 
1.4.2. HERV expression in humans ………………………………………61 
1.4.3. HERVs and human disease ………………………………….........67 
1.4.4. HERVs and their association with RA …………………………….70 
1.4.5. Mechanisms by which HERVs may induce autoimmunity ………72 
1.4.5.1. Superantigenicity  …………………………………………72 
1.4.5.2. Neoantigenicity  …………………………………………...73 
   1.4.5.3. Trascriptional activation ………………………………….73 
1.4.5.4. Host immune response modulation  …………………….74 
1.4.5.5. Molecular mimicry ………………………………………...75 
1.5. Aims and Objectives …………………………………………………..........80 
2. MATERIALS AND METHODS …………………………………………………………81 
 2.1. Ethics approval .………………………………………………………….......81 
2.2. Collection and processing of patient samples ………………………....81 
2.3. In silico bioinformatic analysis ………………………………………..82
  2.3.1. B Lymphocyte epitope mapping ………………………………...82
  2.3.2. The Sliding window approach …..…………………………….......84
  2.3.3. T Lymphocyte epitope mapping …..………………………………86
  2.3.4. Pairwise epitope alignment ………………………………………...86 
2.3.5. Replacement score determination ……………………….………..87 
2.4. Molecular modelling …………………………………………………………87 
2.5. Peptide synthesis and bleed evaluation …………………………………88 
 2.6. Serological analysis and antibody optimisation .………………………89 
2.6.1. Antibodies for immunotesting ………………...……………………89 




 2.6.3. Inhibition ELISA ……………………………………………….........91 
 2.6.4. Quantitative rheumatoid factor assay ……………………………..91 
 2.6.5. Quantitative anti-citrullinated protein antibody assay ……….......91 
 2.6.6. Immunocytochemistry ………………………………………….......92 
 2.6.7. Immunofluorescence and confocal laser microscopy ……………92 
 2.6.8. Western blotting ……………………………………………………..93 
 2.6.9. Flow cytometry ………………………………………………………94 
2.6.10. Antibody labelling with fluorescein isothiocyanate (FITC)..........94 
 2.7. In vitro cell culture …………………………………………………………...95 
  2.7.1. Propagation of adherent cells ……………………………………...95 
  2.7.2. Cytospin preparation for staining from single cell  
                                suspension  ………………………………………………….……....96 
2.7.3. Cryopreservation of cells ………………………………………......96 
2.7.4. Resuscitation of frozen cell lines …………………………….........97 
 2.8. In vitro citrullination of protein targets …………………………………..97 
  2.8.1. Protein and peptide citrullination …………………………………..97 
 2.8.2. Citrulline-specific reporter assay …..………………………………98 
  2.8.3. Antibody digestion with pepsin …………………………………….98 
 2.9. Statistics ………………………………………………………………….......99 
3. Molecular mimicry between RA autoantigens and HERV-K10 peptides……..100 
 3.1. Introduction …………………………………………………………………100 
 3.2. Results ……………………………………………………………………….102 
3.2.1. Epitope mapping and comparison of BcePred versus ExPASy 
Protscale B lymphocyte epitope prediction software ………………….102 
3.2.2. Identification of HERV-K10 epitope candidates for testing their 
potential role in molecular mimicry ………………………………………110 
3.2.3. Incorporation of negative controls into the study ………………..115 
3.2.4. Shortlisting of candidate epitopes for synthesis as peptides ….117  







4. Generation and characterisation of a polyclonal antibody to HERV-K10 
    Gag ...…….......................……………………………………………………………..134 
 4.1. Introduction …………………………………………………………………134 
 4.2. Results ……………………………………………………………………….136 
  4.2.1. Peptide/antigen selection and antiserum development ………..136 
4.2.2. Bleed evaluation …………………………………………………...138 
  4.2.3. Optimisation of anti-MAG1 polyclonal antibody ………………...140 
  4.2.4. Assessment of PAbMAG1 antibody reactivity to IgG1 Fc …......147 
  4.2.5. Inhibition assay confirming specificity of PAbMAG1 for  
                                  MAG1 peptide ……………………………………………….......149 
4.2.6. Assessment of HERV-K10 expression in cultured cells using  
          immunocytochemistry and immunofluorescence in vitro 
                               assays……………………………………………………………….151 
4.2.7. Assessment of PAbMAG1 antibody reactivity to IgG1 Fc 
          linear epitopes using western blotting ………………………......158 
4.2.8. Assessment of HERV-K10 expression in cultured cells using 
          a flow cytometry based in vitro assay ……………………………161 
 4.3. Discussion …………………………………………………………………..166 
5. Serological investigation of RA patient samples for reactivity to  
     HERV-K10 ……………………………………………………………………………..172 
 5.1. Introduction …………………………………………………………………172 
 5.2. Results ……………………………………………………………………….174 
  5.2.1. Validation of reactivity to MAG1 in RA …………………………...174 
  5.2.2. Serological analysis of patient cohorts for anti-MAG1 
                                reactivity ....…………………………….…………………………..182 
5.2.3. Serological reactivity of patient serum antibodies to other 
          HERV-K10 peptides ………………………………………………190 
 5.3. Discussion …………………………………………………………………..206 
6. Impact of HERV-K10 and autoantigen citrullination on RA serum 
     antibody reactivity …………………………………………………………………..212 





6.2. Results ……………………………………………………………………….214  
  6.2.1. RA autoantigen selection and detection of citrullinated 
                                targets ……………………………………………………………...214 
  6.2.2. Serum reactivity to native and citrullinated autoantigens ………222 
6.2.3. Serological response of RF and ACPA antibodies to native 
          and citrullinated RA autoantigens ………………………………..227 
 6.3. Discussion …………………………………………………………………..238 
7. Final discussion and future perspectives ……………………………...………...244 
Appendix ………………………………………………………………………………….251 


















I would like to dedicate this work to my late Father, Dr Ryszard Trela whose  
kind heart, wisdom, passion for life, science and another human being continue to  









First and foremost I want to express my profound gratitude to my mentor and the mastermind of this 
project, Professor Paul Nelson (in memoriam), who saw my potential before I could see it in myself 
and provided me the opportunity to work in his research group. He introduced me not only to the world 
of autoimmunity research, but also to the fascinating world of philosophical thinking in everyday life. 
His excellent guidance, knowledge, unwavering integrity and encouragement enabled me to grow both 
as a person and as a scientist and complete this work successfully. I feel humbled and honoured to 
have contributed to his professional legacy. 
I would like to express my special appreciation and thanks to Dr Kesley Attridge, who did not hesitate 
to step in and become my supervisor in the 2nd year of my doctorate. You have been a tremendous 
mentor to me, your advice on both research as well as on my career have been invaluable and the joy 
and enthusiasm that you have for immunology is contagious and motivational, even during tough 
times in the PhD pursuit.  
I am also very thankful to Dr Shantha Perera and Prof Paul Rylance, my other supervisors, for their 
undivided support and encouragement as well as for their expert guidance and for the many times 
they trusted me to represent our group.  
I am extremely grateful to our collaborators at The Royal Wolverhampton NHS Trust, consultant 
rheumatologists, particularly Dr Thomas Sheeran, and research nurses, whose admirable efforts in 
patient recruitment and sample collection enabled me to complete my work.  
I would also like to thank the South Staffordshire Medical Foundation, Rotha Abraham Bequest, the 
Royal Wolverhampton Hospital Charity, the New Cross Kidney Patients Association, and the James 
Beattie Charitable Trust for supporting this work by providing research grants.  
I gratefully thank Dr Margaret Goodall from the University of Birmingham who has been a true 
inspiration to me and whose expertise and enthusiastic attitude helped me to arrive at my goal. She 
has taught me, both consciously and unconsciously, how good experimental immunology is done and 
I am very thankful for the excellent example she provided as a successful woman immunologist.  
I want to express my gratitude to all the technical staff at the University of Wolverhampton and to my 
colleagues in the lab, in particular Denise Roden for their excellent technical assistance. 
Warm thanks are expressed to Dan Blakeway who have made these years enjoyable both in the lab 
and also at leisure, we have shared the ups and downs during the PhD studies and are almost at the 
end of this road! 
A special thank you to Hoda, you have been one of my greatest supporters since the moment we met. 
Your words of encouragement, understanding and advice on both professional and personal level 
have been invaluable and you are truly my soul-sister. 
To my dearest friends, Ania, Claire, Kasia, Shawna, Hamida, Zaynab, Nelly, the Marras and Yip 
families, your are deeply thanked for your wonderful friendship along the years. Long discussions with 
good food and even better friends have reminded me about the important things in life. 
I render my deepest thanks to Dr Ewa, Andrzej and Tomasz Banyś who I consider my family and who 
I look up to. Your constant support, encouragement and unlimited belief in my abilities from the very 
beginning have made this thesis possible.  
A special thanks to my parents, Drodzy Rodzice, jestem Wam głęboko wdzięczna za Wasze wsparcie, 
wyrzecznia oraz za to że od początku mojego życia wierzyliście we mnie i byliście moimi najlepszymi 
nauczycielami. To dzięki Wam ta praca ziściła się.  
Most of all, I want to thank my partner Rafael, whose support, understanding and patience has helped 






LIST OF FIGURES 
 
Chapter 1: 
 Figure 1.01. Structure of immunoglobulin G (IgG).………………………………20 
 Figure 1.02. Classification of the arthritides.……………………………………..29 
 Figure 1.03. The inflammatory processes in active and established 
            rheumatoid arthritis (RA).……………………….………………………….36 
 Figure 1.04. Schematic diagram of structural organisation of human 
            endogenous retrovirus with the basic genomic structure and 
encoded proteins..…………………………………………………………..57 
Figure 1.05. Cladogram showing events resulting in the introduction of 
HERV groups within the primate lineage.…………….………………….60 
 Figure 1.06. Schematic diagram representing approximate DNA 
            breakdown of the human genome composition highlighting 
percentage of HERV classes.…….……………………………………….62 
 
Chapter 2: 
Figure 2.01. Sliding window principle in action.…………………………………85 
 
Chapter 3: 
 Figure 3.01. Workflow presenting the main components of the in silico 
             epitope mapping..…………………………………………………………103 
Figure 3.02. B cell epitope prediction success of ExPASy and BcePred 
platforms in identifying 19 previously published linear epitopes……...108 
 
Chapter 4: 
 Figure 4.01. The reactivity of pre-bleed, 1st bleed, 2nd bleed and terminal 
            bleed from the immunised rabbit with MAG1 peptide…………………139 
 Figure 4.02. Verification of the isotype of PAbMAG1 purified terminal 




Figure 4.03. The reactivity of PAbMAG1 with MAG1 peptides of different 
lengths tested in non-biotinylated ELISA..…………….…………………142 
Figure 4.04. The reactivity of purified IgG PAbMAG1 with MAG1 peptides 
of different lengths tested in biotinylated ELISA…….………………….143 
Figure 4.05. The effect of biotinylation of MAG1 peptides of different 
lengths on PAbMAG1 reactivity in ELISA……………………………….145 
Figure 4.06. Cross-reactivity profile of PAbMAG1 with a panel of four MAG 
biotinylated peptides………….……………………………………..........146 
Figure 4.07. Cross-reactivity of PAbMAG1 with linear/peptide and 
             conformational/protein epitopes of IgG1 Fc and HERV-K10 MAG1 
mimics..……………………………….…………………………………….148 
Figure 4.08. Inhibition of PAbMAG1 achieved with MAG1 peptide 
demonstrating the antibody specificity.………….………………………150 
Figure 4.09. Examples of HERV-K10 Gag immunostaining in 
representative cytospins of GH teratocarcinoma positive control cell 
line…………………….…………………………………………………….153 
Figure 4.10. Examples of HERV-K10 Gag immunostaining in 
representative cytospins of MCF-7 breast cancer cell lines…………...154 
Figure 4.11. Examples of HERV-K10 Gag immunostaining in 
representative cytospins of T-47D breast cancer cell lines…………...155 
Figure 4.12. Examples of HERV-K10 Gag immunostaining in 
representative cytospins of KM-H2 Hodgkin lymphoma negative 
control cell line….……...…………………………………………………..156 
Figure 4.13. Mean fluorescence intensity (MFI) of intracellular staining 
observed in four malignant cell lines upon incubation with 
PAbMAG1 and control antibodies.……………………………………….157 
Figure 4.14. Positive reactivity of pan-IgG A57H monoclonal antibody to 
two IgG1 Fc preparations…………………………………………………159 





Figure 4.16. HERV-K10 Gag immunostaining of GH, MCF-7, T-47D and 
KM-H2 cancer cell lines with fluorochrome-tagged PAbMAG1 
antibody….….………………………….……………………………………162 
Figure 4.17. Assay restriction profile of PAbMAG1 antibody in K10 
harbouring GH teratocarcinoma cell line determined by flow 
cytometry..……………………..………..………………………………….163 
Figure 4.18. Assay restriction profile of PAbMAG1 in four cancer cell lines 
determined by flow cytometry.……………………………………………164 
Figure 4.19. Poor antibody titration of PAbMAG1 in K10-harbouring GH 
teratocarcinoma cell line in flow cytometry……………………………..165 
 
Chapter 5: 
Figure 5.01. Parallelism of titration profiles of IgG from two RA patients 
and PAbMAG1 antibody to biotinylated MAG1 peptide……………….177 
Figure 5.02. Poor titration profiles of IgG from six patients with RA to  
non-biotinylated MAG1 peptide.……….…………………………………178 
Figure 5.03. Enhanced titration profiles of IgG from six patients with RA to 
biotinylated MAG1 peptide.……………………………………………….179 
Figure 5.04. High levels of non-specific binding observed for patient 
serum diluted in BSA blocker.……….…………………………..............180 
Figure 5.05. Low levels of non-specific binding observed for patient serum 
diluted in Hammarsten casein blocker.………………………………….181 
Figure 5.06. Increased mean serological response to HERV-K10 
biotinylated matrix peptide MAG1 in patients with RA………………...183 
Figure 5.07. Increased mean serological response to HERV-K10 
biotinylated matrix peptide MAG1 in RA patients with positive 
rheumatoid factor profiles.………………………………………………...186 
Figure 5.08. Correlation of RA serological activity to HERV-K10 Gag 
matrix peptide MAG1 with rheumatoid factor levels……..…………….187 
Figure 5.09. Negative serological response to control peptide NC1GTY3 
in patients with RA and control cohorts……..…………………………...189 
4 
 
Figure 5.10. Increased mean serological response to HERV-K10 
biotinylated matrix peptide MAG2 in patients with RA…..…….............191 
Figure 5.11. Increased mean serological response to HERV-K10 
biotinylated matrix peptide MAG3 in patients with RA..........................192 
Figure 5.12. Correlation of RA serological activity to HERV-K10 Gag 
matrix peptide MAG2 with rheumatoid factor levels…..………………..193 
Figure 5.13. Correlation of RA serological activity to HERV-K10 Gag 
 matrix peptide MAG3 with rheumatoid factor levels…..……………….194 
Figure 5.14. Increased mean serological response to HERV-K10 
biotinylated matrix peptide MAG4 in patients with RA…..……………..196 
Figure 5.15 Correlation of RA serological activity to HERV-K10 Gag matrix 
peptide MAG4 with rheumatoid factor levels…..………………………..197 
Figure 5.16. Patients with newly diagnosed (2017) RA demonstrate 
serological reactivity with HERV-K10 peptides MAG1 – 4 that does 
not correlate with rheumatoid factor levels.…..…………………………200 
Figure 5.17. Serological response to HERV-K10 biotinylated matrix 
peptide MAG1 at different intervals reported for 20 patients with 
RA.…...……………………….................................................................201 
Figure 5.18. Negative correlation of RA serological activity to HERV-K10 
peptide MAG1 with patient’s age…..………………………………........203 
Figure 5.19. Marginally enhanced mean serological response to HERV 
K10 peptides MAG1 - 4 in female versus male patients with RA……...204 
Figure 5.20. Heat map of antibody profiles showing the intensity of 
reactivity to four HERV-K10 MAG peptide mimics of IgG1 Fc in 
individual RA patient serum samples.…..…………………………........205 
 
Chapter 6: 
Figure 6.01. Molecular models demonstrating structural mimicry between 
           immunodominant epitopes of HERV-K10 and RA autoantigens 




Figure 6.02. Molecular models demonstrating structural mimicry between 
HERV-K10, IgG1 Fc and fibrinogen in their native and citrullinated 
form..…..…………….………………………………………………………...218 
Figure 6.03. Poor reactivity of three commercial anti-citrulline polyclonal 
antibodies with citrullinated fibrinogen.….……………………...............220 
Figure 6.04. Verification of citrullination protocol with citrulline-specific 
probe on modified and native fibrinogen and IgG1 Fc………………….221 
Figure 6.05. Reactivity of peptide- and protein-specific polyclonal 
antibodies to MAG1 – 4, IgG1 Fc and fibrinogen in their native and 
citrullinated forms…….……………………...........................................224 
Figure 6.06. Increased mean serological response of six pooled RA 
patient serum samples to citrullinated versus native forms of 
MAG1 – 4 peptides, IgG1 Fc and fibrinogen..………………………….225 
Figure 6.07. Low mean serological response of six pooled serum samples 
from healthy individuals to native and citrullinated forms of  
MAG1 – 4 peptides, IgG1 Fc and fibrinogen.……………………..........226 
Figure 6.08. Rheumatoid factor IgG titres determined for the four RA sera 
sub-types..……………………..............................................................228 
Figure 6.09. Anti-citrullinated protein antibody IgG titres determined for the 
four RA sera sub-types.……………………………………….................229 
Figure 6.10. Cross-reactivity of RF+ serum with citrullinated fibrinogen in 
the absence of ACPAs.…………………………………………………...232 
Figure 6.11. Citrullination facilitates cross-reactivity of ACPA+ serum with  
           IgG1 Fc in the absence of RF in ELISA..……………………………...…233 
Figure 6.12. Citrullination facilitates cross-reactivity of RF+ serum with 
fibrinogen in the absence of ACPAs in ELISA..…………………………234 
Figure 6.13. RF reacts with additional epitopes on citrullinated fibrinogen 
and IgG1 Fc in the presence of ACPAs. ………………………………..237 
 
Chapter 7: 
Figure 7.01. A model for the initiation of rheumatoid pathology in RA 
synovium proposed in the current study…………………………….......250 
6 
 
LIST OF TABLES 
 
Chapter 1:  
 Table 1.01. The 2010 American College of Rheumatology/European League 
Against Rheumatism classification criteria for rheumatoid arthritis.…...33   
 Table 1.02. Classification of human endogenous retroviruses (HERVs)….......59 
 Table 1.03. Association of retroviral elements with human physiological 
functions and disorders as reported previously within the literature........65  
 Table 1.04. HERVs associated with autoimmune diseases.…………..............69  
 Table 1.05. Association of exogenous viral agents with human autoimmune 
diseases as reported previously within the literature.……………...........77  
 
Chapter 2:  
 Table 2.01. Antibodies for immunotesting in ELISA, immunocytochemistry, 
                      immunofluorescence, flow cytometry and western blotting…………….89 
 
Chapter 3: 
 Table 3.01. Most prevalent autoantigens in rheumatoid arthritis selected as 
gold standards.…………….................……………...............................104   
Table 3.02. Parameters used by ExPASy Protscale and BcePred servers to 
predict linear B cell epitopes...........................………..........................106  
 Table 3.03. Summary of the levels of success of two in silico methods of B cell 
                      epitope prediction, ExPASy Protscale and BcePred, in assessing 19 
previously published linear epitopes....................................................107  
 Table 3.04. Degree of homology between 19 most prevalent autoantigens in 
                      rheumatoid arthritis that were included in the epitope mapping in this 
investigation.……………......................................……........................109  
Table 3.05. Potential B cell antigenic regions mapped out on the surface of 
human endogenous retrovirus K10 in matrix, capsid and nucleocapsid 
regions..….…………......................................……................................111 




 Table 3.07. T-cell epitope predictions using IEDB MHC-II binding predictions 
for alleles HLA-DRB1*01:01, *01:04, *04:01, *04:04, *04:05, *09:01...114   
 Table 3.08. The potential antigenic determinants predicted for tartrate resistant 
acid phosphatase (TRAP) and plant retroelement of Arabidopsis 
thaliana negative controls……………...…………................................116   
 Table 3.09. Four rheumatoid factor-accessible epitopes on IgG1 Fc with their 
location within the protein secondary structure...........……………......119   
 Table 3.10. Identification of five HERV-K10 homologues within antigenic 
regions of IgG1 Fc……………..............………….................................120   
 Table 3.11. Suggested HERV-K10 matrix epitopes have physico-chemical 
features of immunodominant epitope..................................................121 
 Table 3.12. Molecular models of homologous epitopes located on HERV-K10 
Gag1/Gag2 and IgG1 Fc presented as ‘mesh structure’……...............123    
 Table 3.13. Peptides selected as best homologue candidates for implicating 
HERV-K10 in the pathogenesis of rheumatoid arthritis……………......125   
 
Chapter 4: 
 Table 4.01. Peptides selected as candidates for synthesis and testing as 




 Table 5.01. Stratification of serum reactivity to MAG1 peptide in RA patients 
and control cohorts…….......................………….................................184 
 
Chapter 6: 
 Table 6.01. Regions of sequence homology established in silico for IgG1 Fc, 
fibrinogen and HERV-K10……..................................…………........... 216 
Table 6.02. Stratification of rheumatoid arthritis patients according to serum 
titres of RF and ACPAs……................……………...............................230  
8 
 
LIST OF ABBREVIATIONS 
 
Ab…………………………………………………..………………………………....antibody 
ACR…………………………………………….……..American College of Rheumatology 
Ag…………………………………………………..…………………………………..antigen 
ACPA……………………………………………………..anti-citrullinated protein antibody 
AID………………………………………...……….activation-induced cytidine deaminase 
AIRE…………………………………………………..……………....autoimmune regulator 
ALS…………………………………………………..………..amyotrophic lateral sclerosis  
APC…………………………………………………..……………..antigen presenting cells 
BAFF…………………………………………………..…………..….B cell activating factor 
BCR…………………………………………………..……………………..…B cell receptor 
Bregs…………………………………………………..…………………...regulatory B cells  
CCR…………………………………………………..……………..CC chemokine receptor 
CD…………………………………………………..……………….cluster of differentiation 
CDR…………………………………………………complementarity determining regions 
CH…………………………………………………..……...…heavy chain constant domain 
CIA…………………………………………………..………….…collagen-induced arthritis  
CAIA…………………………………………………….collagen antibody-induced arthritis 





cTEC…………………………………………………..……...cortical thymic epithelial cells 
CXCL…………………………………………………..……..……...CXC chemokine ligand 
DAMP………………………………………….…...damage-associated molecular pattern 
DC……………………………………………………………………...…….…..dendritic cell 







ELF…………………………………………………..…………..….ectopic lymphoid follicle 
Env…………………………………………………..…………………………….....envelope 
ERV…………………………………………………..………………endogenous retrovirus  
ESR…………………………………………………..…..…erythrocyte sedimentation rate 
EULAR…………………………………………...European League Against Rheumatism 
Fab…………………………………………………..…………….fragment antigen binding 
Fc…………………………………………………..…………fragment crystallisable region 
FLS…………………………………………………..……….…fibroblast-like synoviocytes 
Foxp3……………………………………………………………...…….…..forkhead box p3 
Gag…………………………………………………..………………..group specific antigen  
GCT…………………………………………………..…………………....germ cell tumours  
HCV…………………………………………………..……………………...hepatitis C virus 
HERV…………………………………………………..…....human endogenous retrovirus 
HHV…………………………………………………..…………….……human herpes virus  
HIV…………………………………………………..……...human immunodeficiency virus  
HLA…………………………………………………..……………human leukocyte antigen 
HSC……………………………………………………hematopoietic precursor stem cells 
HTLV…………………………………………………..……..human T cell leukaemia virus 
IC…………………………………………………..……………………..…immune complex 




iTreg…………………………………………………..…………..induced regulatory T cells  
JAK……………………………………………………………………….……....janus kinase 
LINE…………………………………………………….long interspersed nuclear element    
LTR…………………………………………………..………………….long-terminal repeat 






MSRV……………………………………………..multiple sclerosis associated retrovirus 
mTEC…………………………………………………..….medullary thymic epithelial cells 
NET…………………………………………………..…………neutrophil extracellular trap 
NSAID………………………………………………..non-steroidal anti-inflammatory drug 
nTreg…………………………………………………..…...……….natural regulatory T cell 
OA…………………………………………………..……………………………osteoarthritis  
PBMC………………………………………………….peripheral blood mononuclear cells  
Pol…………………………………………………..……………………………...polyprotein 
PsA…………………………………………………..……………………....psoriatic arthritis  
PAD…………………………………………………..………….peptidylarginine deiminase  
PAMP....…………………………………………..pathogen-associated molecular pattern 
PD…………………………………………………..………………………….....periodontitis 
PD-1……………...…………………………………………………….programmed death 1 
PRR..………………………………………………………..….pattern recognition receptor 
PTM…………………………………………………..……...post-translational modification 
RA…………………………………………………..…………………....rheumatoid arthritis 
RANKL……………………………….receptor activator of nuclear factor kappa B ligand 
RF…………………………………………………..……………………....rheumatoid factor 
RN…………………………………………………..…………………...rheumatoid nodules 
ROS…………………………………………………..…………….reactive oxygen species  









TCR…………………………………………………..………………………...T cell receptor 
Tfh…………………………………………………..……………………....T follicular helper  
TGFβ…………………………………………………..………transforming growth factor β 
Th…………………………………………………..………………………………….T helper 
TLR…………………………………………………………………………...toll-like receptor 
TNFα…………………………………………………..…………...tumour necrosis factor α 
TRA…………………………………………………..……………tissue-restricted antigens 
Treg...………………………………………………………………………..regulatory T cell 
V, D, J…………………………………………………..…………variable, diversity, joining 
VEGF……………………………………………………vascular endothelial growth factor 
VH….………………………………………………..….………heavy chain variable domain 







1.1. Overview of the immune system 
The immune system evolved as a rapid, specific, and multilayered defence against 
harmful pathogens or their biologic products. It functions as an interactive network of 
lymphoid organs, cells, humoral factors and cytokines across a broad spectrum of 
challenges preserving the integrity of the host. It can be broadly divided into two 
subsystems, the innate and adaptive arms, determined by the speed and specificity of 
the responses. Although the two elements of the immune system exhibit distinct 
effector mechanisms, they are intricately intertwined and mutually supportive.  
 
1.1.1. Innate immunity 
The innate immune system provides the first line of defence against infections or injury 
via diverse components and mechanisms which are typically present before the onset 
of a pathogenic attack. Anatomical barriers in the form of the skin and mucosal 
membranes  prevent breach of the host and allow an equilibrium between local harmful 
environmental insults (toxins, pathogens) and favourable components such as 
commensal microbiota (Catrina et al., 2016). Innate immunity employs two basic 
mechanisms of immune recognition: recognition of foreign substances (non-self) and 
recognition of missing self. Recognition of microbial non-self becomes activated by 
‘danger signals’, known as pathogen-associated molecular patterns (PAMPs), which 
constitute molecular motifs common to various pathogenic microorganisms. These 
molecules become intercepted by germline-encoded pattern recognition receptors 
(PRRs) present on neutrophils, macrophages, NK cells and dendritic cells (DCs) which 
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signal the presence of infection and trigger phagocytosis (Medina, 2016). Toll-like 
receptors (TLRs), which constitute a major family of PRRs, are responsible for the 
recognition of motifs broadly shared by pathogenic organisms and act as critical 
mediators of innate immunity (Skwarczynski and Tóth, 2016).  The TLR family 
comprises two groups based on subcellular localization with cell-surface receptors 
(TLR1, TLR2, TLR4, TLR5 and TLR6) recognising primarily bacterial and fungal 
PAMPs and intracellular receptors in endosomal compartments (TLR3, TLR7, TLR8, 
TLR9 and murine TLR11) sensing viral PAMPs as well as self and foreign nucleic acid 
structures (Kay, Scotland and Whiteford, 2014). TLRs can also recognise damage-
associated molecular patterns (DAMPs) released in the body from damaged cells 
which are thereby tagged for elimination. Recognition of missing self relies on the 
detection of functional molecules typically expressed on normal cells unique to the 
host, which cease to be presented upon infection or cellular transformation (Medzhitov 
and Janeway, 2002). This strategy is also employed by the complement system. One 
of the complement components, C-type lectin mannose receptors recognise repeated 
mannose units on the surface of infectious agents and trigger an enzymatic cascade 
that ultimately leads to cell lysis. The complement system can also be initiated via an 
alternative pathway through the binding of C3b to bacterial cells or viral particles. 
Complement, together with TLRs, act as mediators between the innate and adaptive 
systems. Indeed, the classical complement pathway is dependent on the formation of 
soluble antigen-antibody complexes which are characteristic of adaptive immune 




1.1.2. Adaptive immunity 
A clear dialogue exists between innate and adaptive immunity where dendritic cells 
form the chief interface between these two systems. This interaction is initiated upon 
endocytosis of a pathogen by DCs. For example, following TLR ligation, bacteria are 
internalised into the phagosome, wherein bacterial peptide antigens are processed and 
loaded onto major histocompatibility complex II. MHC-peptide is then trafficked to the 
cell surface for presentation to cells of the adaptive immune system. DC directly 
infected by an intracellular pathogen, such as a virus, recognise cytosolic PAMPs with 
the use of RIG-1 like receptors. Viral products are then processed, coupled with MHC 
class I and displayed at the plasma membrane where they can trigger adaptive 
immunity. Once activated, dendritic cells migrate to secondary lymphoid organs, such 
as lymph nodes, where they present antigens to T lymphocytes to initiate adaptive 
immune responses to the vast majority of potential pathogens, be they extra- or 
intracellular (Iwasaki and Medzhitov, 2010).  
Two major cell populations, T and B lymphocytes, occupy the centre stage of adaptive 
immunity by dictating the specificity of immune responses and orchestrating the 
effector arms of these processes. T lymphocytes recognise antigenic peptides 
complexed with an MHC molecule. Recognition of a particular antigen is facilitated by 
highly specific T cell receptors (TCRs) which, unlike germline-encoded PRRs derived 
from innate responses, are assembled via a series of genomic rearrangements known 
as somatic V(D)J recombination. TCR specificity is determined by each assembled V-
D-J cassette which represents a vast number of possible permutations of 
recombinations of the gene segments of each type (V, D or J). This repertoire of 
pathogen detection regions encoded by the TCR greatly exceeds the number of known 
pathogens by many orders of magnitude (Bonilla and Oettgen, 2010). Activation of 
native T lymphocytes is initiated upon antigen recognition and is followed by their 
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proliferation and migration to infection sites. Small populations of these cells will 
differentiate into long-lived memory T lymphocytes which can mount protective 
immune responses upon pathogen re-encounter (Farber, Yudanin and Restifo, 2014).  
Pre-existing diversity in the antigen receptor repertoire is also used by B lymphocytes 
which constitute second major cell population of adaptive immunity. These cells 
identify their cognate antigen in its native form displayed by dendritic cells, or engage 
with soluble antigen in the extracellular space (Heesters et al., 2016). In contrast to 
TCR, the antigen receptors on B lymphocytes, known as B cell receptors (BCRs) are 
surface-bound immunoglobulins which can be secreted as soluble receptors. The 
process of BCRs assembly from V(D)J gene segments is entirely analogous to the 
mechanism for TCR. Following antigen engagement, B cells receive stimulatory 
signals from cognate T cells which encourage them to proliferate into short-lived 
plasma cells (plasmablasts) or form specialised germinal centres where they 
differentiate into long-lived memory B cells (Harwood and Batista, 2010). Upon antigen 
re-exposure, these cells will exhibit rapid and robust responses resulting in proliferation 
and plasma cell formation (Kurosaki, Kometani and Ise, 2015). The ability of T and B 
lymphocytes to communicate in this highly sophisticated and specific manner greatly 
contributes to host defence against infection.  
 
1.1.3. B lymphocytes 
B lymphocytes develop from hematopoietic precursor stem cells (HSCs) in the bone 
marrow where they undergo distinct developmental stages to attain their antigen 
specificity via V(D)J rearrangement of the BCR, which may be further enhanced by 
random addition of ‘non-templated’ N nucleotides onto DNA strands via terminal 
dideoxyl transferase (TdT). Before entering the periphery, B cell progenitors are 
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subject to rigorous checkpoints for highly self-reactive BCRs which undergo deletion. 
This process constitutes the antigen-independent phase of B cell development which 
transpires in the absence of any interaction with exogenous antigen (Pieper, 
Grimbacher and Eibel, 2013, Motea and Berdis, 2010). Subsequently, the antigen-
dependent phase of B lymphocyte differentiation occurs. Immature B cells leave the 
bone marrow and mature in the spleen into B2-type cells termed naïve follicular or 
marginal zone cells. A third category of mature B lymphocytes is the B1-type cells 
which unlike the other two types derive from foetal liver and neonatal bone marrow and 
are subdivided into the B1a (CD5+) and B1b (CD5-). These cells reside primarily in the 
pleural and peritoneal cavities (Montecino-Rodriguez and Dorshkind, 2012). B1-type 
together with marginal zone B cells exhibit heightened propensity for differentiation into 
plasma cells which are the source of natural serum immunoglobulin M (IgM). They 
have been defined as innate-like cells due to their rapid and shortlived T-cell 
independent antibody responses of poor specificity. These two cell types express 
BCRs in conjunction with pathogen-recognising TLRs which are essential for their 
immune responses and contribute to the interaction between the innate and adaptive 
systems. Moreover, B1-type and marginal zone B cells have been implicated in 
perpetuating autoimmune responses as a result of their polyspecific BCR repertoire 
(Rawlings et al., 2012). T-dependent follicular B cell responses on the other hand are 
mediators of highly specific adaptive immune responses. Antigen recognised by the 
surface IgM of the B lymphocyte is processed and presented in complex with MHC 
class II to follicular helper CD4+ T cells at the border of the B cell follicle and T cell 
zone. The T lymphocytes in turn generate accessory signals which enable B cell 
activation and further differentiation. Assistance is predominantly provided via CD40 
signalling and cytokines IL-4 and IL-21 which induce isotype switching from IgM to IgG, 
IgA, or IgE (Iwasaki and Medzhitov, 2015). Upon T cell priming, antigen-activated B 
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cells can either exit the follicle to become short-lived plasmablasts, or migrate to the 
follicles to establish germinal centres. At this site B lymphocytes diversify their antibody 
variable regions through somatic hypermutation (SHM) which leads to the production 
of high-affinity antibodies for the antigen involved. This process constitutes affinity 
maturation and results in the production of long-lived plasma cells, many of which travel 
to the bone marrow and continue releasing antibody for several weeks. Memory B cells 
are also generated and can differentiate into plasma cells upon recall antigen 
exposure. In addition to the immunoglobulin gene rearrangement and hypermutations 
in the variable regions which provide high antigen specificity, class-switch 
recombination (CSR) is catalysed by components of the SHM machinery, including 
activation-induced cytidine deaminase (AID). During CSR, the constant regions of IgM 
and IgD (Cμ and Cδ, respectively) become replaced by Cα, Cε or Cγ, giving rise to 
IgA, IgE or IgG isotypes which determine the type of the immune response. Therefore, 
CSR provides functionally distinct antibodies while preserving antigen specificity 
(Bürgler, 2017).  
 
1.1.4. Antigen and antibody interactions 
One of the main events in the neutralisation of pathogenic microorganisms or foreign 
particles by the adaptive immune system is the specific binding between 
immunoglobulins and their target antigens. The connection between an antibody (Ab) 
and an antigen (Ag) requires numerous non-covalent interactions between the antigen-
binding site and the epitope (antigenic determinant) (Kringelum et al., 2013). Since 
epitopes have the ability to bind both soluble Ab molecules and membrane-bound 
BCRs, they are often termed B cell epitopes to distinguish them from the proteolytically 
cleaved T cell epitopes and will be referred to as epitopes in this section. Epitopes of 
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proteins are generally classified as either continuous or structural (conformational). 
The latter consist of key amino acid residues which are brought together by protein 
folding, whereas continuous epitopes are composed of a single, linear fragment of the 
antigen’s amino acid residues which come into direct physical contact with antibody 
residues (Regenmortel, 2009). Antibody molecules are large (150kDa) plasma 
glycoproteins composed of an immunoglobulin monomer which constitute their basic 
functional unit. Abs consist of four polypeptide chains: two identical heavy (H) and two 
identical light (L) chains linked by disulphide bonds (Cuesta et al., 2010). They each 
create the arms of a Y-shaped structure know as fragment antigen binding (Fab), giving 
rise to hypervariable Ag binding sites or paratopes (Sela-Culang, Kunik and Ofran, 
2013). The latter include six flexible complementarity determining regions (CDRs) 
which harbour hotspot residues and mediate Ag recognition by adopting a three-
dimensional confirmation (Nikoloudis, Pitts and Saldanha, 2014; Wei et al., 2015) (Fig. 
1.01). Each immunoglobulin monomer is bivalent and can bind concurrently two 
identical antigenic molecules resulting in an avidity-driven increase in Ab affinity and 
its long-term retention on the antigen (Deyev and Lebedenko, 2009). The Fab consist 
of two variable domains (VH and VL) and two constant domains (CH1 and CL). The 
base of the Y, known as the fragment crystallisable (Fc) region is composed of two 
heavy chain domains, CH2 and CH3 and connected with two Fabs via a hinge region. 
Fc fragment confers the isotype of the immunoglobulin and mediates the effector 
functions of the Ab such as complement binding, half-life, avidity and Fc receptor 
binding (Janda et al., 2016). Immunoglobulin G constitutes the major serum isotype 
and comprises four subtypes, IgG1, IgG2, IgG3 and IgG4 (Panda and Ding, 2015). 
Antibody molecules can be produced by different clones of plasma B cell and therefore 
exhibit polyclonal responses to different epitopes in the same antigen whereas 
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monoclonal antibodies originate from the same clone and bind to a unique epitope 






Figure 1.01. Structure of immunoglobulin G (IgG). Depicted are the heavy (dark 
gray) and light (lighter gray) chains with fragment antigen binding (Fab) and constant 
(Fc) domains. The insert represents the six complementarity determining regions 





1.1.5. T lymphocytes 
As with B cells, T lymphocytes originate from bone marrow resident multipotential 
HSCs which upon differentiation become either common myeloid progenitors or 
common lymphoid progenitors with the latter being B and T cell precursors. In order to 
acquire their identity, T lymphocytes migrate to the thymus via the blood (Krueger, 
Ziętara and Łyszkiewicz, 2017). Upon interaction with thymic cells and chemokines, T 
cell progenitors migrate to the outer cortex where they differentiate based on the cell-
surface expression of CD4 and CD8, progressing from the double-negative (DN) into 
double-positive (DP) cells. These cells subsequently mature into single-positive (SP) 
cells which express either CD4 or CD8 exclusively. At this stage, developing T cells 
express low levels of the membrane TCR and are attracted to the thymic medulla 
where they mature and subsequently exit into the circulation to patrol peripheral tissues 
(Hosokawa and Rothenberg, 2017). Mature T lymphocyte populations, CD4+ and 
CD8+ T cells have very distinct effector functions. CD8+ cells act to remove cells 
infected with intracellular pathogens, including viruses and dysfunctional cells. They 
induce cytolytic molecules such as granzymes/perforin and Fas/FasL pathways to kill 
infected cells (Müllbacher et al., 2002). In contrast, CD4+ T cells serve a helper 
function by producing a range of cytokines to augment the phagocytic activity of 
macrophages and assist B cells in generation of high affinity antibodies. Mature T 
lymphocytes are activated upon engagement of their TCRs with antigenic peptide 
displayed on MHC molecules. CD8+ T cells recognise antigen (typically 9 amino acids 
in length) presented by MHC class I, whilst CD4+ T cells require antigen presentation 
(generally 15 amino acid peptide) by MHC class II (Kiecker et al., 2004; Luckheeram 
et al., 2012). The type of effector response generated depends upon the nature of the 
pathogen. All nucleated cells display MHC class I molecules complexed with 
endogenous antigens, therefore cells infected with intracellular pathogens will be 
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cleared by CD8+ T cells. In contrast, MHC class II molecules are present on 
professional antigen presenting cells (APCs), including macrophages, B cells and 
dendritic cells (Parkin and Cohen, 2001), and initiate CD4+ T cell responses to 





1.2. Immunological tolerance and autoimmunity 
The ability to mediate self-defence while avoiding excessive immune reactions that 
would be deleterious to the host is a fundamental attribute of the immune system. 
Continuous generation of an enormous diversity of antigen recognition receptors 
inherent to random V(D)J gene rearrangement inevitably leads to the development of 
self-reactive B and T cells. The immune system has therefore evolved robust 
mechanisms ensuring the generation and preservation of lymphocyte self-tolerance. 
Classically, these processes are mediated within the bone marrow and the thymus 
where they constitute central tolerance, or in the periphery forming peripheral 
tolerance.  
  
1.2.1. Central tolerance 
Central B cell tolerance comprises the regulatory mechanisms that negatively select 
immature B lymphocytes which react with self-antigens in the bone marrow. Ligation 
of the BCR by self-peptides results from the random nature of V(D)J rearrangement. It 
has been reported that up to 75% of BCRs are self-reactive at this stage, therefore 
stringent checkpoints exist to prevent B cells from migrating into peripheral 
compartments (Nemazee, 2017). Autoreactive immature clones become eliminated 
through the mechanisms of clonal deletion and anergy (partial or total 
unresponsiveness). They can also undergo receptor editing which enables 
reprogramming of the Ig V gene fragment to form a non-autoreactive BCR. If this 
process proves unsuccessful in removing self-reactive receptors, deletion occurs. High 
avidity interactions of immature B cells with self-antigen leads to cell apoptosis whilst 
low avidity interactions are thought to permit receptor editing (Pelanda and Torres, 
2012). Some weakly self-reactive clones emerge into the periphery without being 
24 
 
eliminated or inactivated but do not differentiate and are effectively ignored (clonal 
ignorance) (Tsubata, 2017). 
In order to maintain immune homeostasis, developing T lymphocytes undergo 
verification at several immune checkpoints prior to their maturation and exit from the 
thymus. The first stage of the selection process involves DN progenitors (CD4-CD8-) 
which will not be allowed to progress to DP thymocytes (CD4+CD8+) without 
rearranging their TCR β chain locus. The TCR affinity for MHC-self-peptide presented 
by cortical thymic epithelial cells (cTEC) determines the fate of the remaining T 
lymphocytes. DP cells which fail to bind (Gururajan, Sindhava and Bondada, 2014) 
with a minimum level of affinity and avidity die by neglect, whereas T cells that interact 
with self-MHC are positively selected and migrate to the medullary area to differentiate 
into CD4 or CD8 SP thymocytes (Xing and Hogquist, 2012). Here, medullary thymic 
epithelial cells (mTEC) present a broad array of tissue-specific self-antigens. The 
autoimmune regulator (AIRE), together with other costimulatory molecules, plays an 
important role in the expression of a broad array of these antigens (Metzger and 
Anderson, 2011). Strongly self-reactive TCRs represent a potential danger of 
autoimmunity and they can elicit a number of outcomes. Thymocytes exhibiting 
autoreactivity are either eliminated through negative selection (clonal deletion), 
anergised or are skewed to the regulatory lineage. Central tolerance mechanisms are 
so efficient that out of approximately fifty million T lymphocytes produced daily in the 







1.2.2. Peripheral tolerance 
Although 90% of autoreactive B cell clones become eliminated through deletion, 
receptor editing or anergy, a small number of self-reactive cells will survive and migrate 
to the periphery as transitional B cells. Here peripheral tolerance mechanisms, 
including the interaction between tonic BCR-mediated signals and B lymphocyte 
stimulator (BAFF/BLyS) signalling, determine whether transitional B lymphocytes 
undergo positive or negative selection (Gururajan, Sindhava and Bondada, 2014). 
Moreover, if a naïve mature B cell recognises its antigen in peripheral tissues in the 
absence of cognate T cell help (CD40 engagement or cytokine stimulation) it will be 
functionally inactivated or undergo apoptosis (Tobón, Izquierdo and Cañas, 2013). 
Alternatively, mature B lymphocytes become partially activated which results in their 
exclusion from lymphoid follicles and premature death (Romagnani, 2006). 
Should self-reactive T lymphocytes avoid deletion through the process of thymic 
negative selection, several mechanisms operate on autoreactive mature clones in the 
periphery. One level of peripheral control comprises physical separation of potentially 
self-reactive T lymphocytes from tissue-restricted antigens (TRA), such as that 
facilitated by the blood-brain barrier. Naïve T cells are directed towards the lymph node 
by the expression of CCR7 and CD62L which limit their migration to the nonlymphoid 
peripheral tissues with a high density of TRAs (Mueller, 2010). Immunologically 
privileged sites are protected from the entry of naïve clones through low expression of 
selectin and integrin receptors, which are necessary for transendothelial migration. 
Occasional T lymphocyte infiltration of immune-privileged organs such as the ocular 
system is associated with high expression of immunomodulatory mediators such as IL-
10/TGFβ which suppress autoreactive clones (Shechter, London and Schwartz, 2013). 
However, due to the migration of antigen-presenting mature dendritic cells into the 
lymph nodes, the majority of naïve T cells do not need to enter the non-lymphoid 
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tissues to encounter their cognate antigen. Tolerogenic dendritic cells are a specialised 
subset which present TRA under non-inflammatory conditions in the absence of 
adequate costimulatory signals. This results in Fas- and Bim-mediated apoptotic cell 
death of autoreactive T lymphocytes or anergy induction (Luckashenak et al., 2008; 
Raker, Domogalla and Steinbrink, 2015). Differentiation of highly self-reactive T 
lymphocytes into the FOXP3+ natural regulatory (nTreg) cell lineage constitutes a vital 
process for peripheral tolerance. These cells enter the periphery and have the ability 
to suppress autoreactive T cell clones.  Here, nTregs convert to FOXP3+ induced T 
cells (iTreg) upon TGFβ or retinoic acid stimulation and suppress the activation and 
expansion of autoreactive cells (Bilate and Lafaille, 2012; Lourenço and La Cava, 
2011). Therefore, deletion, anergy, clonal ignorance and active regulation by nTreg 
and iTreg result in the maintenance of peripheral tolerance.  
  
1.2.3. Autoimmunity 
Despite the broad array of mechanisms utilised by the immune system to maintain self-
tolerance, a dysregulation between effector and regulatory responses can lead to 
autoimmune reactions. Whilst a low degree of autoimmunity may be beneficial to the 
host, such as in anti-tumour responses, persistent high levels of self-reactivity result in 
tissue damage and disease (Cristaldi et al., 2011). This may arise through a breakdown 
in tolerance, together with a genetic predisposition, gender, and environmental agents. 
In general, both innate and acquired immune systems may play a role in the spectrum 
of organ specific and non-organ specific (systemic) autoimmune diseases. Despite 
numerous differences in their clinical manifestations, autoimmune disorders appear to 
follow sequential stages of initiation, propagation and resolution (Rosenblum, 
Remedios and Abbas, 2015). 
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Evidence for the role of predisposing genetic polymorphisms in autoimmunity derives 
from the identification of disease clustering in families and higher disease concordance 
rates in monozygotic (25-57%) and dizygotic twins (2-9%) (Hewagama and 
Richardson, 2009). The MHC locus, also known as the human leukocyte antigen 
(HLA), has been strongly associated with susceptibility to autoimmune disease but the 
mechanisms involved are not fully elucidated (Matzaraki et al., 2017). Moreover, since 
approximately 80% of individuals suffering from autoimmunity are women, sex 
hormones and epigenetic silencing of one X chromosome in females is believed to 
contribute to their predisposition to autoimmune diseases (Amur, Parekh and 
Mummaneni, 2012). However, the apparent gender bias appears to be disease-
specific since SLE, MS, Hashimoto’s thyroiditis and RA have been shown to be more 
prevalent in women (Voskuhl, 2011) whilst autoimmune diabetes prevalence is higher 
in men (Brahmkshatriya et al., 2012). The nature of the environmental factor in 
autoimmunity is also unclear, however recent evidence suggests that environmentally-
induced epigenetic alterations (without genome modification) could mediate certain 
forms of autoreactivity (Brooks and Renaudineau, 2015). Other potential 
environmental triggers of autoimmunity include exposure to toxins, microbial infections, 
nutrition, dysbiosis and UV irradiation. Infectious agents have long been suspected to 
induce or exacerbate autoimmune disorders via different possible mechanisms such 
as epitope spreading, molecular mimicry, bystander activation and excessive pattern 
recognition receptor activation (Trela, Nelson and Rylance, 2016; Vojdani, 2014). 
These mechanisms together with an inflammatory environment encourage the self-




1.3. Rheumatoid Arthritis 
 
1.3.1. General Introduction 
The term ‘arthritis’ derives from the Greek arthron meaning ‘joint’ and is used for over 
200 forms of musculoskeletal, connective tissue and non-articular disorders which 
affect both young and old alike. These arthritides can have different clinical 
manifestations and be of either an inflammatory or non-inflammatory origin. The most 
common form of chronic inflammatory arthritis is Rheumatoid Arthritis (RA) with a 
prevalence of approximately 1% of the population worldwide (Gerlag, Norris and Tak, 
2016). Other inflammatory arthropathies include ankylosing spondylitis, gout, psoriatic 
arthritis (PsA), spondyloarthritis, and systemic lupus erythematosus (SLE) (Chang et 
al., 2016; Valesini et al., 2015) (Fig. 1.02). Although these rheumatic disorders are 
typically associated with certain elements of joint inflammation, their presentation can 












The mechanism of inflammation constitutes a crucial protective strategy in response 
to pathogenic intruders and tissue injury. It enables restoration of cellular homeostasis 
by the removal of harmful pathogens as well as the healing of damaged cells. 
Therefore, inflammatory responses are considered as an element of innate immunity 
and first line of host defence (Foley, 2013). They can be classified as either systemic 
or localised with an acute or chronic response.  
The entire course of inflammation, its duration and intensity need to be closely 
controlled to prevent collateral damage and pathology. In several autoimmune 
conditions, this process extends toward systemic acute phase mechanisms via the 
increased generation of inflammatory cytokines and acute phase plasma proteins such 
as C-reactive protein (Ahmed, 2011). The inflammatory signals which trigger a chain 
of non-specific protective events, limit inadvertent targeting of host tissues. Local 
inflammatory response is initiated and symptoms such as redness, pain, swelling, heat 
and functional impairment ensue (Ashley, Weil and Nelson, 2012). Within minutes after 
the injury, soluble factors such as bradykinin and prostaglandins facilitate vasodilation 
and increased vascular permeability resulting in oedema at the site of injury (Serra et 
al., 2017). Within hours of onset, neutrophils mediated by pro-inflammatory cytokines 
(i.e. interleukin-1, interleukin-6, tumour necrosis factor-alpha) and adhesion molecules, 
such as selectins or integrins, interact with vascular endothelium near the perturbed 
tissue.  
In a sequence of adhesive steps, circulating neutrophils are tethered to the endothelial 
surface and transmigrate into the damaged tissue, following chemotactic gradients in 
the area (Muller, 2013). Upon entering the area of disturbance, neutrophils promote 
the chemotaxis of other immune cells via upregulation of receptors for chemokines and 
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expression of immunoregulatory cytokines such as interferon-γ. Activated neutrophils 
express high-affinity Fc receptors which contribute to the recognition of Ig-opsonised 
microorganisms (Futosi, Fodor and Mócsai, 2013). Moreover, neutrophils release 
reactive oxygen species (ROS) and lytic proteases such as defensins or cathepsins to 
destroy pathogens. Phagocytosis is facilitated by neutrophil extracellular traps (NETs) 
which immobilise harmful microorganisms. Nevertheless, neutrophils may also 
mediate the tissue damage through generation of membrane metalloproteinases 
(MMPs) which cleave different forms of collagen and degrade extracellular matrix 
(ECM) (Kolaczkowska and Kubes, 2013). 
Concomitantly with the arrival of neutrophils, free-flowing monocytes are recruited to 
the site and differentiate into mature macrophages. These cells promote further 
phagocytosis and inflammatory responses through the production of cytokines 
including IL-1, IL-12 and TNF-α as well as inducible nitric oxide synthase (Koh and 
DiPietro, 2011). The release of these cytokines causes further recruitment and 
infiltration of monocytes and neutrophils at the site of injury. Consequently, an 
amplification of acute inflammation, in the presence of persistent antigen, may result 
in a sustained (chronic) inflammatory response leading to overt tissue destruction 
and/or autoimmunity (Selders et al., 2017). 
 
1.3.3. Clinical manifestations of RA 
RA, like the majority of rheumatologic disorders, is a multifactorial disease 
characterised by a wide variation of clinical and pathologic features with unpredictable 
prognosis. This heterogeneity, which leads to considerable challenges in the 
development of diagnostics and therapeutic strategies, results in periods of remission 
and relapse (Chang et al., 2016). The disease typically presents as symmetrical 
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polyarticular arthritis with a gradual onset of additive joint tenderness, stiffness and 
swelling. RA primarily affects small diarthrodial joints such as metacarpophalangeal or 
proximal interphalangeal joints, followed by larger joints including ankles, shoulders, 
and knees.  
In approximately 60% of RA patients the onset is acute with palindromic (episodic) joint 
involvement or with monoarticular presentation which lead to the joint destruction. Up 
to one-third of patients experience systemic symptoms with prominent myalgia, fever, 
decreased appetite, weight loss and fatigue (Jeffery, 2010). In order to make an early 
diagnosis of RA, an individual is assessed according to the most recent classification 
criteria for RA developed in 2010 by the American College of Rheumatology/European 
League Against Rheumatism (ACR/EULAR) (Table 1.01). Such criteria enable 
stratification of patient subgroups, aid diagnosis and prevent individuals from 
developing the chronic destructive RA (Aletaha et al., 2010).  
In addition to joint inflammation patients with RA, in particular with early polyarticular 
onset and aggressive course of the disease, may also develop extra-articular 
complications. Fibrinoid subcutaneous or internal rheumatoid nodules (RN) occur in 
around 30% of seropositive patients. They may be co-presented with vasculitis which 
affects small and mid-sized vessels resulting in cardiac abnormalities, peripheral 
gangrene and inflammatory eye disease. Pulmonary involvement is also not 
uncommon and includes pleurisy, pulmonary RN and interstitial lung disease 
(Romanowska-Prochnicka et al., 2013). Overall, RA typically progresses from the 
periphery to more proximal joints and leads to substantial locomotor impairment within 
10 to 20 years without effective treatment strategies (Venables and Maini, 2017). 
Therefore, clinical, laboratory and radiologic findings play a crucial role in early 
diagnosis and effective therapy to improve clinical outcomes in RA patients (Sudoł-
Szopińska, Jans and Teh, 2017).   
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2010 ACR/EULAR CLASSIFICATION CRITERIA FOR RA 
 
Requirements for using the criteria: Patients should have at least 1 swollen joint 
(synovitis) which is not better explained by another condition. 
To classify for RA: Add all the applicable scores from categories A-D. A score of ≥ 
6 is required for classification as definite RA.  
 
 SCORE 
A. Joint involvement 
1 large joint 
2-10 large joints 
1-3 small joints 
4-10 small joints  









RF- and ACPA- 
Low RF+ and low ACPA+ 






C. Acute-phase reactants 
Normal CRP and normal ESR 





D. Duration of symptoms  
< 6 weeks 







Table 1.01. The 2010 American College of Rheumatology/European League 
Against Rheumatism classification criteria for rheumatoid arthritis. Adapted from 
(Aletaha et al., 2010). ACPA, anti-citrullinated protein antibody; CRP, C-reactive 




1.3.4. Rheumatoid Arthritis (RA) 
RA is a chronic autoimmune inflammatory disease associated with progressive 
degradation of articular cartilage and underlying bone. It primarily affects the joints but 
extra-articular features such as rheumatoid nodules, pulmonary manifestations or 
vasculitis, and systemic effects are common. In industrialised countries, RA has an 
incidence rate of 0.5% to 1% (Choy, 2012), although some populations such as North 
American Natives may have rates as high as 5% (McDougall, Hurd and Barnabe, 
2017). Being the most common inflammatory systemic autoimmune condition, 
rheumatoid arthritis incurs considerable socioeconomic burden with an estimated 
annual cost in the UK of £4 billion (NICE, 2009). RA is characterised by the production 
of rheumatoid factor (RF) autoantibodies reactive with the constant region (Fc) of IgG 
and anti-citrullinated peptide antibodies (ACPAs) (Brink et al., 2016). There is a strong 
association with the HLA system, responsible for displaying processed peptide to T 
lymphocytes, which accounts for 30-50% of the genetic susceptibility to RA (Boissier 
et al., 2012). Although RA is present in all ethnic groups and at all ages, its prevalence 
increases together with age (Innala et al., 2014). Moreover, hormonal factors appear 
to contribute to RA development with women being at three times greater risk than 









1.3.5. Pathogenesis of RA 
The normal joint lining (synovium) is composed of synoviocytes (FLS and MLS), which 
provides structural support, lubrication and nutrients to the cartilage. The sublining 
layer consists of blood and lymphatic vessels, lipocytes, fibroblasts, sparse 
lymphocytes and macrophages in a bed of collagenous extracellular matrix (Smith, 
2011).  
Rheumatoid arthritis typically affects synovium-lined joints and is usually found in the 
small joints of the hands and feet, although larger joint involvement is also frequent. 
The arthritis is characteristically symmetrical and often leads, if untreated, to cartilage 
and bone erosion with other systemic complications. Cell-mediated immune responses 
contribute to initiation and propagation of tissue-destructive processes (Fig. 1.03). 
Although the exact cause of RA has not been fully elucidated, a large body of evidence 
supports a role of HLA-DR1 and HLA-DR4 alleles (DRB1*0101, *0401, *0404, *0405, 
*0901) which reside on chromosome 6 and encode MHC II on APCs. Common amino 
acid sequences (QRRAA, KRRAA and RRRAA) at positions 70-74 in the MHC II 
peptide-binding groove comprise the shared epitope (SE) which confers susceptibility 
to RA and is associated with the presence of RFs or ACPAs (Boissier et al., 2012). 
Moreover, HLA-DRB1*1001 SE allele can accommodate arginine-replacing citrulline 
residues in its antigen binding pockets, which elicits citrullinated protein-specific CD4+ 
T cell and ACPA responses. On conversely, HLA-DR3 alleles appear to be associated 
with ACPA negative RA and a less severe disease course. Non-HLA loci such as 
PTPN22, PADI4, STAT4, TRAF1 and CD40 account for only around 5% of the genetic 





Figure. 1.03. The inflammatory processes in active and established rheumatoid 
arthritis (RA). RA pathology involves the infiltration of numerous inflammation-
inducing cells into synovial fluid and synovium. Articular manifestations result from the 
presentation of MHC II-bound antigen to T cells which release chemokines and pro-
inflammatory cytokines that further perpetuate the inflammatory reactions. TNF-α is 
the predominant cytokine in RA joint which indirectly leads to cartilage and bone injury 
via immune cell recruitment and induction of osteoclast differentiation. Reproduced 




The earliest process in the disease pathogenesis is activation of dendritic cells by 
autologous antigen which together with other APCs, including macrophages, and 
activated B lymphocytes, display RA-related antigens to T lymphocytes (Choy, 2012). 
Autoantigenic peptide can also bind to antibody resulting in the formation of IgG-
containing immune complexes (IC), such as those containing RF and ACPA 
autoantibodies found abundantly in serum and synovial fluid from RA patients. These 
ICs together with CD4+ T cell-derived IFN-γ activate the monocyte/macrophage cell 
lineage which promotes inflammatory responses (Cooper et al., 2012).  
Macrophages constitute central effectors of synovitis and are present in large 
quantities in the rheumatoid joint. Through the release of pro-inflammatory cytokines 
such as TNF-α, IL-1, IL-6 and matrix metalloproteinases (MMPs) they activate 
endothelial cells leading to acute phase reactions and cartilage degradation. 
Macrophages encourage the recruitment of additional leukocytes to the inflamed joints 
via expression of chemokines and adhesion molecules (Roberts, Dickinson and 
Taams, 2015). Recruited neutrophils, which constitute the most abundant cells in 
synovial fluid, release degradative enzymes and reactive oxygen species (ROS) upon 
immune complex encounter. These oxygen radicals, inappropriately generated in RA 
pathology, lead to genetic damage which can result in immunoglobulin mutations and 
thus RF production. Moreover, the enhanced release of neutrophil extracellular traps 
during cellular death (NETosis) exposes a range of citrullinated antigens which are 
targets of ACPAs (Rosas, Correa and Henriques, 2017).  
Conditions within the rheumatoid joint such as hypoxia and production of antiapoptotic 
cytokines promote neutrophil survival from 4 hours (physiological half-life) to several 
days contributing to the chronic nature of synovitis. Further generation of cytokines 
such as interferons leads to harmful positive-feedback loops for additional T cell, 
neutrophil, macrophage and B cell interactions. Moreover, within the synovial 
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membrane there is a dramatic increase in activated fibroblast-like (FLS) and 
macrophage-like synoviocytes (MLS) which contribute to overproduction of pro-
inflammatory cytokines. FLS, which express various ECM proteins including vimentin 
and collagens, display an aggressive phenotype within the synovium. Therefore, the 
rheumatoid joint transforms from a quiescent relatively acellular milieu to an invasive, 
hyperplastic membrane, known as rheumatoid pannus, which increases in FLS and 
MLS density from 2-3 layers to up to 15 layers. This structure becomes densely 
infiltrated with innate and adaptive immune cells such as macrophages, plasma cells 
and neutrophils and erodes the adjacent articular cartilage and subchondral bone 
(Rosas, Correa and Henriques, 2017).  
Moreover, synovial neo-angiogenesis mediated by vascular endothelial growth factor 
(VEGF) is a key process for the development of proliferative synovitis (Bartok and 
Firestein, 2010; Araki and Mimura, 2016). Pannus invasion, displaying a ‘tumour-like’ 
phenotype, causes radiologically detected joint space narrowing which can also be 
induced by immune complexes deposited on the articular cartilage surface (Sudoł-
Szopińska, Jans and Teh, 2017). Structural deformities are initially triggered by the 
activation of bone-resorbing osteoclasts by immune complexes and subsequently 
aggravated by pro-inflammatory cytokines which lead to osteoclast differentiation via 
RANKL (receptor activator of nuclear factor kappa B ligand) (McInnes and Schett, 
2017). Eventually, the joint space is destroyed leading to the fibrous or bony fusion of 
the bone ends termed ankylosis (Sophia and Ramesha, 2017).  
Strong environmental factors operate on a background of genetic pre-disposition to 
trigger the development of RA. Cigarette smoking is the dominant environmental pro-
disease factor which affects the prevalence and severity of RA in a dose-dependent 
manner. Smoking doubles the risk of developing the disease. It also augments the risk 
of ACPA production in individuals with HLA-DRB1 SE alleles (Chang et al., 2014). 
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Other bronchial irritants such as silica dust have also been implicated in RA as a risk 
factor (Burska et al., 2014).  
Moreover, infectious agents have been proposed to perpetuate the disease. Among 
them, Porphyromonas gingivalis, recognised as causative pathogenic organism linked 
with smoking-related periodontitis (PD), which promotes aberrant tissue citrullination. 
PD is associated with HLA-DR4 expression and is at least two-fold more prevalent in 
RA patients (Koziel, Mydel and Potempa, 2014; Lee et al., 2015). In addition, other 
infectious pathogens such as Epstein-Barr virus (EBV), Escherichia coli or Proteus 
mirabilis have been proposed to trigger RA through the mechanisms of molecular 
mimicry (sequence or structural homology) (Smolen, Aletaha and McInnes, 2016).  
Epigenetic regulation of gene expression through DNA methylation status in chromatin 
appear to play an important role in RA development. This process integrates 
environmental and genetic risk factors. Altered methylation signatures (global 
hypomethylation), which were found in T cells and FLS derived from RA patients, can 
affect gene expression levels and properties of these cell types (Viatte, Plant and 
Raychaudhuri, 2013). Epigenetic modifications of FLS also contribute to their intrinsic 
activation and increased expression of demethylated repetitive DNA elements such as 
the retrotransposon LINE-1 (Klein and Gay, 2015; Hewagama and Richardson, 2009). 
Moreover, environmental triggers such as smoking could lead to substantial genome-







1.3.6. Post-Translational Modifications (PTMs) of proteins in RA 
Human cells are capable of sustaining their high efficiency as a result of several finely 
coordinated mechanisms such as DNA transcription or protein synthesis which are 
directly dependent upon chemical reactions known as posttranslational modifications. 
PTMs encompass any alteration that affects a protein’s chemical structure or property. 
They take place at the time of or after protein translation and are generally catalysed 
by enzymes. Currently more than 300 PTMs are recognised with over 200 of them 
being enzyme-mediated. It is widely accepted that PTMs are physiological processes 
essential for the development and evolution of all living organisms (Mastrangelo et al., 
2015). PTMs and their dysregulation have attracted increasing attention over the last 
few decades as potential contributing factors in numerous pathological conditions such 
as rheumatoid arthritis. There are several PTMs including citrullination, carbamylation 
and glycosylation that seem to play an important role in RA pathogenesis and the 
impairment of tolerance.  
 
1.3.6.1. Citrullination 
Citrullination (deimination) entails the switch of the iminic nitrogen of protein-bound 
arginine to oxygen, in the presence of Ca2+-dependent peptidylarginine deiminases 
(PAD) enzymes, resulting in the formation of a non-standard amino acid citrulline. Each 
residue conversion leads to 0.984 Da mass increase and the loss of one positive 
charge, with the latter affecting the acidity and iso-electric point of the protein’s side 
chain. In humans, PADs occur in five isoforms i.e. PAD1-4 and PAD6 which are tissue 
restricted and closely controlled (Witalison, Thompson and Hofseth, 2015). Proteins 
undergo citrullination in the physiological development of tissues and organs as well 
as in inflammation (Pratesi et al., 2014). 
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In RA synovium, intrinsic PADs are activated in neutrophils, which due to their 
excessive mobilisation to the articular space constitute 90% of all RA joint cells. 
Neutrophils arrive in synovium already primed for the production of reactive oxygen 
species which together with calcium-induced PADs lead to hypercitrullination of 
proteins (Rosas, Correa and Henriques, 2017; Damgaard et al., 2017). The 
conformational alterations resulting from citrullination can lead to neoepitope 
production and thus generation of new autoantigens, different to those apprehended 
by self-tolerance mechanisms (Valesini et al., 2015). In this case, elevated number of 
citrullinated autoantigens stimulate the generation of ACPA antibodies which 
contribute to IC formation and complement fixation (Tan and Smolen, 2016). 
Citrullination is also associated with NET production and has several different 
implications for protein conformation such as change in protein folding and tertiary 
peptide structure. Moreover, new citrullinated epitopes can be generated by PAD 
derived from P.gingivalis bacterium or via nanoparticles inhaled with tobacco smoke 
(Mastrangelo et al., 2015). Therefore, it has been implied that RA initiation could take 
place at mucosal compartments such as the lungs or gums (Catrina et al., 2017). A 
total of 53 citrullinated proteins have been detected in RA sera and synovium to date, 
which have been collectively termed the ‘citrullinome’ (van Beers et al., 2013). 
 
1.3.6.2. Carbamylation 
Carbamylation is a physiological, non-enzymatic PTM which involves binding of a 
cyanate group on self-proteins and leads to the formation of a carbamyl group upon 
urea degradation. Excessive carbamylation can lead to the loss of native protein 
conformation and a breakdown of tolerance (Shi et al., 2014). Lysine carbamylation 
leads to the formation of homocitrulline in RA patients (Pruijn, 2015) and has been 
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suggested as a link between smoking, uremia and inflammation which may enhance 
cyanate levels resulting in the formation of neoepitopes (Turunen et al., 2015; Firestein 
and Mcinnes, 2017). Moreover, anti-carbamylated protein antibodies, with low cross-
reactivity with ACPAs, can be detected in some RA patients however their pathogenic 
role is unknown (Spinelli et al., 2016).  
 
1.3.6.3. Glycosylation 
Glycosylation involves the attachment of sugar moieties on oxygen or nitrogen atoms 
of the protein’s side chain and is essential for protein folding or cellular interactions. 
Alterations in the Fc-connected carbohydrate backbone through the addition of sialic 
acid, galactose, fucose and GlcNAc residues affects humoral immune responses 
(Scherer et al., 2010). In RA, it can lead to pathological antigen presentation to the 
immune system as a result of aberrant glycosylation of synovial and plasma proteins 
(Mastrangelo et al., 2015). Abnormalities in N-glycosylation of the Fc region of IgG 
have also been reported in RA with a decrease in galactosylated and sialylated glycans 
in proinflammatory phenotypes (Huang et al., 2017). Moreover, different glycosylation 
patterns may affect immunological properties of RF and ACPA autoantibodies in RA 









1.3.7. The immunology of RA 
 
1.3.7.1. The role of B Lymphocytes in RA 
B lymphocytes are likely to be responsible for RA pathogenesis via several 
mechanisms including autoantibody production, antigen presentation, T lymphocyte 
activation, cytokine secretion, bone homeostasis and ectopic lymphoneogenesis 
(Marston, Palanichamy and Anolik, 2010). A high number of mature naïve autoreactive 
B cells accumulate in the B cell compartment of RA patients due to defective central 
and peripheral tolerance checkpoints (Menard et al., 2011). The relative contribution 
of B cells to the disease pathogenesis of RA seems variable, as inferred by the 
presence of seropositive and seronegative RA (Ajeganova and Huizinga, 2014). 
However, the importance of B cells in seropositive RA progression has been 
demonstrated by the success of neutralising anti-CD20 (rituximab) treatment (Buch et 
al., 2011).   
Initially suggested by the presence of rheumatoid factor and more recently by the 
identification of anti-citrullinated peptide autoantibodies, Ab-dependent and Ab-
independent pathogenic roles of B cells are corroborated by a growing body of human 
studies and experimental work. Autoantibodies lead to the formation of immune 
complexes which are thought to play a major pathogenic role through costimulation of 
TLR, B cell receptor engagement and activation of the complement cascade 
(Elshahaly et al., 2012). Arthritogenic autoantibodies may be generated from joint-
derived synovial plasma cells which originate from locally activated B lymphocytes. 
Molecular evidence indicates that lymphoid infiltrates organise within the inflamed RA 
synovial joint as B/T cell discrete areas with germinal centre-like structure and activity. 
This tertiary lymphoid tissue (ectopic lymphoid follicle, ELF) containing follicular 
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dendritic cells is present in around 40% of RA patients and is promoted by synovial 
fibroblasts via secretion of chemokines such as CXCL13, CXCL21 and CXCL12. 
Moreover, effector B cells may contribute to ELF formation and osteoclastogenesis by 
secreting lymphotoxin-β and RANKL, respectively (Hamze et al., 2013).  
Synoviocytes, by producing B-cell activating factor and a proliferation-inducing ligand, 
also propagate local antigen-specific autoreactive responses through AID-mediated 
somatic hypermutation and class switch recombination in B cells (Jones and Jones, 
2016). B cell clones within ELFs exhibit highly mutated variable VH and VL genes which 
have been acquired locally as confirmed by lineage-tree analysis suggesting a critical 
role for ELFs in the initiation or/and amplification of RA pathology. In some patients, 
over 30% of the general synovial B cell response has a bias toward citrullinated 
antigens. Lymphoid aggregates can also form in extra-articular sites such as the lung 
and subchondral bone marrow. ELF formation is closely correlated with T follicular 
helper (Tfh) cells which perpetuate chronic autoantibody production through CD40L 
and IL-21 signalling (Bombardieri, Lewis and Pitzalis, 2017).  
B cells can also serve as efficient APCs to activate T cells and enable optimal memory 
development in the CD4+ T cells. In RA, their antigen uptake was observed to be highly 
selective, in particular for RF+ B cells, as compared to nonspecific uptake by other 
professional APCs. Moreover, B cells could activate pathogenic T cell reactions via 
cytokines such as IL-6 which is produced in chronic autoimmune responses. This pro-
inflammatory cytokine regulates the balance between Th17 cells and Tregs in the 
presence of TGFβ. Dysregulation of IL-6 leads to Th17-medited B cell proliferation, 
differentiation, and antibody production suggesting a positive feedback loop between 
these two cell types (Bugatti et al., 2014). In addition, effector B cells can affect other 
pathologically relevant populations through the release of a wide spectrum of 
inflammatory cytokines including TNF-α, IL-12, IL-23 and IL-1α (Hamze et al., 2013). 
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The role of B cells in regulating bone homeostasis is believed to be developmental and 
stage-dependent. Inflammatory cytokines (IL-6, IL-1, IL-17, TNF-α) together with 
RANKL, promote bone loss in rheumatoid joint. 
Moreover, ACPA-mediated osteoclastogenesis, which likely promotes bone resorption 
and disease perpetuation, has also been observed in RA patients (Meednu et al., 2016; 
Kurowska et al., 2017). Recent findings also indicate the coexistence of a different B 
cell subset termed B regulatory cells (Bregs). In active RA, the immunosuppressive 
function of these cells on Th1 and Th17 responses is partly impaired (Bankó et al., 
2017). In addition, Breg levels are reduced in the systemic circulation and enriched in 
the synovial fluid of RA patients, when compared to healthy individuals, which might 
indicate their active migration to the inflamed synovium (Flores-Borja et al., 2013).  
 
1.3.7.2. The role of T Lymphocytes in RA 
For many decades RA has been considered a T-cell driven disease. CD4+ T cells are 
the predominant subtype of lymphocytes in RA synovial infiltrate and appear to be 
central in the disease pathogenesis (Aterido et al., 2014). They contribute to tissue 
damage, both in the synovium and in extra-articular sites, via diverse mechanisms 
including pro-inflammatory cytokine release and cooperation with B cells for 
autoantibody production. Breakdown of immunological tolerance and enhanced self-
antigen recognition by CD4+ T cells is associated with certain MHC II alleles 
(particularly HLA-DRB1) and dysregulation of signalling molecules such as PD-1 and 
LYP. In RA synovium, infiltrating CD4+ T cells interact with DCs and B cells which are 
crucial for their co-stimulation and thus for the progression of the disease. Through the 
production of TNF-α, IFN-γ, IL-1α and IL-15, CD4+ T cells reduce collagen production 
by FLS and induce the release of pro-inflammatory cytokines by FLS and 
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macrophages, which triggers cartilage damage (Castro-Sánchez and Roda-Navarro, 
2017). CD4+ T cells are also a major source of RANKL which induces osteoclast 
generation and therefore contributes to bone resorption (Elshahaly et al., 2012). Hyper-
activation of this cell population in RA has been reported not only for synovium-
infiltrating but also for peripheral blood T cells (López-Santalla et al., 2011). In addition 
to distortions of the CD4+ T cell repertoire and phenotype in RA patients, premature 
cellular aging with telomere shortening in this cell population appears to contribute to 
their autoreactivity (Ponchel et al., 2012).  
Upon activation, CD4+ T cells differentiate into distinct effector subsets, Th1, Th2, 
Th17, Tfh and Treg cells, which may become dysregulated in RA and drive synovitis. 
Disease activity appears to correlate with Th1/Th2 balance biased towards the former 
subset with increased IFN-γ and TNF-α expression and reduced expression of IL-6 
and IL-10 by Th2 subset in RA plasma. Conversely, this balance is also disturbed by 
RA microparticles via TNF-α reduction and IL-6 and IL-10 increase (He et al., 2017).  
Th17 cells play a predominant role in RA pathology through the release of IL-17 in the 
synovium. This cytokine promotes inflammation by stimulating the production of pro-
inflammatory mediators including TNF-α, IL-6, IL-1β, chemokines and 
metalloproteinases which induce osteoclastogenesis and cartilage damage. Moreover, 
increased IL-17 levels correlate with more severe synovial lesions (Noack and 
Miossec, 2014). The pathogenic role of IL-17 is corroborated by the beneficial effects 
of the Th17/IL-17 inhibitor (secukinumab) in the treatment of RA (Li et al., 2012; Blanco 
et al., 2017). Tregs are present at increased levels in rheumatoid synovium compared 
with peripheral blood indicating an active recruitment of this cell subset to the affected 
joint. In RA, they exhibit impaired suppressive functions associated with 
polymorphisms in their suppressive molecules and are unable to control the production 
of pro-inflammatory cytokines such as TNF-α and IL-6 (Morita et al., 2016). However, 
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due to developmental and functional discrepancies between Treg subsets among RA 
populations, their specific identification and role in RA is still elusive (Fessler et al., 
2017).  
Furthermore, there is a growing evidence base which implies that CD8+ T cell 
homeostasis is dysregulated in RA and could play a role in disease pathogenesis. The 
contribution of this cell population to RA is demonstrated by the association of MHC I 
polymorphisms with disease risk. CD8+ T cells comprise around 40% of all infiltrating 
T cells in rheumatoid synovium and are detected in the preclinical stages of RA 
development. The levels of memory CD8+ T cells appear to be increased in the 
peripheral blood and synovial fluid from RA patients when compared to healthy 
individuals suggesting their active generation. The frequency of these cells correlates 
with IgM-RF levels in the serum. Through the production of cytolytic proteins, CD8+ T 
cells are also vital for the formation of ectopic germinal centres in RA synovium 
(Carvalheiro, da Silva and Souto-Carneiro, 2013; Carvalheiro et al., 2015; 
Ramwadhdoebe et al., 2016). In arthritic joints, CD8+ T cells constitute a heterogenous 
population with both pro-inflammatory function via IL-6/TNF-α release and anti-
inflammatory effects through IL-4/IL-10. The regulation and balance of both of these 
cell subtypes was reported to be impaired and resistant to suppression in RA. 
Moreover, the TCR repertoire of synovial CD8+ T cells in RA has been observed to be 
specific for several types of viruses including EBV, cytomegalovirus and influenza virus 
(Petrelli and van Wijk, 2016).  
 
1.3.7.3. The role of Rheumatoid Factor (RF) autoantibody in RA 
Rheumatoid factors, first reported by Waaler in 1940 as antibodies reacting with 
gamma globulins, are autoantibodies targeting the C-terminal part of the constant 
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region (Fc) of IgG heavy chain in the γ2-γ3 cleft.  They are detected in 60-80% of RA 
patients and together with ACPAs, represent the major serological marker for disease 
diagnosis in the current classification criteria. The presence of these autoantibodies 
precedes the onset of RA symptoms by several years. RFs have also been detected 
in other autoimmune diseases such as systemic lupus erythematosus and Sjögren 
syndrome as well as in non-autoimmune conditions. Moreover, RF positivity has been 
observed in normal individuals upon secondary immune responses to infections and 
immunisations. However, in healthy subjects these antibodies are typically polyreactive 
IgMs of low affinity and act in host defence through the generation and clearance of 
immune complexes (IC). Their global variability in distribution appears to be affected 
by genetic and environmental elements, with the highest prevalence of up to 30% 
reported in North American Indians (Ingegnoli, Castelli and Gualtierotti, 2013; Anquetil 
et al., 2015). They resemble natural antibodies generated by CD5+ B1 cells which 
unlike B2 cells do not undergo somatic hypermutation. In RA, RF+ B cells are activated 
more efficiently by immune-complexed IgGs when compared to their monomeric 
variant, implying that effective BCR cross-linking is necessary for the propagation of B 
cell activation signal (Song and Kang, 2010a). Moreover, RF may be produced as a 
result of B cell stimulation by EBV which acts as polyclonal activator (Adtani and 
Malathi, 2015). EBV has been reported at elevated frequencies in rheumatoid 
synovium (Tan and Smolen, 2016), particularly in RF positive RA patients 
(Westergaard et al., 2015). Local formation of RF has been observed in the inflamed 
synovium where ectopic lymphoid follicles are found (Song and Kang, 2010b). In RA, 
RFs undergo isotype switching from IgM to IgA and IgG and affinity maturation which 
might be T cell dependent. Due to their local production, levels of RFs in the synovium 
are likely higher than those in the circulation (Jones et al., 2013). The arthritogenic role 
of RF remains unclear, however high IgA RF titres have been associated with bone 
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erosions, extra-articular symptoms, and poor prognosis. High-affinity RFs in synovium 
may potentiate inflammation and antigen trapping through enhanced IgG-binding and 
complement fixation (Song et al., 2010b). Moreover, IgG RFs can form large ICs and 
stimulate inflammatory cells leading to RA perpetuation. High RA activity, independent 
of ACPA presence, is also exhibited by patients with RFs (Tan and Smolen, 2016).  
Pepscan and in-silico epitope mapping studies have contributed to identification of 
potential RF epitopes within CH2 and CH3 domains of IgG1 Fc in the pathological 
mechanism of RA. It is apparent that a series of 7 to 10 CH3 regions constitute potential 
major conformational IgG sites targeted by RF (Westwood et al., 2008; Nelson et al., 
2003). Although RFs are not RA-specific, they constitute important diagnostic and 
prognostic markers and may be the first autoantibodies to appear at the site of disease 
(Brink et al., 2016).  
 
1.3.7.4. The role of Anti-Citrullinated Protein Antibody (ACPA) in RA 
The other major group of autoantibodies present in around 60 to 70% of RA patients’ 
sera constitute anti-citrullinated proteins/peptide antibodies (ACPAs) (Fernandes-
Cerqueira et al., 2015).  They also occur in other conditions such as multiple sclerosis 
(MS), psoriatic arthritis and SLE but at a reduced frequency (Abdel Fattah et al., 2009; 
Singh et al., 2011). ACPAs have been observed to exhibit a high specificity for RA 
although the existence of citrullinated synovial proteins is not disease-specific (Jilani 
and Mackworth-Young, 2015). ACPA positivity has been incorporated in the 2010 
ACR/EULAR classification criteria for RA and they have been shown to predate the 
onset of RA by several years (Valesini et al., 2015). The targets of ACPAs identified 
thus far in RA constitute numerous citrullinated proteins including fibrinogen, fillagrin, 
vimentin, type II collagen, α-enolase, aggrecan and several viral antigens (Glaant et 
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al., 2016). However, recognition of abundant citrullinated autoantigens might suggest 
that no traditional antigenic determinant is targeted by ACPAs and that the culpable 
autoantigens can indeed change over time instigating new reactivities in the ACPA 
responses (Trier et al., 2015). Therefore, antibodies generated against citrullinated 
epitopes could sustain the immune response via epitope spreading and cross-reactivity 
with a broad array of citrullinated proteins (Pratesi et al., 2013; Quirke et al., 2014).  
 
1.3.8. Treatment strategies in RA 
The treatment of rheumatoid arthritis has undergone significant changes over the last 
20 years and focused on rapid diagnosis and treat-to-target approach. There is 
currently no reliable cure for RA thus the existing treatment strategy has evolved 
towards early, aggressive therapy to increase the likelihood of clinical remission, to 
prevent joint damage and systemic manifestations (Losina and Katz, 2017). An 
optimum therapeutic window of opportunity of up to 6 months at the onset of RA 
symptoms appears to have lasting benefits in terms of disease progression (Raza and 
Filer, 2015).  
Treatment of RA is a multifaceted process which incorporates both pharmacological 
and non-pharmacological approaches such as physical therapy, lifestyle changes and 
surgical intervention (Sophia and Ramesha, 2017). Conventional RA therapies include 
non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, diclofenac, ibuprofen, 
and sulphonamides, which inhibit inflammation by blocking prostaglandin production. 
They are effective analgesic drugs, which improve physical function but do not prevent 
joint degradation and may cause many adverse effects such as bleeding and 
gastrointestinal toxicity (Crofford, 2013). Glucocorticoids such as prednisone are a 
class of steroid hormones which have rapid disease-modifying and anti-inflammatory 
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effects. However, they are associated with long-term adverse events such as 
hypertension or osteoporosis and are typically used as adjunct therapy (Cantley, Smith 
and Haynes, 2009).  
One of the most widely used approaches for the effective treatment of RA are disease-
modifying antirheumatic drugs (DMARDs) which have anti-inflammatory properties and 
inhibit structural damage progression. They are of synthetic and biological origin and 
are used for long-term disease control. Synthetic DMARDs are further defined as 
conventional synthetic (e.g. methotrexate, leflunomide, hydroxychloroquine, gold salts) 
and targeted synthetic such as janus kinase (JAK)-inhibitors (tofacitinib, baricitinib), 
with the latter modulating specific inflammatory targets (Smolen, Aletaha and McInnes, 
2016).  
Biological DMARDs achieve their therapeutic effect through TNF-α, IL-1 and IL-6 
receptor inhibition, T cell co-stimulation blockade and B cell depletion. Currently, five 
TNF-α inhibitors including monoclonal antibodies (infliximab, adalimumab, 
certolizumab pegol, and golimumab) and a TNF-receptor construct (etanercept) are 
approved for RA therapy. Whereas monoclonal antibodies tocilizumab, abatacept and 
rituximab target IL-6 receptor, T cell co-stimulation and B cells, respectively (Rein and 
Mueller, 2017). Anakinra together with TNF inhibitors constitute ‘first-generation’ 
biologicals and acts as an IL-1 receptor antagonist. However, the clinical potency of 
this approach is inferior to that of anti-TNF-α therapy. The clinical efficacy of biological 
DMARDs is comparable across all types and DMARDs can be used as monotherapy 
or in combination with other pharmaceutical agents. 
Although a significant proportion of RA patients respond favourably to DMARD 
treatment, there have been reports of toxicity and numerous adverse events such as 
gastrointestinal complications, renal damage and serious infection risk (Umićević 
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Mirkov and Coenen, 2013). Due to their substantial cost, the use of DMARDs has been 
restricted. However, the advent of biosimilars, which are clinically equivalent to existing 
biological agents such as infliximab, rituximab or etanercept, provides an appreciably 
cheaper alternative, which makes them widely available (Smolen et al., 2017). 
Nevertheless, despite recent advances in therapeutic approaches for RA, up to 40% 
of patients do not respond to treatment and only 20-25% of patients achieve complete 
remission (Zampeli, Vlachoyiannopoulos and Tzioufas, 2015). Therefore, the need for 
new RA therapies and strategies, which could achieve cessation of disease 
progression and disability, still remains. 
 
1.3.9. Animal models of RA 
Animal models of arthritis can function as informative tools to analyse the 
pathophysiological pathways of the developing immune response, establish drug 
targets and test potential therapeutic agents (Mcnamee, Williams and Seed, 2015). 
The most commonly utilised animal species, which recapitulate many features of 
human RA, are mice and rats.  
RA animal models are categorised into induced models (via arthritogenic stimuli or 
active/passive immunisation) and spontaneous models (Fischer et al., 2017). 
Collagen-induced arthritis (CIA) is the archetypical experimental model of inflammatory 
arthritis induced in genetically susceptible animals (MHC haplotype q) by immunisation 
with collagen II, the major component of articular cartilage. Mice or rats progress on to 
acute erosive polyarthritis within three weeks of onset with extensive cellular infiltrates 
and joint damage. CIA species exhibit autoreactive B/T cell responses and produce 
both RF and ACPA autoantibodies. On the other hand, in antigen-induced arthritis 
animals develop monoarticular pannus and lymphoid follicles upon injection of 
53 
 
exogenous protein antigen (e.g. methylated bovine serum albumin) (Alves et al., 2016). 
Whereas in streptococcal cell-wall induced model animals exhibit systemic symptoms 
with chronic erosive polyarthritis which is thought to be caused by microbial 
superantigens that stimulate T lymphocytes with specific Vβ genes in an antigen-
independent fashion.  
Arthritis can also be induced in susceptible strains of rats following administration of 
adjuvants such as complete or incomplete Freund’s adjuvant, pristine and squalene, 
possibly due to increased response to self-antigens. Animals in this model exhibit 
chronic relapsing disease course or go into remission depending on the adjuvant used 
(Mcnamee, Williams and Seed, 2015). Autoreactive sera from RA patients or CIA can 
be used to generate collagen antibody-induced arthritis (CAIA) model. In this 
experimental model, animals develop invasive pannus which leads to cartilage and 
bone damage within 8 days, however the disease induction is B and T lymphocyte 
independent (Caplazi et al., 2015). In K/BxN antibody-transfer arthritis model, mice 
spontaneously develop a progressive arthritis with rapid onset. This model is mediated 
by neutrophils, immune complex accumulation and TNF-α and therefore focuses on 
immune recruitment and synovial damage (Rohrbach et al., 2012).  
A number of inbred mouse strains are susceptible to development of spontaneous 
arthritis and several models have been established including SKG, GP130, IL-1 RA-/-, 
and TNF transgenic models. However, these models do not exhibit full penetrance and 
reproducible arthritis progression (Kollias et al., 2011; Fischer et al., 2017). Studies 
involving animal models in autoimmunity are rendered difficult due to the complexity of 
disease susceptibility loci which may or may not be present in different species. 
Moreover, certain translated targets such as endogenous retroviruses, which are of 
primary interest in this thesis, may be specific to humans therefore no suitable animal 
model might be available for their assessment in vivo (Curtin et al., 2015). 
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Nevertheless, this research has been instrumental to the development of novel 
biological agents and can serve as a useful tool in considering the heterogeneity of 




1.4. Human Endogenous Retroviruses (HERVs) 
 
1.4.1. Introduction 
Retroviruses, found in all mammals, abundant among vertebrates and other species, 
constitute a diverse family of small ssRNA viruses capable of reverse transcribing their 
genomes into dsDNA molecule and integrating it into the chromosomal DNA of the 
host. Retroviruses exist in exogenous or endogenous forms. Exogenous retroviruses 
such as human immunodeficiency virus (HIV) and human T cell leukaemia virus 
(HTLV) target primarily somatic cells and remain infectious through the production of 
viral particles, or virions. Whereas endogenous retroviruses (ERVs) have become 
permanently embedded within germline DNA and are inherited in a Mendelian fashion 
(Escalera-Zamudio and Greenwood, 2016). ERVs are therefore relics of ancestral, and 
possibly extinct, exogenous retroviruses. Upon insertion into the host’s germline, most 
ERVs have become defective for replication through frameshift mutations, insertions 
and deletions. They are therefore unable to assemble their virions and thus transmit 
infections between individuals. However, certain ERVs such as HERV-K are replication 
competent and can express their virus-like particles (Weiss, 2016). Cross-species viral 
transmission has been reported between baboons and cats (Shimode, Nakagawa and 
Miyazawa, 2015) as well as between gibbons and koalas (Tarlinton, Meers and Young, 
2006). Moreover, the process of ongoing viral endogenisation has been reported in 
different extant species such as mouse or koala where both forms of the virus co-exist 
and can be transmitted horizontally as well as vertically. However, the vast majority of 
endogenised viruses constitute non-infectious ‘retroviral fossils’ including human ERVs 
(Vargiu et al., 2016). Although HERVs can be found in all nucleated cells, their mRNA 
and protein expression varies among individuals. They are broadly distributed 
56 
 
throughout the genome and exist as single or multicopy retroelements on 
chromosomes as a result of their numerous amplifications via 
reinfection/retrotransposition (Trela, Nelson and Rylance, 2016; Nelson et al., 2014b).   
HERVs have similar although basic genomic structure common to exogenous 
retroviruses and are composed of three highly conserved genetic regions, Gag, Pol 
and Env, flanked by two long-terminal repeats (LTRs) which regulate viral gene 
insertion and expression. Group specific antigen (Gag) codes for viral matrix, capsid 
and nucleocapsid, Pol encodes enzymes reverse transcriptase, protease and 
integrase, and Env encodes the surface and transmembrane envelope domains (Fig. 








Figure 1.04. Schematic diagram of structural organisation of human endogenous 




Due to the lack of standardised nomenclature, HERVs have been classified within 
three groups based on sequence and structural similarity in the Pol region to present 
day exogenous retroviruses. Thus, Class I, Class II and Class III HERVs are related to 
Gammaretroviruses, Betaretroviruses and Spumaviruses, respectively (Table 1.02) 
(Tugnet et al., 2013). Phylogenetic studies allowed identification of around 30 distinct 
HERV groups (‘families’), with the majority expressed in old-world monkeys and some 
recently integrated elements such as HERV-K (HML-2) which are human-specific and 
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HERV-E (4-1, ERVA, NP-2) 
51-1 HERV-R (ERV-3) 
RRHERV-1 
 
Group 4: HERV-T 
HERV-T (CRTK1, CRTK6, 
S71) 
 








Group 1: HML-1 
HERV-K (HML-1.1) 
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(HML-3.1) 
 
Group 4: HML-4 
HERV-K-T47D 
 
Group 5: HML-5 
HERV-K- NMWV2 
 
Group 6: HML-6 
HERV-K (HML-6p) 
 
Group 7: HML-7 
HERV-K- NMWV7 
 
Group 8: HML-8 
HERV-K- NMWV3 
 
Group 9: HML-9 
HERV-K- NMWV9 
 









Table 1.02. Classification of human endogenous retroviruses (HERVs). Class I 
HERVs cluster with Gammaretroviruses, Class II with Betaretroviruses, Class III with 

















Figure 1.05. Cladogram showing events resulting in the introduction of HERV 




1.4.2. HERV expression in humans 
The haploid human genome occupies a total of 3 billion DNA base pairs of which only 
about 3% code for proteins. In contrast, long terminal repeat (LTR) retrotransposons 
namely HERVs and their solitary LTRs, represent approximately 8% of human DNA 
sequences (Fig. 6) which contribute to over 500,000 retroelements present in the 








Figure 1.06. Schematic diagram representing approximate DNA breakdown of 
the human genome composition highlighting percentage of HERV classes. 




Multiple HERVs integrated into primate genomes over 30 million years ago and have 
been passed onto offspring through vertical inheritance (Krzysztalowska-Wawrzyniak 
et al., 2011). Even though the majority of retrotransposons are present in the 
intergenic/intronic regions, some of them harbour promoters and enhancers and can 
exhibit relevant host function in promoting mRNA synthesis of nearby host genes (Pi 
et al., 2010). HERV LTRs naturally possess transcriptional regulatory signals thus their 
involvement in regulation of genes is very probable (Cohen, Lock and Mager, 2009). 
Therefore, depending on their location relative to host genes, HERVs can serve as 
transcriptional promoters or repressors of adjacent genes.  
Although the acquisition of these transposable elements is usually considered to be 
detrimental, parasitic or redundant, depending on the HERV, their existence may be 
neutral or they can impart a beneficial effect on mammalian chromosomes by 
facilitating genomic and regulatory evolution. This advantage for the population 
outweighs possible negative effects that are likely to be removed through selection. 
HERVs can also serve as restriction factors and therefore interfere with other infecting 
exogenous retroviruses by blocking viral receptors on the host cell (Weiss, 2016).  
In addition to providing protection against exogenous viral infection, several 
endogenous viral gene products have evolved to contribute to other important 
physiological functions. The best-characterized of these proteins are known as 
syncytins which constitute Env fragments of HERV-W and HERV-FRD known as 
syncytin-1 and syncytin-2, respectively. They serve in human placental development 
through syncytiotrophoblast formation and cell fusion promotion. Syncytin-2, HERV-H 
Env and HERV-K proteins exhibit immunosuppressive properties which may serve in 
protection of the developing foetus from attack by the maternal immune system. ERV-
3 (HERV-R) enhanced expression has been observed in different foetal tissues and 
may play a role in placental development and cellular differentiation (Kaer and Speek, 
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2013; Jern and Coffin, 2008). The enhanced expression of numerous HERV families 
in human placentas has likely resulted from repressing LTR hypomethylation within 
these tissues (Schroeder et al., 2015). Syncytin-1 may also exert its fusogenic activity 
in striated muscles and osteoclasts (Søe et al., 2011). Moreover, increased activity of 
HERV-H and HERV-K has been observed in early human embryogenesis and 
embryonic stem cells. Therefore, it has been suggested that these families may 
contribute to embryonic development and pluripotency (Meyer et al., 2017).  
HERVs, through the insertion of their regulatory sequences, can also generate novel 
patterns of genomic expression. This has been observed in ERV-9 which has an 
important role in the maintenance of male germ line integrity (Liu and Eiden, 2011) and 
in HERV-E which controls the expression of salivary amylase and may have had an 
impact on high-starch diet in humans (Gonzalez-Hernandez et al., 2012). More 





Retroelement Role References 






organisation of the human 
MHC class II region 
(Tighe et al., 2002;  
Apoil et al., 2006;  
Andersson et al., 1998) 
 
ERV-1 (MER21A) Involved in endometriosis 
and breast cancer; 
Protein glycosylation in 






Oduwole et al., 2004;  
Cohen, Lock and Mager, 
2009; Tsuchiya et al., 
2005;  
Harduin-Lepers et al., 
2001) 
HERV-E (LTR-2B) Neurodegenerative 
diseases; 
Heparin-binding growth 
factor in neural 
development 
(Kadomatsu and 
Muramatsu, 2004; Deuel 
et al., 2002; Marchionini 
et al., 2007) 
 
HERV-K (DQ-LTR3) Enhanced susceptibility to 
RA and IDDM (LTR present 
in the gene coding for MHC 
class II receptor HLA-DQ) 
(Larek-Rapala et al., 
2011;  
Seidl et al., 1999) 
 
 
HERV-K (DRB7) MHC class II-dependent 
superantigen in IDDM 
(Andersson et al., 1998) 
 
HERV-P (LTR9) Inhibition of apoptosis and 
innate immunity 
(Liston, Fong and 
Korneluk, 2003; 
Chamaillard et al., 2003) 
 
LINE (L1) Chronic granulomatous 
disease 




(Rohrer et al., 1999) 
 
HERV-P Neuronal apoptosis 
inhibitory protein 
(Romanish et al., 2007) 
 
MER39B Immune and cardiovascular 
systems 
(Robson, Sévigny and 
Zimmermann, 2006) 
 
ERV-1 (MER41E) Pregnancy (pre-eclampsia) (Overgaard et al., 2001;  





ERV-L (MER54B) Cancer; 
Cell-surface glycoprotein 
with secreted cytokine 
component 
(Chang and Pastan, 
1996;  
Hassan and Ho, 2008) 
HERV-9 (LTR12C) Immune response to 
intracellular pathogens; 
Axon guidance in brain and 
cell-cell interactions in 
immune system 
(Oduwole et al., 2004;  




ERV-9 LTR Regulation of basal and 
tissue-specific retroviral 
transcription in MHC class 
II region (HLA-DR) 
(Andersson et al., 1998) 
 
MaLR (THE1D) T-cell proliferation (Minami et al., 1993) 
 
HERV-E (4-1) Regulation of the human 
salivary amylase 
(Samuelson, Phillips and 
Swanberg, 1996;  
Ting et al., 1992) 
 
HML-5 (LTR22B) Insulin-like growth factor 
involved in placental 
morphogenesis 
(Bièche et al., 2003) 
 
 
HERV-9 (LTR12D) Signalling regulation 
(oxidoreductases) 
(Gabrielli et al., 1995;  
Shafqat et al., 2006) 
HERV-E Apolipoprotein CI (Medstrand, Landry and 
Mager, 2001) 
HERV-H Phospholipase A2-like (Feuchter-Murthy, 
Freeman and Mager, 
1993) 
HERV-L (MLT2B3) Carbohydrate synthesis (Isshiki et al., 1999) 
HERV-E (LTR2) Lipid metabolism (Shachter, 2001) 
 
Table 1.03. Association of retroviral elements with human physiological 




1.4.3. HERVs and human disease 
HERVs have been repeatedly discussed as etiological factors in a large number of 
clinical human pathologies. HERVs association with multiple human malignancies 
have been well demonstrated and they appear to exert their tumourigenic effects 
through oncogene transduction and retroviral insertion near protooncogenes. HERV-
K mRNA and proteins are overexpressed in ovarian cancers, melanoma tissue and 
cell lines as well as in germ cell tumours (GCT) such as teratocarcinoma, where 
retrovirus-like particles are released (Hohn, Hanke and Bannert, 2013). Increased 
levels of HERV-K Env RNA and immunoglobulins against viral proteins have also been 
found in breast and prostate cancer patients whilst Gag RNA was also detected in 
these cancers and in chronic lymphocytic leukaemia patients (Wang-Johanning et al., 
2014; Wallace et al., 2014). HERV-W-derived syncytins have been detected in human 
malignancies and are suggested to play a role in cancer cell modification or metastasis 
(Kassiotis, 2014). Both HERV-W and HERV-K Env domains expressed in tumours may 
exert immunosuppressive properties and therefore prevent its rejection (Morozov, Dao 
Thi and Denner, 2013). In addition, HERV-H products have been detected in colon 
cancer tissues (Alves et al., 2008) and in Hodgkin’s lymphoma patients (Woo et al., 
2014). 
HERVs have been demonstrated to be associated with viral infections through 
mechanisms which may involve cooperation or recombination with exogenous viruses. 
HIV-1 infection appears to increase the expression levels of HERV-K (HML-2) RNA in 
peripheral blood mononuclear cells (PBMCs) or serum from affected patients. 
Moreover, enhanced expression of HERV-K Gag products has been reported in CD4+ 
and CD8+ T lymphocytes from HIV-1 infected individuals (van der Kuyl, 2012). It has 
been reported that HERV-K may also contribute to the perpetuation of long-term 
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infection by Epstein-Barr virus and human herpes virus 6 (HHV-6) leading to the 
development of associated clinical conditions (Vincendeau et al., 2015). 
Enhanced expression of HERV products has also been reported in a variety of 
neurological diseases. Increased levels of HERV-W Env and Gag proteins have been 
observed in muscle biopsies from patients with amyotrophic lateral sclerosis (ALS), 
whereas HERV- K activity was found in the brain tissue from those patients. Both 
HERV-W and HERV-K are also upregulated in CSF, blood and brain biopsies from 
patients with schizophrenia and bipolar disorder (Douville and Nath, 2014). In multiple 
sclerosis (MS), which constitutes an autoimmune neurodegenerative disease, HERV-
W Env proteins were found in PBMCs and brain lesions of affected patients. The 
corresponding HERV-W mRNA levels have been frequently detected in cerebrospinal 
fluid (CSF), plasma and brain samples from patients with MS (do Olival et al., 2013). 
Moreover, enhanced expression of HERV-H/F family HERV-Fc1 RNA has been 
reported in T cells and plasma from individuals with MS (Laska et al., 2012). Various 
HERVs have also been implicated in other autoimmune disorders (Table 1.04), which 




Autoimmune disorder Human Endogenous Retroviruses 
Rheumatoid Arthritis (RA) 
 
HERV-K10 






Systemic Lupus Erythematosus 
(SLE) 











Insulin Dependent (Type 1) 
Diabetes Mellitus (IDDM) 
HERV-K18 
LTR13 
Sjögren’s Syndrome (SS) 














Congenital heart block 
ERV-3 
Autoimmune liver disease 








Mixed connective tissue disease 
HERV-E (4-1) 
 
Table 1.04. HERVs associated with autoimmune diseases. Adapted from (Trela, 
Nelson and Rylance, 2016; Freimanis, 2008). 
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1.4.4. HERVs and their association with RA 
Several exogenous viruses including EBV, parvovirus B19, cytomegalovirus and 
hepatitis C have been detected within the synovial tissue, although there is no clear 
causative association between these pathogens and RA (Tugnet et al., 2013). The 
potential contribution of endogenous retroviruses in the aetiology and pathogenesis of 
rheumatoid arthritis partly stems from the ineffective attempts to detect known human 
infectious retrovirus, such as HIV-1 or HTLV-1 in the rheumatoid synovium (di Giovine 
et al., 1994). Although antibodies to both of these viruses have been reported in RA 
sera, molecular investigations failed to identify viral sequences, which would indicate 
active infection (Nelson et al., 1994). Therefore, cross reactions with HERVs or 
autoantigens were suggested (Brookes et al., 1992). Moreover, HTLV-I-derived (p19, 
p24) and HIV-derived (p17, p24) antigens were detected in RA synovium, however no 
antibody reactivity was demonstrated to those targets (Ziegler et al., 1989; Ziegler and 
Thomas, 1991). In addition, viral particles resembling those of type C retrovirus have 
been reported in RA synovial fluid (Kalden and Gay, 1994).  
Human retrovirus 5 (HRV-5) has also been implicated in the disease upon detection of 
increased levels of proviral DNA in the inflamed synovium and blood samples from 
rheumatoid patients (Griffiths et al., 1999), however this finding was not further 
corroborated (Piper et al., 2006). With the advent of more sensitive assays, such as 
reverse transcription-polymerase chain reaction (RT-PCR), enhanced levels of several 
HERVs including HERV-K, HERV-L and ERV-9 were detected in synovial fluid from 
patients with RA (Nakagawa et al., 1997). ERV3 mRNA and ERV λ4-1 mRNA species 
were found in PBMCs and synovial tissues from RA patients, however their expression 
was also detected in osteoarthritis and healthy subjects (Takeuchi et al., 1995). HERV-
E CD5 has been reported in B cell subsets (B-1 type) which are responsible for the 
generation of rheumatoid factor autoantibodies in rheumatoid patients. This virus is 
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believed to be involved in the formation of truncated CD5 protein end products, which 
in turn lead to reduced BCR transduction and autoantibody production (Renaudineau 
et al., 2005).  
Moreover, enhanced HERV-K18 superantigen transcripts levels have been reported in 
PBMCs and synovial fluid mononuclear cells from patients with juvenile rheumatoid 
arthritis (Sicat, Sutkowski and Huber, 2005). Whilst the prevalence of a relatively young 
virus HERV-K113 was significantly increased among RA patients (Krzysztalowska-
Wawrzyniak et al., 2011). HERV-K (HML-2) Rec products have been detected in 
arthritis and normal synovia, however the authors concluded that it is unlikely to be 
causal of the disease mechanism. They also observed that HERV-K (HML-2) Env-
derived transcripts expression was decreased in rheumatoid synovial cells when 
compared to normal synovium (Ehlhardt et al., 2006). On the other hand, Mameli and 
colleagues reported an increased reactivity of RA serum to HERV-K-6 Env region in 
Sardinian population (Mameli et al., 2017).  
The viral loads of HERV-K (HML-2) type 1 and type 2 were found to be increased in 
RA plasma and synovial fluid samples from individuals with RA and correlated with the 
disease activity (Reynier et al., 2009). Nelson and colleagues reported a significant 
increase in the frequency of HERV-K10 mRNA in RA synovial fluid, when compared to 
healthy controls (Nelson et al., 1999), which was further corroborated in PBMCs 
obtained from rheumatoid patients (Ejtehadi et al., 2006). Significant up-regulation of 
HERV-K gag1 gene transcript levels in PBMCs and of serum antibody response to 
HERV-K10 Gag region (KPR) has been reported in rheumatoid patients by Freimanis 
and colleagues (Freimanis et al., 2010). Moreover, HERV-K10 solitary LTR element 
(DQ-LTR3) has been reported at increased levels within HLA-DQB1 locus in RA 
patients compared to healthy subjects. It has been suggested as a potential disease 
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marker for RA and could play a role in enhanced susceptibility to the disease (Seidl et 
al., 1999; Pascual et al., 2001).  
 
1.4.5. Mechanisms by which HERVs may induce autoimmunity 
HERVs may be associated with diseases in humans as causative agents through 
several mechanisms including superantigen motifs, neoantigens gene modulation and 
molecular mimicry.  
 
1.4.5.1. Superantigenicity 
Superantigens (SAgs) are proteins derived from bacteria and viruses which are potent 
mitogenic activators of B and T cells independent of the specificity of their antigen 
receptor. Once secreted, SAgs do not need to be processed for presentation as 
classical antigens and interact with antigen presenting cells and MHC II outside of the 
peptide binding groove. This unorthodox binding results in Vβ-restricted activation of 
up to 20% of total resting T cells and extensive cytokine secretion which leads to 
immune dysregulation (Solanki, Srivastava and Singh, 2008). Conrad and colleagues 
reported the first HERV SAg derived from IDDMK1,222 Env protein in type 1 diabetes 
(Conrad et al., 1997), which was subsequently observed to correspond to the HERV-
K18 Env allele with superantigenic activity in IDDM (Stauffer et al., 2001). Moreover, 
HERV-K18 expression levels are increased in subjects with juvenile idiopathic arthritis 
suggesting possible SAg involvement in overstimulation of auto-reactive T 
lymphocytes (Sicat, Sutkowski and Huber, 2005). Emmer and colleagues have 
reported a polyclonal expansion of Vβ T cells in the brain samples from MS patients 
which appears to be stimulated by MSRV SAg. They also implied that B cell SAg may 
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contribute to MS pathogenesis via oligoclonal bands (immunoglobulin) stimulation. 
Moreover, SAg-activated T lymphocytes can also lead to bystander cell damage 
(Emmer, Staege and Kornhuber, 2014). Elevated frequencies of Vβ T cells have also 
been reported in rheumatoid synovium which may suggest SAg involvement in RA 
aetiology (Li et al., 2013). Moreover, SAg could stimulate B lymphocytes to generate 




Being an integral part of the human genome, HERV-derived proteins are expected to 
be perceived as auto-antigens and tolerated by lymphocytes. However, if they are not 
presented during thymic selection they can become immunogenic neo-antigens 
(Gröger and Cynis, 2018). Viral protein combinations of endogenous and/or 
exogenous viruses could lead to the formation of neo-antigens (Balada, Ordi-Ros and 
Vilardell-Tarrés, 2009). Moreover, post-translational modifications such as citrullination 
converts native epitopes into neo-antigens which may differ sufficiently to drive loss of 
tolerance reactions in RA (Lerner, Aminov and Matthias, 2016).  
  
1.4.5.3. Trascriptional activation 
HERV expression in autoimmunity can be modulated by infectious agents such as 
exogenous viruses. It has been observed that HERV-K18 Env protein expression can 
be transactivated by EBV in resting B cells, which leads to SAg formation (Hsiao et al., 
2006). HHV-6 has also been reported to induce transcriptional activation of HERV-K18 
Env (Turcanova, Bundgaard and Höllsberg, 2009) whereas human simplex virus type 
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1 (HSV-1) induced HERV-W Gag and Env proteins in MS (Ruprecht et al., 2006). 
Assinger and colleagues have recently reported that human cytomegalovirus (CMV) 
upregulates HERV-K (HML-2), HERV-W, HERV-F, HERV-L and HERV-T activity 
(Assinger et al., 2013). Moreover, HIV-1 Tat protein has been shown to transactivate 
HERV-K (HML-2) LTR whilst HTLV-1 Tax protein upregulated HERV-W and HERV-H 
LTRs. HERV-K Gag is also upregulated in HIV-1-infected CD8+ T lymphocytes (van 
der Kuyl, 2012).   
 
1.4.5.4. Host immune response modulation 
HERV sequences can become integrated into any fragment of the human genome and 
may lead to activation, inhibition and differential splicing of regulatory genes. 
Transposable element-mediated defects in the Fas gene can lead to apoptosis 
disruption in autoreactive lymphocytes in SLE. Moreover, HERV-K10 has been 
reported to have an integration site inside the C2 complement gene (Perl, 1999) whilst 
HERV-K(C4) contains the entire sequence within C4 complement gene and therefore 
could affect the complement cascade. HERV Env proteins constitute possible 
modulators of cytokine expression which in turn can act on lymphocyte responses. In 
SLE, HERV clone 4-1 is capable of inducing T cells, pro-inflammatory cytokines and 
anergy in PBMCs. HERV integration within MHC I and MHC II genes is also believed 
to contribute to self-reactivity through defective MHC expression and polymorphisms 
in autoimmune-prone DR haplotypes (Balada, Ordi-Ros and Vilardell-Tarrés, 2009). 
Moreover, LTR-mediated expression of ectopic host genes and generation of HERV 
gene products could cause or exacerbate disease. HERVs have also been reported to 
activate both the innate and adaptive immune systems (Lock et al., 2014; Young, Stoye 
and Kassiotis, 2013). HERVs have the ability to induce chronic inflammation through 
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the activation of PRRs of the innate immune system. HERV-W Env protein elicits pro-
inflammatory cytokine release through interaction with CD14 and TLR4 which could 
elicit autoinflammatory and autoimmune conditions. HERVs could also stimulate the 
production of autoantibodies by PRRs as shown with TLR-activating self nucleic acids 
in SLE. Alternatively, HERV proteins could lead to immune suppression as 
demonstrated for HERV-FRD Env in pregnancy protection and for HERV-K Env in 
immunosuppressive cytokine (IL-10) production (Magiorkinis and Hurst, 2015). 
 
1.4.5.5. Molecular mimicry 
The notion of molecular mimicry relies on the observation that microbial agents may 
share structural motifs or sequence homology with that of a host component. As a 
result, an immune response to a foreign epitope could also induce cross-reactive 
antibodies and T cell immunity directed against host proteins. Ultimately, this 
mechanism may lead to a loss of clonal anergy by B and T lymphocytes, consecutive 
reactivity to a range of autoantigens via epitope spreading and result in autoimmune 
injury (Nelson et al., 2014b).  
A classic example of post-infectious autoimmune responses evoked by molecular 
mimicry events is observed in rheumatic fever and glomerulonephritis following 
infection with the gram-positive bacterium Streptococcus pyogenes. Host antibodies 
generated to bacterial epitopes, virulence factors and exotoxins cross-react with 
cardiac and renal components leading to organ damage (Cusick, Libbey and Fujinami, 
2012).  
Exogenous viral agents have been implicated in the pathogenesis of multiple human 
autoimmune diseases (Table 1.05) including parvovirus B19 infection in RA. Here, viral 
capsid protein VP1 is homologous with human cytokeratin and persistent infection with 
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this virus can perpetuate the generation of antiviral antibodies that show cross-
reactivity with collagen II, a major autoantigen in RA (Lunardi et al., 2008). Epstein-
Barr virus has also been reported to share sequence similarities with RA-specific 
proteins such as synovial proteins or shared epitope QKRAA motif which is 
homologous with EBV-encoded gp110 protein (Costenbader and Karlson, 2006). Much 
interest has also surrounded the finding of molecular mimicry between HERVs and 







Exogenous viral agent  References 
Acute disseminating 
encephalomyelitis 
(Myelin basic protein) 
Measles virus, rabies 




Epstein-Barr virus (EBV), 
Semliki Forest virus 




Coxsackie virus  (Cunningham, 2004) 
Coeliac disease 
(Transglutaminase) 
Adenovirus 12, hepatitis 
C virus (HCV) 
 
 
(Dieterich et al., 1997; 
Plot and Amital, 2009) 
 
Cogan's syndrome 
(SSA/Ro; connexin 26) 
Reovirus III major core 
protein lambda 1 




HCV  (De Re et al., 2006) 
Graft vs host disease 
(HLA-DR, aminopeptidase N) 
Human cytomegalovirus 
(hCMV) 
 (Nauclér, Larsson and 
Möller, 1996) 
Insulin dependent diabetes 
(type I) 
(Islet antigens- GAD 65, 
proinsulin 
carboxypeptidase H, tyrosine 
phosphatase IA-2) 
Coxsackie B4 virus, 
rubella, rotavirus, 
herpes, rhinovirus, 







(van der Werf et al., 
2007; Baum et al., 
1995; Jones and 
Armstrong, 1995; Endl 
et al., 1997; Steed and 
Stappenbeck, 2014) 
Multiple sclerosis 
(Myelin basic protein) 
Corona, measles, 
















Herpes simplex virus 




Schwimmbeck et al., 
1989) 





(Shimoda et al., 2003; 
Selmi et al., 2011; Kita 
et al., 2002) 
Rheumatoid arthritis 
(Collagen type II) 
Parvovirus B19  (Sfriso et al., 2010) 
Scleroderma 
(Tetraspan novel antigen-2) 
hCMV UL94 protein  
 





hCMV (pUL57)  
 
(Ali et al., 2011; 
Hiemstra et al., 2001) 
Systemic lupus 
erythematosus 
(Ro60 kD, SmB’) 
EBV (nuclear antigen-1)  (McClain et al., 2005) 
Sjögren's syndrome 
(Ro60 kD) 
Coxsackie virus  (Stathopoulou et al., 
2005) 
 
Table 1.05. Association of exogenous viral agents with human autoimmune 
diseases as reported previously within the literature.  
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Multiple sequence homologies between HERV-W (MS associated retrovirus element, 
MSRV) Env regions and myelin proteins have been demonstrated in multiple sclerosis. 
These viral fragments are found in MS active brain lesions and are believed to 
contribute to the disease pathogenesis. Increased anti-HERV-W Env reactivity has 
also been observed in MS serum samples compared to healthy controls (Ramasamy, 
Joseph and Whittall, 2017; do Olival et al., 2013). MSRV-Env pathogenic effects have 
been successfully antagonised by the GNbAC1 monoclonal antibody which has 
recently undergone a Phase 2b clinical trial and exhibits anti-inflammatory properties 
and permits remyelination in MS patients (Derfuss et al., 2015). This biological agent 
is currently also in a Phase 2 clinical trial for type 1 diabetes (IDDM) as increased 
expression of HERV-W Env has been detected in serum, PBMCs and pancreata from 
IDDM patients and has been suggested as a causative factor in disease pathogenesis 
(Levet et al., 2017).  
Moreover, our group has reported multiple homologous regions between HERV 
proteins and autoantigens in systemic lupus erythematosus. One such protein is 
HRES-1 p30 gag protein which shares amino acid sequence similarity with several 
SLE autoantigens including SmD1, Ribosome P, SmN, Ro/SSA-60, La/SSB, anti-U1 
RNP and histone H2B. We also demonstrated several regions of homology between 




1.5. Aims and Objectives 
A major aim for this research project was to analyse in more detail the role of molecular 
mimicry in Rheumatoid Arthritis via two major mechanisms: HERV-K10 involvement 
and post-translational autoprotein citrullination. 
We wished to ascertain the processes by which HERVs may play a role in, or trigger 
RA immunopathology. We also wished to establish whether the citrullination of RA 
autoantigens and HERV-K10 viral targets could perpetuate the disease. Several 
approaches were used to establish the foregoing aims. An overview of the approach 
taken is set out below. 
• In-silico investigation of the homologous amino acid regions between HERV-
K10, IgG1 Fc and other autoantigens in rheumatoid arthritis (Chapter 3) 
• Although HERVs are of great interest in the pathogenesis of diseases, there 
is a current lack of reagents to fully investigate the link. Therefore, an anti-
HERV-K10 polyclonal antibody was developed and characterised as a 
potential diagnostic reagent in RA and in detection of HERV-K10 expression 
(Chapter 4) 
• Serological analysis of RA patient serum samples for the detection of HERV-
K10 viral titres and their association with the disease (Chapter 5) 
• Investigation of the effects of endogenous protein citrullination on RA 
autoantibody reactivity (Chapter 6) 
Hypothesis:  
We propose that immunodominant peptides of HERV-K10 matrix region could 
facilitate a secondary, antigen-driven immune response in rheumatoid arthritis via 
mechanisms of molecular mimicry with the key RA autoantigen, IgG1 Fc.        
Further, we hypothesise that this phenomenon could be enhanced by global 
hypercitrullination within RA synovial joints.   
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2. MATERIALS AND METHODS 
 
2.1. Ethics approval 
Ethics approval for working with NHS patient samples during the project was provided 
by the Black Country Research Ethics (REC reference number 08/985). Ethical 
approval for the project was also sought from the University Life Sciences Ethics 
Committee (LSEC/201516/SP/148). The ethical approvals were in line with the revised 
Declaration of Helsinki, 2013 (https://www.wma.net/policy/current-policies/, 2013).  
 
2.2. Collection and processing of patient samples  
The Black Country Research Ethics Committee granted ethical approval for the 
collection of patient samples at New Cross Hospital, Wolverhampton and at Cannock 
Chase Hospital. All patients with RA fulfilled the diagnostic criteria of the American 
College of Rheumatology (ACR). Blood samples were also obtained from patients with 
systemic lupus erythematosus, psoriatic arthritis, osteoarthritis, and from healthy 
individuals. All blood samples were collected in sterile BD Vacutainer Serum Separator 
Tubes and the serum fraction was transferred into cryovials after centrifugation for 
storage at -80°C. Samples were collected from patients after obtaining written consent. 
In order to maximize accuracy of the investigation all blood samples were processed 




2.3. In silico bioinformatic analysis  
In-silico (bioinformatic) tools were used to acquire accession numbers and sequences 
of HERV-K10 Gag and the most prevalent autoantigens in rheumatoid arthritis 
identified from the literature including aggrecan, alpha 1B-glycoprotein, alpha 1 
antitrypsin, alpha 2HS-glycoprotein, alpha-enolase, BRAF, calpastatin, collagen type 
II, fibrinogen beta and gamma, filaggrin, gelsolin, glial fibrillary acidic protein, human 
cartilage glycoprotein 39, IgG1 Fc, keratin type II, lumican, peptidyl arginine deiminase 
4, tubulin beta-chain and vimentin. Their protein sequences were extracted from the 
National Center for Biotechnology Information/Genbank online database 
(www.ncbi.nlm.nih). Bioinformatic analysis of the protein residues was performed using 
established algorithms (Westwood et al., 2008), based on physicochemical 
parameters, to ascertain the antigenic profiles and immunodominant regions of each 
protein. Algorithms included hydrophilicity, residue polarity, surface accessibility, 
flexibility and β-turn propensity.  
 
2.3.1. B Lymphocyte epitope mapping 
B cell epitope predictions in this study were based on four assumptions made in 
previously published investigations.  
I. B cell epitopes can comprise continuous (linear/sequential) or discontinuous 
(conformational) amino acid fragments (Potocnakova, Bhide and Pulzova, 
2016). 
II. B cell epitopes are surface exposed and solvent accessible polar amino acids 
depleted of hydrophobic residues (Kringelum et al., 2013). 
III. B cells epitopes are typically situated within regions of high flexibility and exhibit 
site mobility (Mukonyora, 2015). 
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IV. Complex proteins contain numerous overlapping B cell epitopes with some 
showing immunodominant properties (Annadurai, 2008). 
Linear B cell epitope predictions were performed using two online software 
programmes -ExPASy ProtScale (http://www.expasy.ch/cgi-bin/protscale.pl), and 
BcePred software (http://crdd.osdd.net/raghava/bcepred/), with the latter used as an 
additional programme to compare and contrast the performance of ExPASy and thus 
enhance prediction accuracy. BcePred programme offers predictions based on 
automated combinations of all five physicochemical algorithms as opposed to 
propensity measures used by ExPASy that depend on individual properties and require 
manual formatting (El-Manzalawy and Honavar, 2010).  
These primary structure properties have been established as the most common criteria 
for identification of linear regions of antigenicity (Sanchez-Trincado, Gomez-Perosanz 
and Reche, 2017; Mukonyora, 2015). Thus, hydrophilicity criterion for B cell epitope 
mapping was employed on the assumption that hydrophilic residues, which confer 
antigenicity, are typically exposed on the protein surface (Hopp and Woods, 1981; 
Hopp, 1993). The accuracy of predictions is further enhanced when combined with 
other amino acid propensity scales such as accessibility (Lins, Thomas and Brasseur, 
2003) and flexibility (Parker, Guo and Hodges, 1986; Karplus and Schulz, 1985), which 
confer suitable residue positioning and mobility, respectively (Saha and Raghava, 
2004; Vihinen, Torkkila and Riikonen, 1994). Two additional criteria that improve B cell 
epitope predictions constitute residue polarity (with more polar residues situated on the 
surface of proteins) (Lee and Richards, 1971; Shrake and Rupley, 1973) and 
secondary structure criterion termed β-turns (Pellequer, Westhof and Van 
Regenmortel, 1993), which correlates with antigenicity, acts as ligand binding sites, 
and is responsible for protein globular structure (Yu-Bin Dong et al., 2003). 
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2.3.2. The Sliding window approach 
To improve the robustness of algorithm-based linear B cell epitope predictions, a 
‘sliding window’ principle was incorporated within a query protein sequence by ExPASy 
ProtScale and BcePred servers. Upon establishing a window size, which in this case 
was 15 amino acids wide, the window moved along the length of the sequence 
incrementally one amino acid (AA) at a time. The residue in the middle of each window 
had its value estimated by assigning it the mean value of the hydrophilicity parameter 
of all amino acids within the window. Then the window was shifted by a single position 
to the next residue (maintaining a consistent level of overlap) and the process 
continued until the end of the query sequence was reached (Figure 2.01). The 
propensity scores, which depend on correlations between amino acid properties, were 
utilised to predict the antigenic residues and their location within the query sequence 














Figure 2.01. Sliding window principle in action. Hydrophilicity values established 
by Hopp and Woods (1981) (box on the left) are allocated to individual amino acids 
within a default window of 15 residues. An average of all 15 hydrophilicity values is 
established and assigned to the amino acid in the centre of the window (Serine; red 
box). The window then shifts by a single position along the full length of the protein 
sequence and the process is repeated for every residue (Sivalingam and Shepherd, 





2.3.3. T Lymphocyte epitope mapping 
Additional epitope predictions were performed to identify potential T cell epitopes which 
may coincide with B cell epitopes. Peptides which are capable of binding to HLA-
DRB1*01:01, *01:04, *04:01, *04:04, *04:05, *09:01 (RA alleles) were analysed using 
the Immune Epitope Data Base (www.iedb.org) server. The default peptide length of 
15 amino acid residues, which was applied in the analysis, encompasses the core 
nonamer peptides that are expected to bind to the HLA DR molecule and form the 
major portion of the T cell epitope. The prediction method selected was the Stabilised 
Matrix Method (SMM) where the peptides are graded according to their predicted 
binding affinities IC50 value (indicating the concentration of peptide (nM) needed to 
achieve 50% saturation of the HLA molecule). Thus, a lower number implies higher 
affinity and peptides with IC50 <50 nM are considered to bind with high affinity, <500 
nM with intermediate affinity and <5000 nM with low affinity. 
 
2.3.4. Pairwise epitope alignment 
The level of homology (similarity) between the extracted protein sequences of HERV-
K10 Gag and RA autoantigens was evaluated using global pairwise Basic Local 
Alignment Search Tool (BLAST) analysis carried out online 
(https://www.ncbi.nlm.nih.gov/BLAST/). They were subsequently scanned for regions 
of homology using ExPASy SIM (http://web.expasy.org/sim/) and LALIGN 
(http://www.ebi.ac.uk/Tools/psa/lalign/) online local alignment tools with their default 
parameters. Global and local alignments depend on algorithms which assess an 
optimal alignment of two sequences with the former creating an end-to-end sequence 
comparison and the latter matching the most similar regions within the two query 
sequences (Brown, 2000). BLOck SUbstitution Matrix 62 (BLOSUM62) was applied 
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within the local similarity programmes to score pairs of aligned residues. Produced 
alignments were visually inspected for regions of homology. 
 
2.3.5. Replacement score determination  
Replacement scores were obtained from a substitution matrix developed by Tűdős et 
al. (1990) for all amino acid pairs to allow the identification of homology between 
specific amino acid pairs. Therefore, the higher the correlation between residues 
(higher positive value), the greater the similarity between them. Individual replacement 
scores were extracted for matching amino acid pairs and applied manually to predicted 
alignments between two query sequences.  
 
2.4. Molecular modelling 
Visualisation of epitopes and potential structural homologies between protein 
fragments was undertaken using PyMOL (Molecular Graphics System, Version 
1.2r3pre, Schrodinger, LLC: https://www.pymol.org/) and UCSF Chimera 
(http://www.cgl.ucsf.edu/chimera/) molecular visualisation software. Molecular models 
of the homologous regions between amino acid pairs were generated and inspected 
visually for structural mimicry. 
The crystal structure of IgG1 Fc (entry: 4DZ8) was extracted from the Protein Data 
Bank (www.rcsb.org) and used as a template for a structural model of HERV-K10 Gag 
generated by the SWISS-MODEL server (https://swissmodel.expasy.org/). 
In-silico simulation of post-translational modification of arginine residues to citrulline 
was achieved using a PyMOL PyTMs citrullination plugin (Warnecke et al., 2014). 
Three-dimensional models of the human fibrinogen (entry: 3GHG) and IgG1 Fc (entry: 
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5JII) were obtained from the Protein Data Bank. Their ribbon models were processed 
with PyTMs plugin and enhanced using UCSF Chimera.    
 
2.5. Peptide synthesis and bleed evaluation  
Following bioinformatic analysis, the HERV-K10 Gag immunodominant fragment 
denoted by our group as MAG1: (Matrix Gag peptide 1) was synthesised commercially 
(Severn Biotech, Kidderminster, UK) as N-terminal biotinylated and non-biotinylated 
peptides of different lengths: 15-mer (RIGKELKQAGRKGNI;), 12-mer 
(RIGKELKQAGRK), 9-mer (RIGKELKQA), 7-mer (IGKELKQ), 5-mer (GKELK), 4-mer 
(GKEL), and 3-mer (GKE). Polyclonal antibodies were generated commercially 
(Severn Biotech) to the 15-mer MAG1, which was used to immunize New Zealand 
White rabbits. The IgG fraction was subsequently purified from immunised rabbit sera 
(final bleed), acquired at 42 days following the first antigen injection, using NAb Protein 
G affinity columns (Thermo Fisher Scientific, Rugby, UK). Total protein concentration 
of the purified rabbit IgG was assessed using the BCA Protein Assay Kit (Thermo 





2.6. Serological analysis and antibody optimisation 
2.6.1. Antibodies for immunotesting 
Primary antibodies 
Specificity Application Valency Supplier Dilution/Concentration 
MAG1 ELISA/ICC/IF/WB PAb Severn 
Biotech 
2 μg/ml 
MAG3 ELISA PAb Severn 
Biotech 
8 μg/ml 
MAG4 ELISA PAb Severn 
Biotech 
2 μg/ml 
Citrulline ELISA PAb Abcam 8 μg/ml 
Citrulline ELISA PAb Millipore 8 μg/ml 
Citrulline ELISA PAb Abcam 8 μg/ml 
Fibrinogen ELISA, WB PAb Abcam 1 μg/ml 
Pan-IgG 
(A57H) 
ELISA, WB MAb Birmingham 
University 
1 μg/ml 
HLA-ABC ICC/IF MAb DAKO 2 μg/ml 
Secondary antibodies 
Specificity Conjugate Supplier Dilution/Concentration 
Human IgG 
F(ab’)2 




FITC GeneTex 1/500 
Goat IgG HRP Abcam 1/5000 
Mouse IgG HRP Sigma-
Aldrich 
1/4000 
Rabbit IgG HRP DAKO 1/5000 
Rabbit IgM HRP DAKO 1/5000 
Rabbit IgA HRP DAKO 1/5000 
MAG1 FITC In-house 25 μg/ml 
Table 2.01. Antibodies for immunotesting in ELISA, immunocytochemistry (ICC), 
immunofluorescence (IF), flow cytometry (FACS) and western blotting (WB). 




2.6.2. Indirect Enzyme-Linked Immunosorbent Assay (ELISA) 
Wells of a 96-well plate (2 HB Immulon, Dynex Technologies, Worthing, UK for non-
biotinylated peptides or NeutrAvidin Protein plates, Thermo Fisher Scientific, for 
biotinylated peptides) were coated with the indicated peptide at the indicated 
concentration and incubated overnight at 4°C. Plates were then washed three times 
with phosphate-buffered saline (PBS, pH 7.2) using an automatic Wellwash Microplate 
washer (Thermo Fisher Scientific), and blocked with 2% bovine serum albumin (BSA) 
in PBS (for purified primary antibody preparations) or with 1% Hammarsten grade 
casein in PBS (for crude serum preparations) at room temperature for 1h. After three 
washes with PBS/Tween20 (PBS-T) (0.1%), 50 µl of a purified primary antibody at the 
indicated concentration (Table 2.01) diluted in PBS-T (0.05%)/ BSA (2%) or human 
patient sera diluted in 1% Hammarsten casein/PBS at 1/200 was added to the wells 
and incubated at room temperature for 1 hour. After washing three times with PBS-T 
(0.1%), horseradish peroxidase (HRP)-conjugated secondary antibody was diluted in 
PBS-T (0.1%)/ BSA (2%) to the indicated dilution (Table 2.01) and incubated at room 
temperature for 1 hour. Plates were washed with PBS-T (0.1%) before 50 µl of 3, 3’, 
5, 5’-tetramethyl benzidine (TMB; Sigma-Aldrich, Cambridge, UK) liquid substrate 
system was added to each well. The colourimetric reaction was allowed to develop for 
4min in the dark at room temperature and was subsequently stopped by addition of 
50µl of 2N hydrochloric acid. The optical density (OD) was measured at 450 nm using 







2.6.3. Inhibition ELISA 
An inhibition assay was performed as described previously (Freimanis et al., 2010) on 
two 96-well plates i.e. target and inhibition plate. Standard curves were obtained for 
each antibody of interest using the indirect ELISA protocol (Section 2.6.1.). Primary 
antibody dilutions that gave 90% of maximal binding with a corresponding antigen were 
selected. The antibody was subsequently diluted in PBS-T (0.05%)/ BSA (2%) and pre-
incubated with a 2-fold serial dilution of the appropriate or control peptide on the 
inhibitor plate at room temperature for 1 hour. Incubated preparations (100 µl) were 
then transferred to the target plate pre-coated with the corresponding peptide and the 
ELISA assay was performed as outlined in the indirect ELISA protocol above.  
 
2.6.4. Quantitative rheumatoid factor assay 
The presence of rheumatoid factor (RF) autoantibody titres in patient serum samples 
was assessed using a commercially available sandwich ELISA kit (Abnova, Taiwan). 
The assays were performed according to the manufacturer’s instructions, with positive 
and negative controls supplied by the kit included on each plate. Patient RF titres were 
established by interpolation from a calibration curve produced for calibrator RF sera 
provided in the kit.  
 
2.6.5. Quantitative anti-citrullinated protein antibody assay 
A quantitative commercial ELISA test (Axis-Shield, Dundee, UK) was used to detect 
anti-CCP (ACPA) autoantibodies in 46 RA serum samples. The assays were 
performed according to the manufacturer’s instructions, with positive and negative 
controls supplied by the kit included on each plate. Patient ACPA titres were 
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established by interpolation from a calibration curve produced for calibrator ACPA sera 
provided in the kit.  
 
2.6.6. Immunocytochemistry    
All stages of this protocol were performed in a humidity chamber. Cell sections were 
rehydrated in PBS and fixed with 20 µl of acetone at 4°C for 5 min. Cell sections were 
blocked with PBS/ BSA (3%) for 5 min at room temperature and incubated for 40 min 
with a primary antibody diluted to the indicated concentration (Table 2.01) using PBS/ 
BSA (3%) at room temperature. Slides were washed twice with PBS for 5 mins under 
agitation, before a secondary anti-species HRP-conjugated antibody (Agilent) was 
added at the indicated dilution (Table 2.01) for 30 min at room temperature. Following 
two washes with PBS, cell sections were developed for 8 min in 0.5 mg/ml 
diaminobenzidine hydrochloride (DAB; Sigma-Aldrich). Cells were then counter-
stained with Mayer’s hematoxylin (Sigma-Aldrich) before a single drop of Fluoromount 
(Sigma-Aldrich) was added to the slide. Sterile glass coverslips were placed over the 
stained cell monolayers and sealed with nail varnish before drying for 5 min. Images 
were acquired using an inverted phase contrast microscope (Olympus UK, UK) at x20 
magnification and processed using Image J (NIH, Maryland, USA).  
  
2.6.7. Immunofluorescence and confocal laser microscopy 
All stages of this protocol were performed in a humidity chamber. Cell sections were 
rehydrated in PBS and fixed with 20 µl of acetone/methanol (50/50) at 4°C for 5 min. 
Sections were then blocked with PBS/ BSA (3%) for 1 hour. Blocking buffer was 
removed and cells were incubated for 1 hour with a primary antibody diluted to the 
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indicated concentration (Table 2.01) using PBS/ BSA (3%). Cells were washed twice 
with PBS for 5 mins under agitation and treated with a secondary fluorescein 
isothiocyanate (FITC)-conjugated antibody (Agilent) at the indicated dilution (Table 
2.01) for 30 min in the dark. Following three washes with PBS (5 min each), cell 
sections were incubated for 5 min with 4’, 6-diamidino-2-phenylindole (DAPI; Sigma-
Aldrich) at 1/1000 dilution in PBS. Cells were then washed twice in PBS before a single 
drop of Fluoromount (Sigma-Aldrich) was added to the slide. Sterile glass coverslips 
were placed over the stained cell monolayers and sealed with nail varnish before drying 
for 5 min in the dark. Images were acquired using a Zeiss LSM 510 inverted laser 
scanning confocal microscope with a 40x objective. Images were processed using 
Image J (NIH, Maryland, USA). 
 
2.6.8. Western blotting  
Protein samples were resuspended in Laemmli sample buffer (Sigma-Aldrich) and 
heated at 96°C for 30min to denature proteins. Samples were stacked on a 4% (v/v) 
stacking gel and separated out on a 6% (v/v) sodium dodecyl-sulfate polacrylamide gel 
(SDS-PAGE) at 200 V, 400 mA for 35 min using a BIO-RAD Mini-PROTEAN tetra cell 
system (BIO-RAD Ltd., Hertfordshire, UK). Proteins were subsequently transferred 
onto a nitrocellulose membrane by electroblotting at 100 V, 400 mA for 1 hour. The 
membranes were stained with Ponceau S staining solution (Sigma-Aldrich) to 
ascertain successful protein transfer. After destaining in PBS, the membrane was 
blocked with PBS-T (0.05%)/ non-fat skimmed milk (Marvel) (5%) for 1 hour at room 
temperature. Primary antibody at the indicated concentration (Table 2.01) or human 
patient sera at 1/200 diluted in PBS-T (0.05%)/ non-fat skimmed milk (Marvel) were 
incubated with the membrane overnight at 4°C, followed by three 15 min washes in 
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PBS-T. Any bound antibodies were detected with anti-species HRP-labelled conjugate 
diluted in PBS-T (0.05%)/ non-fat skimmed milk (Marvel) at the indicated dilution (Table 
2.01) upon 1 hour incubation at room temperature. Following washing, membrane was 
exposed to enhanced chemiluminescence detection system (ECL+, Amersham, 
Buckinghamshire, UK) for 5 min. Bands were visualized using a STORM 860 
Phosphorimager (GMI, MI, USA) at 450 nm.  
 
2.6.9. Flow cytometry   
All cells were cultured in triplicate in 6 well flat bottom plates at 1x106 cells per well at 
37°C, 5% CO2.  Single cell suspensions were obtained by trypsinisation of adherent 
cells. For intracellular staining, cells were fixed and permeabilised with 2 ml of ice-cold 
methanol for 15 min at room temperature. After washing with PBS, cells were stained 
with FITC-conjugated primary antibody at the indicated concentration (Table 2.01) 
diluted in PBS/ BSA (1%) / Triton (0.06%) and incubated for 30 min at room 
temperature. Cells were then washed with PBS and acquired on an Accuri™ C6 Plus 
(BD Biosciences, San Jose, CA, USA) flow cytometer. Analysis was performed using 
FlowJo (TreeStar, Ashland, OR, USA). 
 
2.6.10. Antibody labelling with fluorescein isothiocyanate (FITC) 
In-house FITC conjugation of anti-MAG1 antibody was achieved using a commercial 




2.7. In vitro cell culture 
All cell culture work was performed in a laminar flow hood under appropriate aseptic 
conditions. Cell lines were maintained in DMEM or RPMI-1640 cell culture medium 
(Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine serum (FBS) (Sigma-
Aldrich) and 1% penicillin 10000 units/ml - streptomycin 10000 µg/ml solution (Sigma-
Aldrich). The culture medium is henceforth referred to as “complete medium”.            
Four adherent cancer cell lines were grown for work within the project: GH 
teratocarcinoma (DSMZ no. ACC 811), KM-H2 Hodgkin lymphoma (DSMZ no. ACC 
8), MCF-7 (ATCC HTB-22) and T-47D (ATCC HTB-133) breast cancer cell lines. Cells 
were grown in freshly made up medium supplemented according to their requirements 
(DMEM for MCF-7 and GH cell lines and RPMI-1640 for T-47D and KM-H2 cell lines). 
 
2.7.1. Propagation of adherent cells 
Cells were cultured in complete medium and incubated at 37°C with 5% carbon dioxide 
(CO2) in a humidified air incubator prior to use. Cultures were inspected using an 
inverted microscope (Olympus, UK) to assess cell confluency and the presence of 
bacterial or fungal contamination. Spent medium was discarded using disposable 
sterile Pasteur glass pipettes and the monolayer was washed twice with a volume 
equivalent to half the culture medium of sterile phosphate buffered saline (PBS) to 
remove any FBS particles. After washing, 0.25% (v/v) trypsin-ethylene diamine tetra 
acetic acid (EDTA) solution (Sigma-Aldrich) was added to the cell monolayer using 1 
ml per 25cm2 of surface area to dislodge cells. The flask was tilted to allow the whole 
monolayer to be exposed to trypsin before incubating at 37°C for 5 min or until cell 
detachment was evident. Trypsin was deactivated by adding 9ml of complete medium. 
Cells were transferred to a sterile universal and centrifuged at 250 gx for 5 min. 
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Supernatant was removed and the cell pellet was re-suspended in 10 ml of pre-warmed 
complete medium. Cells were then counted using a bright-line haemocytometer 
(Sigma-Aldrich). The average of four different counts was used to establish cell 
numbers in a 10 ml suspension. Following cell counting, cell suspension was either 
split in a ratio of 1 to 5 into a new 75 cm2 cell culture flask or seeded into multi-well cell 
culture plates to be used for subsequent procedures. Cells were incubated at 37°C and 
5% CO2 in humidified air until cultures reached 70-90% confluency at approximately 4-
5 days at which point further cell passage or splitting was performed. 
 
2.7.2. Cytospin preparation for staining from single cell suspension   
Single cell suspensions of adherent cells were generated through trypsinisation as 
described in 2.7.1., and cells were subsequently counted using a Coulter counter (Z1; 
Beckman Coulter Inc., High Wycombe, UK) to obtain approximately 1x105 cells per 
cytospin. Cells were centrifuged in culture medium at 2000rpm for 4 min and washed 
three times in PBS. The pellet was resuspended in 200 µl of PBS and cytospun in 
Shandon™ EZ Single Cytofunnel™ (Thermo Fisher Scientific) using a Cytospin™ 4 
cytocentrifuge (Thermo Fisher Scientific) for 5 min at 2000rpm onto poly-L-lysine 
coated glass slides (Sigma-Aldrich). Mounted slides were air dried and used 
immediately or stored at -80°C.  
 
2.7.3. Cryopreservation of cells 
Cells were counted and diluted to 2-5 x 106 cells per ml of 10% (v/v) sterile dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich) in pre-chilled neat FBS. The suspensions were 
stored in cryovials overnight in a -80°C freezer for slow cooling after which they were 
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transferred into a cryogenic freezer containing liquid nitrogen at a temperature of -
180°C. 
 
2.7.4. Resuscitation of frozen cell lines 
Cryovials containing cell aliquots were retrieved from liquid nitrogen, moved into a 
water bath and heated to 37°C for about 1 min until about 80% defrosted. The contents 
of the vial were transferred into 10 ml of pre-warmed complete medium and centrifuged 
at 250 gx for 5 min. The supernatant was discarded and cells were re-suspended in 
10 ml of fresh growth medium. Cells were transferred into a 25 cm2 cell culture flask 
and an appropriate volume of growth medium was added to allow cell growth. Medium 
in each flask was replaced every 48-72 hours and cells were passaged until 
confluency.  
 
2.8. In vitro citrullination of protein targets 
 
2.8.1. Protein and peptide citrullination  
Arginine residues from fibrinogen, IgG1 Fc, MAG1 and MAG3 peptides were converted 
into citrulline residues in vitro using an active recombinant peptidylarginine deaminase 
(PAD) enzyme cocktail (SignalChem, Richmond, British Columbia, Canada). 
Proteins/peptides were incubated with PAD enzyme at a ratio of 10:1 
(protein/peptide:PAD enzyme) in 0.1M Tris-HCl (pH 7.6)/ 10mM CaCl2/ 5mM 
dithiothreitol (DTT, Sigma-Aldrich) buffer for 3 hours at 55°C. Citrullinated samples 




2.8.2. Citrulline-specific reporter assay 
A rhodamine-phenylglyoxal (Rh-PG, Cayman Chemical, Ann Arbor, Michigan, USA) 
citrulline specific chemical probe, was used to assess in-house protein citrullination. 
Citrulline labelling was performed at 37°C for 30 mins with 100μM Rh-PG in 20% (w/v) 
trichloroactic acid (TCA) at 1:1 ratio with citrullinated protein. Commercially citrullinated 
fibrinogen (Cayman Chemical) was used as a positive control for citrullination. For 
detection in western blotting, Rh-PG labelled protein samples were resuspended in 
loading buffer (2 µg protein/lane), separated via SDS-PAGE and visualised as 
described in 2.6.8.   
 
2.8.3. Antibody digestion with pepsin 
Serum antibodies from ACPA+RF- RA cohort were reduced via pepsin digestion to 
obtain intact F(ab’)2 fragments. 0.4% pepsin solution (Sigma-Aldrich) was prepared in 
cold 10mM HCl to activate the enzyme. Sera from 9 RA patients with ACPA+RF- profile 
were pooled and incubated with pepsin solution at a 20 : 1 (serum : enzyme) ratio for 
1h at 37°C. Pepsin was then inactivated by raising the pH to 6 to stop further digestion 
and the reaction mixture was affinity purified using Protein G spin column (Thermo 
Fisher Scientific) which immobilised the Fc fragments allowing F(ab’)2 separation. 
Intact F(ab’)2 fragments were resuspended in PBS to the initial sample volume and the 
pH was adjusted to neutral (pH 7.2). Low molecular weight fragments were removed 
by diafiltration with a 30-kDa nominal molecular weight cut-off membrane (Merck 






Statistical analysis of differences between 2 groups was performed using unpaired T-
tests in GraphPad Prism (GraphPad Prism version 7.03, San Diego, CA, USA). All 
analyses were two-tailed with a 95% confidence interval. *, p = <0.005, **, p = <0.01, 
***, p = <0.001, ****, p=<0.0001, ns = not significant. For a comparison of more than 








Autoimmune diseases may arise through a breakdown in tolerance, together with a 
genetic predisposition, hormonal factors, and environmental agents. Potentially 
autoreactive B and T cells are deleted during ontogeny through apoptosis although a 
small proportion escape this mechanism but are subject to peripheral tolerance 
(Tobón, Izquierdo and Cañas, 2013). A breakdown in tolerance at this stage may be 
facilitated by a number of mechanisms including molecular mimicry, epitope spreading, 
superantigen motifs and bystander activation of cells through microbial agents 
(Vojdani, 2014), leading to autoimmunity. A number of autoimmune diseases, including 
rheumatoid arthritis (RA) are primarily antibody (B cell) mediated aided by T cell help 
that facilitates isotype switching and affinity maturation. Several clinically relevant 
autoantibodies are present in patients including ‘rheumatoid factor’ and antibodies to 
citrullinated products (ACPAs) such as vimentin, fibrinogen and collagen type II 
(Ajeganova et al., 2016; Glaant et al., 2016). In particular IgM and IgG rheumatoid 
factor autoantibodies bind to immunoglobulin IgG1 Fc and are present in 75-80% of 
RA patients. The presence of RF is associated with a poorer prognosis in terms of 
disease outcome (Song and Kang, 2010b).  
Human endogenous retroviruses (HERVs), which account for up to 8% of the human 
genome, have been recently implicated as potential aetiological agents within RA. 
Whilst many HERVs have become defective over time through accumulated genetic 
and frame-shift mutations a few, including the human endogenous virus HERV-K10, 
have retained intact open reading frames within gag, pol and env genes with the 
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capacity to produce viral products (Löwer et al., 1993) and particles in RA synovial 
tissue (Stransky et al., 1993; Takeuchi et al., 1995). Accumulated evidence from our 
research group and others has suggested that HERV-K10 could play a pivotal role as 
a viral trigger of RA or augment the immunopathogenesis of disease potentially 
through the mechanism of molecular mimicry (Trela, Nelson and Rylance, 2016; 
Balada, Ordi-Ros and Vilardell-Tarrés, 2009).  
The premise of molecular mimicry is that microbial agents may share homology in 
amino acid sequence, or a structural motif, with human proteins (Tugnet et al., 2013). 
As a consequence, an immune response to a given pathogen could also induce 
undesired B and T cell reactivity to a host protein. In effect, a pathogenic organism 
which constitutes a molecular mimic of the host protein could lead to the generation of 
autoantibodies in RA and thus autoimmune reactions. Therefore, we have sought to 
identify through in silico analysis key epitopes of HERV-K10 Gag, the matrix region 
which is a pre-requisite for viral particle formation (Löwer et al., 1993),  that may share 
identical or similar epitopes on a key RA autoantigen, IgG1 Fc. Moreover, we also 
investigated the possibility of molecular mimicry within other RA autoantigens, 












3.2.1. Epitope mapping and comparison of BcePred versus ExPASy Protscale B 
lymphocyte epitope prediction software 
In silico B cell epitope mapping and non-intersecting pairwise alignments were 
performed on HERV-K10 Gag and RA autoantigens using established algorithms 
within the software (Westwood et al., 2008). Figure 3.01 summarises the process of 
selecting potential antigenic determinants from a database of both nucleotide and 
protein sequences registered in the NCBI database.  
The retrospective prediction of established epitopes of autoantigens associated with 
RA pathogenesis was incorporated within this investigation as a measure of 
independent validation of the method utilised here. A set of 19 autoantigens implicated 
in RA was selected and review of the literature was performed to identify all 
experimentally determined linear epitopes published previously for these antigens. 
They were subsequently employed to verify the performance of both ExPASy and 
BcePred local alignment platforms. Table 3.01 demonstrates details for each RA 






Figure 3.01. Workflow presenting the main components of the in silico epitope 
mapping. This procedure was applied to viral and host proteins for pairwise alignments 







1 Aggrecan NM_001135 Integral part of the extracellular 
matrix in cartilaginous tissue 
(de Jong et al., 2010; 





P04217 Possible role in antigen 
presentation 
(Udby, Johnsen and 
Borregaard, 2010; 
Biswas et al., 2013) 
3 Alpha 1 antitrypsin 
(A1AT) 
P01009 Protection from inflammatory 
cells enzymes 
(Janciauskiene et al., 
2011; Blaurock et al., 
2016) 
4 Alpha 2 HS 
glycoprotein 
(AHSG) 
P02765 Regulator of osteogenesis (Yi et al., 2009; 
Saroha et al., 2012) 
 
5 Alpha-enolase P06733.2 Abundantly expressed in the 
synovial membrane 
microenvironment 
(Terrier et al., 2007; 
Fan et al., 2015) 
6 BRAF P15056 Role in pro-inflammatory 
cytokine generation 
(Charpin et al., 2010; 
Arnoux et al., 2016) 
7 Calpastatin BC013579 Modulator of articular cartilage 
proteolysis 
(Auger et al., 2009; 
Fukuta et al., 2011) 
8 Collagen type II NM_001844 Major component of articular and 
hyaline cartilage 
(Wegner et al., 2010; 
Lindh et al., 2014) 




Regulation of cell adhesion and 
spreading 
(van Beers et al., 
2010; Alemany et al., 
1996) 
10 Filaggrin NM_002016 Filament aggregating protein 
within synovial epithelium 
(Union et al., 2002; 
van Venrooij and 
Pruijn, 2014) 
11 Gelsolin P06396 Actin filaments remodelling 
inside cells 
(Mazumdar et al., 
2012) 
12 Glial fibrillary 
acidic protein 
(GFAP) 
P14136 Abundantly contained in 
chondrocytes 
(García, Weigum and 
Koke, 2003; 
Kanazawa et al., 
2017) 
13 Human cartilage 
glycoprotein 39 
NM_001276 Modulator of tissue remodelling (Boots et al., 2007) 
14 IgG1 Fc AF150959 Effector functions of the antibody (Janda et al., 2016)  
15 Keratin type II Q9NSB2.2 Role in maintaining cell structural 
integrity 
(Wang et al., 2015; 
Bhattacharjee et al., 
2016) 
16 Lumican AAA85268 Regulator of collagen fibril 
organisation 
(Chang et al., 2013; 
Gesteira et al., 2017) 
17 Peptidyl arginine 
deiminase 4 
(PAD4) 
NP_036519 Role in the generation of 
citrullinated epitopes 
(Auger et al., 2012) 
18 Tubulin beta-chain 
(TUBB) 
NP_821133 Major component of cytoskeleton 
and microtubules 
(Libusová et al., 2005; 
Badillo-Soto et al., 
2016) 
19 Vimentin NM_003380 Abundant intermediate filament 





Table 3.01. Most prevalent autoantigens in rheumatoid arthritis selected as gold 
standards. RA autoantigens obtained from the literature used for the validation of B 




Using this dataset, both servers for linear epitope prediction were evaluated for 
accuracy and success of predicting established RA autoantigenic epitopes. Analysis 
was performed using five physico-chemical residue properties i.e. hydrophilicity, 
accessibility, flexibility, polarity and β-turns (Table 3.02) and each of the 19 
autoantigens was used to grade the prediction success rate for each platform. As 
demonstrated in Table 3.03 and Figure 3.02 (A) BcePred server achieved 21% 
increase in prediction accuracy over ExPASy Protscale, predicting 17/19 (89%) 
established epitopes whilst ExPASy recognised 13/19 (68%) regions. Discrepancies 
between the two epitope prediction platforms were observed with BcePred predicting 
some epitopes that ExPASy considered insignificant and vice versa (Figure 3.02 B). 
Following this analysis, it was decided to incorporate both methods as complementary 
tools for increased sensitivity and specificity in B cell epitope predictions, an approach 
previously employed by others (Freimanis et al., 2010). All 19 autoantigen sequences 
were subsequently aligned with one another in order to identify regions of sequence 
homology between antigen pairs (Table 3.04) which could potentially contribute to RA 
perpetuation through mimicry mechanisms and autoantibody generation. Homologies 
of 5 or more consecutive residues between antigenic pairs were selected as significant 
since antibodies typically recognise linear epitopes of between 5 to 8 amino acids. 
Moreover, identical peptide segments of 5 or more residues are considered to be rare 






Table 3.02. Parameters used by ExPASy Protscale and BcePred servers to 
predict linear B cell epitopes. Algorithm profiles were evaluated and optimised by 
the indicated research groups.   
  
Scale 
ExPASy Protscale BcePred 
Hydrophilicity (Hopp and Woods, 1981) Hydrophilicity (Parker, Guo and 
Hodges, 1986) 
Flexibility (Bhaskaran and 
Ponnuswamy, 2009) 
Flexibility (Karplus and Schulz, 1985) 
Accessibility (Janin, 1979) Accessibility (Emini et al., 1985) 
Polarity (Grantham, 1974) Polarity (Ponnuswamy, Prabhakaran 
and Manavalan, 1980) 





Table 3.03. Summary of the levels of success of two in silico methods of B cell 
epitope prediction, ExPASy Protscale and BcePred, in assessing 19 previously 
published linear epitopes. M = match between published epitopes and epitopes 
predicted in this analysis. 0 = no match between predicted epitopes and epitopes 
published in the literature. 
  



































13 263-RSFTLASSETGVG-275 M M 








18 81-FGQIFRPDNFVFGQS-95 M M 
19 428-LDSLPLVDTH-437 M 0 
 Total successfully predicted (out of 19) 13 17 
 Combined % prediction success 
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Figure 3.02. B cell epitope prediction success of ExPASy and BcePred platforms 
in identifying 19 previously published linear epitopes. (A) % prediction success 
presented as successful predictions / total number of published epitopes. (B) Overlap 
between the two platforms in predicting previously published epitopes. Numbers 








































Table 3.04. Degree of homology between 19 most prevalent autoantigens in rheumatoid arthritis that were included in the epitope mapping in this 
investigation. All sequences used for putative autoantigens were published reference sequences on the NCBI public database. Whole protein sequences 
of all autoantigens in the table were aligned against each other using publicly available bioinformatics software ExPASy SIM and LALIGN. Autoantigens: 
A1AT- Alpha-1-antitrypsin, A1BG- α1B-glycoprotein, α-Eno- α-enolase, Aggr- Aggrecan, AHSG- Alpha 2 HS glycoprotein, BRAF- B-raf murine sarcoma viral 
oncogene homolog B1, Calp- Calpastatin, Coll II- Collagen Type II, Fib β- Fibrinogen  beta, Fib γ- Fibrinogen  gamma, Fil- Filaggrin, Gel- Gelsolin, GFAP- 
Glial fibrillary acidic protein, HCG39- Human Cartilage glycoprotein-39, IgG1 Fc- Fc fragment of immunoglobulin G1, Ker- Keratin type II cuticular Hb4, Lum- 







3.2.2. Identification of HERV-K10 epitope candidates for testing their potential 
role in molecular mimicry 
When the sensitivity and specificity of prediction methods was evaluated, the technique 
was applied to predict potential epitopes present within HERV-K10 Gag region. A total 
of six antigenic regions were predicted for both viral matrix and capsid/nucleocapsid 
(Table 3.05). Resulting epitopes were aligned with IgG1 Fc sequence in order to 
identify regions of sequence homology. Table 3.06 demonstrates the alignments 
between epitopes of both HERV-K10 Gag and IgG1 Fc derived regions which exhibited 
high percentage of homology (over 70%). These data highlighted two peptide 
sequences, each composed of 4 linear residues (NGQP, PPSR) with 100% identity in 
terms of alignment scores with HERV-K10, and three 5 residue IgG1 Fc sequences 
(GKEYK, PELLG, VDKSR) with 80% identity to HERV-K10. Overall, the respective 
substitutions (tyrosine/leucine, leucine/methionine and valine/isoleucine) of these 
particular peptides scored highly in terms of amino acid replacement values (+16 to 
+24), meaning that they are structurally similar. The alignment score of one IgG1 Fc 7 
residue sequence KVSNKAL, exhibited 71% similarity to HERV-K10. However, whilst 
the single amino acid substitution asparagine / threonine, provided a reasonable 

























Table 3.05. Potential B cell antigenic regions mapped out on the surface of 
human endogenous retrovirus K10 in matrix, capsid and nucleocapsid regions. 
Immunodominant epitopes (underlined, in bold) were predicted using ExPASy 
Protscale and BcePred in silico bioinformatics platforms. Numerals indicate amino acid 
position with reference to protein accession numbers: HERV-K10 Gag1 (Matrix) 
(AAA88030.1) and Gag2 (Capsid and Nucleocapsid) (AAA88031.1). Amino acid single 
letter code: G=Glycine, A=Alanine, S=Serine, T=Threonine, C=Cysteine V=Valine, 
L=Leucine, I=Isoleucine, M=Methionine, F=Phenylalanine D=Aspartate, E=Glutamate 
N=Asparagine, Q=Glutamine, P=Proline, K=Lysine, R=Arginine, H=Histidine, 
W=Tryptophan, Y=Tyrosine. 
  
 B-cell epitope prediction                    




25                                39 
RGGVKVSTKNLIKLF 
 
60                            72 
WKRIGKELKQAGR 
 
164                        176 
EGKGPELMGPSES 
 
Capsid and Nucleocapsid 
20                         31 
NPMAPPSRQGSE 
 
32                         44 
LHEIIDKSRKEGD 
 









Table 3.06. Amino acid sequence alignments for HERV-K10 and IgG1 Fc. 
Matching homologous amino acid pairs were established using publicly available 
bioinformatics software ExPASy SIM and LALIGN. Residues highlighted in bold 
indicate amino acid substitutions. Align. Score-Alignment score shown as number of 
identical residues / number in peptide segment. Repl. Score-Replacement score for 
amino acid substitution according to Tűdős et al., 1990. Total % homology of HERV-










Align. Score (%) 
Repl. Score 
                               Matrix                                  Capsid and Nucleocapsid 
 
  29-KVSTKNL   64-GKELK   168-PELMG     24-PPSR     36-IDKSR   370-NGQP 
322-KVSNKAL 316-GKEYK   232-PELLG   352-PPSR  412-VDKSR   384-NGQP 
          5/7 (71)          4/5 (80)         4/5 (80)     4/4 (100)          4/5 (80)      4/4 (100) 




We next sought to determine whether the predicted B cell epitopes coincide with 
potential T cell epitope predictions as T cell help is essential in B cell mediated 
mechanisms in RA. Both HERV-K10 Gag and IgG1 Fc regions were assessed by the 
IEDB server for binding to the HLA DRB1 molecule, which appears to confer 
susceptibility to RA. As demonstrated in Table 3.07 there were 4 epitopes in both 
HERV-K10 Gag and IgG1 Fc with an IC50 < 500 nM predicted to be able to bind to the 
HLA DRB1 molecule with intermediate affinity whilst the remaining two epitopes bound 
with either high (IC50 < 50 nM) or low (IC50 < 5000 nM) affinity. From this analysis it 
was concluded that HERV-K10 Gag epitopes are capable of being presented by MHCs 
associated with RA. Overall, the predicted T cell epitopes from HERV-K10 Gag were 
located within regions homologous to the IgG1 Fc protein and therefore coincided with 





















IC50 Strength  Allele (HLA) IC50 Strength 
29-
KVSTKNL 
DRB1*04:05 171 Inter 322-KVSNKAL DRB1*01:01 153 Inter 
64-GKELK DRB1*01:01 46 High 316-GKEYK DRB1*01:01 153 Inter 
168-PELMG DRB1*01:01 382 Inter 232-PELLG DRB1*01:01 38 High 
24-PPSR DRB1*01:01 107 Inter 352-PPSR DRB1*01:01 119 Inter 
36-IDKSR DRB1*01:01 1795 Low 412-VDKSR DRB1*01:01 101 Inter 
370-NGQP DRB1*01:01 356 Inter 384-NGQP DRB1*04:04 2726 Low 
 
Table 3.07. T-cell epitope predictions using IEDB MHC-II binding predictions for 
alleles HLA-DRB1*01:01, *01:04, *04:01, *04:04, *04:05, *09:01. Potential T-cell 
epitopes were predicted using the publicly available bioinformatics methodology 
Stabilised Matrix Method (SMM). Numerals indicate IC50 values representative of 
binding affinity: < 50 nM - high affinity, < 500 nM intermediate affinity, < 5000 nM low 




3.2.3. Incorporation of negative controls into the study 
Frequently small datasets include a significant bias for negative and positive data, as 
data was determined thorough a rigorous set of parameters (Gibb et al., 2015; Soria-
Guerra et al., 2015). In order to reduce potential bias and its effect on a set of results 
we incorporated non-specific epitopes which were expected to show insignificant or no 
binding. Therefore, potential epitopes determined on HERV-K10 Gag and IgG1 Fc 
proteins were aligned with two presumed negative control sequences which were 
predicted by ExPASy and BcePred from the two control sequences i.e. tartrate 
resistant acid phosphatase (TRAP) protein and from retroviral plant protein of 
Arabidopsis thaliana (Table 3.08). No sequence homology was observed for any of the 







Peptide Organism Accession 
number 
Sequence 
Gypsy/Ty3 Arabidopsis thaliana AAG51464.1 413 VAVADGRKLNVDGQIK 428 
TRAP Homo sapiens P13686 311 SGKSLFKTRLPRRARP 325 
MAG1 HERV-K10 AAA88030.1 60 RIGKELKQAGRKGNI 72 
IgG1 Fc Homo sapiens AF150959.1 90 LNGKEYKCKVSNKAL 104 
 
Table 3.08. The potential antigenic determinants predicted for tartrate resistant 
acid phosphatase (TRAP) and plant retroelement of Arabidopsis thaliana 
negative controls. Epitopes were determined using the ExPASy Protscale and 
BcePred platforms. The two underlined epitopes indicate those used as controls for 
the pairwise alignment with HERV-K10 and IgG1 Fc epitopes to reduce bias in the 
investigation and were employed as negative control peptides in subsequent 




3.2.4. Shortlisting of candidate epitopes for synthesis as peptides  
Those epitopes predicted for HERV-K10 Gag that demonstrated the highest degree of 
homology with IgG1 Fc autoantigen were compared with IgG1 Fc sequence to 
determine the best candidates for peptide synthesis and screening of patient serum. 
This was important, as it determined whether the predicted viral epitopes, which 
constitute potential molecular mimics involved in triggering RA pathogenesis, 
correspond to antigenic regions on IgG1 Fc that are recognised by and accessible to 
rheumatoid factor autoantibodies in RA.  
Table 3.09 shows that 232-PELLG-236 was present on a lower hinge region residues 
and part of the fx1 β–pleated face of the CH2 domain which were not solvent 
accessible. Sequences 316-GKEYK-320 and 322-KVSNKAL-328 were present on 
exposed segments of the CH2 domain and located largely on the fy2 β–pleated face 
and on part of the b5 and b6 loop (or bend) of the domain, respectively. Both 
sequences were solvent accessible. Sequence 352-PPSR-355 was located on the fx1 
β–pleated face of the CH3 domain whilst sequence 384-NGQP-387 was present on 
the b3 loop of the domain. Sequence 412-VDKSR-416 was located largely on the fx4 
β–pleated face and a small segment of the b5 loop of the CH3 domain. Since B cell 
epitopes are typically located in the vicinity or within structural loops (Zheng et al., 
2015), it was established that all regions except PELLG were capable of interaction 
with antibodies/rheumatoid factor, therefore PELLG was excluded from further 
investigation. Sequences were subsequently analysed for antigenicity and physico-
chemical properties. As presented in Table 3.10. the remaining five regions were found 
to be within the protein antigenic regions. In addition, all sequences, with the exception 
of KVSNKAL, were also recognised by RFs. Moreover, properties of individual 
residues comprising the predicted epitopes of HERV-K10 Gag and their neighbouring 
amino acids were evaluated to assess their potential for interaction with 
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autoantibodies. Table 3.12 shows that KVSNKAL, GKELK, PPSR and IDKSR epitopes 
contained polar residues with positive charge (highlighted in green) which are crucial 
for antibody reactivity (Dam et al., 2014), whereas NGQP epitope was predominantly 
composed of non-charged (cyan) and aliphatic (magenta) residues, and was therefore 






AA no. 231                       241                       251                       261                          271 
IgGFc1  A PELLG GPSV  FLFPPKPKDT  LMISRTPEVT  CVVVDVSHED  PEVKFNWYVD 
 ---e1---/----- fx1 (CH2 domain) -----/---b1-----/------------ fx2----------------/--- b2 ---/---------fy1-------/ 
AA no. 281                         291                       301                        311                            321 
IgGFc1  GVEVHNAKTK  PREEQYNSTY  RVVSVLTVLH  QDWLN GKEYK VC KVSNKAL PA 
 ---b3-----/--------fx3------------/-b4---/---------------fx4------------/------b5----/---------fy2--------/----b6-----/ 
AA no. 331                    341                        351                       361                         371 
IgGFc1  PIEKTISKAK  GQPREPQVYT  LPPSR DELTK  NQVSLTCLVK  GFYPSDIAVE 
 ---------fy3-----------/-e2-/----- fx1 (CH3 domain) ----/-b1---/----------fx2-----------------/-b2-/-------- 
AA no. 381                          391                       401                      411                             421 
IgGFc1  WES NGQP ENN  YKTTPPVLDS  DGSFFLYSKL  TVDKSR WQQG  NVFSCSVMHE 
 -fy1/---b3------/--------fx3---------------/-b4--/------------fx4--------------/----b5--------/-----------fy2------------ 
AA no. 431                       441                    
IgGFc1  ALHNHYTQKS  LSLSPGK 




Table 3.09. Four rheumatoid factor-accessible epitopes on IgG1 Fc with their 
location within the protein secondary structure. Regions of homology with HERV-
K10 Gag epitopes accessible XX (boxed, green) and non-accessible YY (boxed, red) 
to RF antibodies identified through bioinformatics. Sequences aligned with the protein 
structure taken from Nelson et al., 2008. IgG constant domain segments: face X (fx1-
4), face Y (fy1-3), bends/loops (b1-6), non-β-structure (e1, e2). 








AA no. 231  
IgGFc1 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD  
AA no. 281  
IgGFc1 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA  
AA no. 331  
IgGFc1 PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE  
AA no. 381  
IgGFc1 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE  






Table 3.10. Identification of five HERV-K10 homologues within antigenic regions 
of IgG1 Fc. Homologues XX (boxed), antigenic regions YY (shaded, non-boxed) and 
published epitopes recognised by rheumatoid factor antibodies identified through 
bioinformatics and indicated in red. 








AA no. 1  
K-10 MGQTKSKIKSKYASYLSFIKILL KRGGVKVSTKNLIKLFQIIEQF  
AA no. 60  
K-10 WK RIGKELKQAGRKGNIIPLTVWNDWAIIKAALEPFQTEEDSISVS  
AA no. 162  
K-10 K LEGKGPELMGPSESKPRGTSPLPAGQVLVRLQPQKQVKENKTQ  
AA no. 297  
K-10 PPTR RLNPMAPPSRQGSELHEIIDKSRKEGDTEAWQFPVTLEPMPP  
AA no. 641  





Table 3.11. Suggested HERV-K10 matrix epitopes have physico-chemical 
features of immunodominant epitope. Amino acid sequence of Gag epitopes 
(boxed), which constitute IgG1 Fc mimics, were identified through bioinformatics. 
Physico-chemical properties were specified for the epitopes and neighbouring residues 
constituting 15-mer peptides. 
  
Residues:   WW – non-polar                    XX – polar with (+) charge   
                     YY – polar with no charge   ZZ – polar with (-) charge      
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Four homologous sequences, KVSNKAL, GKELK, PPSR and IDKSR, which were 
selected as potential candidate epitopes were subsequently converted into 3D 
molecular models in order to investigate their structural mimicry. In broad terms, 
HERV-K10 and IgG1 Fc peptides showed very little difference in overall mesh 
structure. This enabled us to demonstrate the conformational similarity between 
epitopes within the RA autoantigen and viral sequences which are likely to be targeted 
by rheumatoid factor autoantibodies in RA (Table 3.12, columns 1 and 2). Additional 
molecular modelling using a PDB file of IgG1 Fc positioned the candidate homologues 
within the tertiary protein structure (Table 3.12, column 3) and showed that all four 
potential peptide mimics were surface exposed and accessible epitopes Visualisation 
of the viral epitopes within HERV-K10 tertiary structure is currently not achievable since 
the protein has not been crystallised and therefore K10 molecular model is not 






Table 3.12. Molecular models of homologous epitopes located on HERV-K10 
Gag1 / Gag2 and IgG1 Fc presented as ‘mesh structure’. Three dimensional 
structures of homologous regions between HERV-K10 and IgG1 Fc were modelled in 
PyMOL and UCSF Chimera molecular graphics systems and presented in mesh mode 
together with their amino acid sequences. Location of Fc1 mimics is presented on IgG 
Fc1 model (arrowed). 
  
HERV-K10 epitope IgG1 Fc mimic Location on IgG1 Fc 
 
Matrix 
GKELK GKEYK IgG1 Fc CH2 
 
 








PPSR PPSR IgG1 Fc CH3 
  
 





Table 3.13 demonstrates those epitopes that are most likely to contribute to triggering 
and/or perpetuation of RA via mechanisms of molecular mimicry. Novel peptides of 
significant interest are all immunodominant ‘MAG’ (MAtrix Gag) peptides that exhibited 
homology to epitopes on IgG1 Fc and coincide with rheumatoid factor binding regions. 
MAG1 is a predicted immunodominant and antigenic B cell epitope which appears to 
resembles the shared epitope motif Q/R-K/R-x-x-A that confers susceptibility to RA 
and is associated with the presence of rheumatoid factors (de Almeida, Ling and 
Holoshitz, 2011). It is also enriched in polar residues with positive charge, features 
characteristic for B cell epitopes (Kringelum et al., 2013), which are structurally 
homologous with those on the corresponding fragment of IgG1 Fc. MAG1 is predicted 
to bind strongly (IC50 = 46) to the RA-associated HLA DRB1 molecule and can be 
potentially presented to Th cells with high affinity. Therefore, the peptide within the 







Table 3.13. Peptides selected as best homologue candidates for implicating 
HERV-K10 in the pathogenesis of rheumatoid arthritis. Peptides were selected 
through bioinformatics for their homology to antigenic regions on the main target of 
rheumatoid factor autoantibody, IgG1 Fc. Immunodominant epitopes were underlined 



















5 amino acid mimic 
with high (+16) 
replacement score 










7 amino acid 
mimicry with 























Yes Yes Yes No 
Comments - 1st most antigenic 
peptide on K10 Gag1 
- high affinity binding 
(IC50 = 46) by HLA 
DRB1 
- resembles shared 
epitope motif Q/R-
K/R-x-x-A 
N/A N/A - 2nd most 
antigenic peptide 




Activation of autoreactive B cells, which upon T cell stimulation produce high levels of 
autoantibodies that bind to antigens at antigenic determinant regions, appears to 
constitute a key element in the pathogenesis of RA. Therefore, knowledge of B cell 
epitopes of proteins is of particular interest in RA as they can contribute to disease 
diagnosis and development of immune-therapeutics. Unlike time-consuming and 
labour-intensive experimental epitope mapping, bioinformatic screening provides a 
faster and low-cost alternative for preliminary epitope mapping. Owing to advances in 
bioinformatic tools and their use in the investigation of HERV involvement in 
autoimmunity, including in silico assessment of HERV-W in MS (Ramasamy, Joseph 
and Whittall, 2017) and HRES-1 in SLE (Nelson et al., 2014b), the role of HERV-K10, 
one of the most biologically active forms of endogenous virus, has gained increasing 
interest in autoimmune arthritis (Nelson et al., 2004; Ehlhardt et al., 2006). Due to the 
recent amplification of the majority of HERV-K elements (less than 3 million years ago), 
they preserved some of their retroviral open reading frames and thus the potential to 
form viral particles (Lemaître et al., 2014).   
In this chapter a method for the prediction of potential viral B cell epitopes, which may 
play a role in the disease pathogenesis, was developed and optimised. An in silico 
approach was employed that permitted epitope mapping of autoantigens and HERVs 
previously associated with RA. For the purpose of this investigation, we compiled 19 
previously published autoantigens which have been implicated in the disease process 
and that represent linear epitopes. These 19 epitopes were used as cross-validation 
controls to assess the performance of B cell epitope prediction platforms. This epitope 
list could be further enhanced by other antigens that are targeted by antibodies in RA 
such as citrullinated histones (Pratesi et al., 2014). The existing procedure employed 
in-house involves predictions based on five properties of individual amino acids i.e. 
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hydrophilicity, flexibility, polarity, solvent accessibility, and β-turn propensity, which 
when considered together have been reported to result in successful epitope 
predictions (Soria-Guerra et al., 2015). Moreover, these computer-aided strategies of 
B cell epitope predictions have been successfully pursued by several groups in design 
and analysis of anti-viral candidate vaccines. Cheung et al. (2010) used in silico 
approach, with similar level of successful predictions to the one established in our 
study, to predict epitopes on H5N1 influenza A, which he later combined with in vitro 
studies to confirm the peptide immunogenic potential, whilst Zheng et al. (2017) and 
Alonso-Padilla, Lafuente and Reche (2017) identified promising linear B cell epitopes 
for HBV and EBV targeting.  
Therefore all 5 algorithms were used to perform initial studies using default values 
established by authors of original experimental antigenic propensity scales (Table 
3.02). Two parallel epitope prediction strategies, which rely on protein composition 
algorithms, were employed to ensure prediction reliability (Table 3.03). It became 
evident that both prediction tools exhibited varying levels of accuracy. Overall, the 
BcePred server, which unlike ExPASy allows users to select two or more residue 
properties simultaneously and does not require manual prediction calculation, 
achieved better performance. When evaluated using the pre-published regions, 
BcePred predicted 89% (17/19) of epitopes compared to the 68% (13/19) established 
by ExPASy. However, when applied together, the prediction platforms exhibited a 
94.7% (18/19) combined success rate. The importance of comparative analysis of 
different epitope prediction tools for enhanced accuracy has been recognised by others 
(Guedes et al., 2018; Moult, 2005) and has therefore been employed in this study. 
Although it appears that predictions obtained through BcePred outperform those made 
by ExPASy, it should be borne in mind that this evaluation relied on a small dataset of 
19 epitopes. Studies with low sample size and small datasets have been reported to 
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yield biased performance estimates (Button et al., 2013; El-Manzalawy and Honavar, 
2010). Therefore, any future experiments should incorporate large and non-redundant 
datasets. Another limitation is related to underperformance of linear epitope predictors 
which can label some amino acids incorrectly as non-epitope or epitope residues and 
therefore lead to false negative or false positive results, respectively. This is 
complicated by processes such as epitope spreading, which involves diversification of 
epitope specificity from dominant to subdominant/cryptic epitopes recognised by 
antibodies, and molecular mimicry which is considered a strong contributor to B cell 
epitope spreading (Cornaby et al., 2015). Nevertheless, sequence-based epitope 
mapping is advantageous for predictions where the structure of the target antigen is 
not known (El-Manzalawy and Honavar, 2010), which is the case with HERV proteins, 
and this prediction method has been shown to achieve an accuracy of up to 72.5% 
(Potocnakova, Bhide and Pulzova, 2016).  
Once developed and optimised, this methodology was used to identify potential 
epitopes of HERV-K10 Gag (Table 3.05). Retroviral Gag polyproteins are crucial for 
the generation of viral particles and contribute to the assembly of key structural regions 
including matrix, capsid and nucleocapsid. These polyproteins assemble at the plasma 
membrane and, despite their loss of infectivity due to inactivating mutations, facilitate 
the release of the viral particles out of the cell (Kraus et al., 2011). Nevertheless, 
constituting part of the human chromosome, HERV-encoded fragments should be 
perceived as autoantigens unless they fail to undergo thymic presentation and are 
regarded as neo-antigens (Gröger and Cynis, 2018). They could also share 
immunologic epitopes with host proteins leading to immunoreactivity (Fujinami et al., 
2006). This phenomenon between human endogenous retroviruses and autoantigens, 
known as molecular mimicry, has been considered a mechanism in the aetiology and 
pathogenesis of several autoimmune diseases. In this light, in silico studies contributed 
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to the identification of homologous epitope pairs between HERV-W and myelin sheaths 
in multiple sclerosis. HERV-W proteins are believed to induce autoreactivity and 
ineffective myelin repair due to its pro-inflammatory properties and oligodendrocyte 
toxicity (do Olival et al., 2013). Novel biological therapy (GNbAC1 monoclonal 
antibody) targeting and blocking these viral regions in MS is currently in clinical phase 
IIb trials (Curtin et al., 2015). In addition, this biological agent is also in clinical 
development for type I diabetes where it has been shown to neutralise the cytotoxic 
effects of HERV-W on glucose and  insulin metabolism (Curtin et al., 2018). Moreover, 
computationally predicted homologous fragments have been detected between HRES-
1 virus and several autoantigens in systemic lupus erythematosus (Nelson et al., 
2014b). Molecular mimicry has also been considered a pathogenic mechanism in RA 
traditionally between Proteus mirabilis bacterium and sequences found in HLA-DR4/1 
haplotypes (Rashid and Ebringer, 2012) and, more recently, HERV-K10 (Trela, Nelson 
and Rylance, 2016). We therefore assessed potential homology between HERV-K10 
Gag and IgG1 Fc, the key known autoantigen protein in RA, using a local alignment 
programme (Table 3.06).  
In total, six regions were found that were either identical (NGQP, PPSR) or possessed 
one or two amino acid substitutions (GKEY/LK, PELL/MG, V/IDKSR, KVSN/TKA/NL). 
Moreover, varying degrees of homology were observed between the 19 most prevalent 
autoantigens in RA with 157 matches of 6 consecutive residues and 93 matches of 5 
consecutive residues some of which, including fibrinogen and α-enolase, coincide with 
regions on IgG1 Fc protein recognised by rheumatoid factor autoantibody (Table 3.04). 
Overall, the sequence homology observed between different proteins with strings of 4 
residues or more declined with increasing peptide length. However, the relative 
significance of the latter was important when discerned from the binomial expansion of 
20n (20, total number of amino acids; n, number of residues).  Here the probability of a 
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unique set of residues in a peptide chain of 3, 4, 5, 6, and 7 amino acids was estimated 
as 1 in 8000, 160,000, 3 million, 64 million, 1,128 million and greater, respectively. 
Consequently it might be perceived that a peptide containing a unique set of residues 
of  ≥ 5 (4 consecutive residues considered as borderline match) that was identical to a 
second peptide, could be significant when assessing potential molecular mimics and 
constitute a ‘rare event’. In addition, a high replacement score for a given amino acid 
substitution (e.g. +24 for valine / isoleucine) that would share similar physio-chemical 
properties was seen as pivotal for retaining peptide / protein structure and function 
(Tűdős, Cserző and Simon, 1990). Indeed, our mesh configurations of molecular 
models (Table 3.11) highlighted little perturbation in shape with acceptable amino acid 
substitutions.  
Both molecular modelling and sequence analysis (Table 3.09 and Table 3.10) of IgG1 
Fc revealed that 4 HERV-K10 / IgG1 Fc peptide mimics were exposed on the surface 
of the protein, accessible, and thus likely to be antigenic sites. This observation was 
consistent with epitope mapping studies in that all 4 regions coincided with linear 
antigenic determinants identified by rheumatoid factor antibodies. In general, relatively 
small linear epitopes (of 5-8 amino acids) can be recognised by rheumatoid factors 
and specifically generated antibodies (Westwood et al., 2008). In addition, 
conformational epitopes from amino acids brought into juxtaposition through molecular 
folding may depend on one or two key residues within a given epitope (Nelson et al., 
1990). 
In light of the above, both linear and conformational epitopes might contribute towards 
molecular mimicry in RA and possible epitope spreading should additional B cells 
become activated (Cornaby et al., 2015). These processes might also be facilitated by 
T cell mimics that would promote T cells to facilitate isotype switching. Thus, it is likely 
that short viral peptide sequences of HERV-K10 could mimic regions of IgG1 Fc in RA. 
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In turn, this might help drive autoantibody production particularly if the IgG 
macromolecule was no longer recognised as body’s own protein by the mechanism of 
self-tolerance (Benson et al., 2010)  due to the physio-chemical degradation or 
structural alteration of IgG e.g. mediated by defects in glycosylation.  
Ordinally, HERV-K integrated into the human genome as closely linked viral peptide 
sequences about 40 million years ago, to subsequently become separated out during 
evolution. We observed that the motif KVSTKNL preceded GKELK in HERV-K10 Gag 
by 28 residues. In the case of IgG1 Fc however, we noticed that the motif order was 
reversed and separated by a single residue. Since HERVs are widely distributed within 
the human genetic material as a result of multiple amplification and transposition 
events (Gröger and Cynis, 2018), and have the potential to generate mutations (Löwer 
et al., 1993), we hypothesise that this viral region became conserved within IgG1 Fc 
giving rise to the predicted regions of homology. It is interesting to note that other 
HERV families have been integrated into the human genome as conserved regions to 
carry out physiological roles such as HERV-W functional protein syncytin-1, which is 
essential for placenta formation, or HERV-H involved in embryonic development (Hurst 
and Magiorkinis, 2017). Moreover, as a result of their relatively recent amplification, 
HERV-K elements exhibit strong polymorphism at viral insertion sites and at specific 
loci, therefore it is possible that certain individuals will have alleles with a particular 
viral sequence whilst others may not have a functional allele in their chromosomes. 
This may affect HERV-K expression and lead to differences in immune responses 
(Lemaître et al., 2014).  
Those epitopes of HERV-K10 Gag which shared sequence homology with IgG1 Fc 
were short-listed as candidates for generation of short polypeptides and for 
subsequent anti-HERV-K10 antibody characterisation as well as serological screening 
of patients’ blood for reactivity to viral epitopes (Table 3.13). Of the short-listed epitopes 
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MAG1 was the first peptide selected for synthesis. This peptide containing 15 residues, 
which was found to be the optimum number of residues in an average B cell epitope 
(Kringelum et al., 2013), showed the best alignment with IgG1 Fc, the primary target 
of rheumatoid factor autoantibodies. This epitope was in the top four most antigenic 
regions on HERV-K10 Gag, in addition to being situated within the K10 
immunodominant region and rheumatoid factor binding region. It is also located within 
the flexible β-turn structure which is highly characteristic of an epitope. MAG1 peptide 
contains multiple polar and charged residues with two hydrophobic amino acids 
(glycine, leucine) situated within the epitope fragment which are typically located 
closest to the antibody (Rahman et al., 2016). Moreover, T cell epitope prediction 
analysis identified that MAG1 can be potentially presented to Th cells with high affinity 
(IC50 < 50 nM) by HLA DRB1, the Class II molecule that has been associated with RA 
(Boissier et al., 2012). Lastly, this peptide resembles the shared epitope motif Q/R-
K/R-x-x-A which resides within HLA DRβ chain and constitutes a major risk factor for 
severe arthritis (Ling et al., 2010). Thus percentage homology, peptide length, 
replacement residue value and molecular modelling may all contribute to the 
successful identification of peptide mimics that could be otherwise overlooked when 
using gross homology searches between proteins. Once identified in silico peptides 
can be developed into research tools, diagnostic applications and therapeutic agents 
such as blocking peptides used in renal idiopathic membranous neuropathy to prevent 
autoantibody interactions induced by molecular mimicry mechanisms (Havasi et al., 
2017). 
Currently there appears to be a limited understanding of the properties that 
characterise a functional B cell epitope, therefore the performance of prediction 
methods is not optimal and requires standardisation. This is further complicated by the 
stochasticity of antibody binding, discontinuous nature of numerous B cell epitopes 
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with closely spaced residues (Rahman et al., 2016) and high genetic variation  in the 
MHC molecule for T cell predictions (de Jong et al., 2010). Therefore, further 
development of standard benchmark datasets used to assess the prediction 
approaches and meta-servers merging the predictions of several prediction methods 
is required. Hence, it is necessary to incorporate the in silico predictions with 
experimental data in order to allocate function (Soria-Guerra et al., 2015), an approach 




4. GENERATION AND CHARACTERISATION OF A POLYCLONAL 
ANTIBODY TO HERV-K10 GAG  
 
4.1. Introduction 
The generation of reliable diagnostic immunoassays or immunotherapeutic strategies 
requires, among others, scrupulous evaluation of potential antibody reagents. 
Polyclonal antibodies enable detection of a variety of epitopes and therefore identify 
antigen from distinct orientations. This may constitute a salient feature in some 
systems which, with the use of a single epitope or certain immobilisation procedures, 
could otherwise exhibit assay restriction phenomenon i.e. an antibody performing well 
in one assay system but reacting poorly in another. Therefore, it is necessary to verify 
the reactivity profiles of novel reagents in different experimental techniques. 
We have previously described (chapter 3) the use of bioinformatic algorithms to predict 
antigenic peptides within host and viral proteins that can be tested in immunoassay 
techniques. In this study, we identified a highly antigenic peptide on the matrix protein 
of HERV-K10 (denoted as MAG1: RIGKELKQAGRKGNI) with sequence and structural 
similarity to IgG1 Fc, which has also been identified as a key antigenic target for RF 
autoantibodies in RA (Nelson et al., 2014a). This finding suggested a potential region 
for molecular mimicry that exhibited little variation in overall structure and sequence. 
In order to further investigate the role of HERV-K10 mimicry with IgG1 Fc in RA, in this 
chapter we developed a polyclonal antibody (PAbMAG1) to the MAG1 peptide 
sequence and tested the reactivity of this antibody to IgG1 Fc mimics. At present, there 
is a paucity of antibodies to HERV-K10. Hence a panel of standardised reagents would 
provide specific laboratory probes to determine molecular mimicry, epitope spreading 
and antibody reactivity to native and modified proteins. Therefore, in this chapter, we 
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set out to generate and characterise the anti-MAG1 (PAbMAG1) antibody in a range 






4.2.1. Peptide/antigen selection and antiserum development  
As demonstrated in Table 4.01, we have determined four synthetic peptides (MAG1 - 
4) of 11-15 residues using in silico investigation of the putative HERV-K10 Gag protein 
sequence, which were then synthesised commercially. These peptides exhibit 
sequence similarity to IgG1 Fc autoantigen and may constitute potential regions for 
molecular mimicry in RA. Additionally, MAG1 peptides of different lengths (3-, 4-, 5-, 
7-, 9-, 12- and 15-mer) were developed to analyse the effect of epitope size on antibody 
binding. Two further peptides termed NC1GTY3 and 8023 incorporating epitopes 
derived from a retroelement of Arabidopsis thaliana and tartrate resistant acid 
phosphatase, respectively, were used as negative control peptides. In our 
bioinformatic analysis we predicted the 15-mer peptide sequence MAG1, which 
contains the immunodominant ‘GKELK’ region homologous to that on IgG1 Fc ’Key’ 
peptide (LNGKEYKCKVSNKAL) derived from IgG CH2 domain, as highly antigenic 
and likely to provoke an immune response. A polyclonal antibody was therefore 
generated for investigation of HERV-K10 mimics. New Zealand white rabbits were 
immunised with PPD-conjugated MAG1 peptide by Severn Biotech Ltd. and antisera 



































on IgG1 Fc 
(synthesised as 
IgG1 Fc ‘Key’ 
peptide) 
(Westwood et al., 
2008) 
 
MAG2 11-mer PMAPPSRQGSE HERV-K10 
Gag 
MI14123 Homology to 
published epitope 
on IgG1 Fc. 
Control sequence 
 
MAG3 11-mer IIDKSRKEGDT HERV-K10 
Gag 
MI14123 Homology to 




MAG4 12-mer KRGGVKVSTKNL HERV-K10 
Gag 
MI14123 Homology to 












































Table 4.01. Peptides selected as candidates for synthesis and testing as coating 
antigens against PAbMAG1 and patient serum samples in ELISA. Underlined 




4.2.2. Bleed evaluation 
Commercially synthesised 15-mer MAG1 peptide and its respective bleeds were 
evaluated in a peptide-based ELISA system to ascertain their functionality in addition 
to establishing the optimal concentration of purified serum for use within the assay. 
Rabbit tail bleeds were acquired pre-immunisation and at 14-day intervals including 
14, 28 and 42 days following consecutive antigen booster injections. Serial dilutions of 
the crude PAbMAG1 pre-, 1st, 2nd, and terminal bleeds ranging from 1/125, down a 
two-fold dilution series to 1/8000 were analysed against a single concentration of 
MAG1 peptide (8μg/ml), which was previously optimised by our group (Freimanis et 
al., 2010), pre-coated on a polystyrene ELISA plate by passive adsorption. Results, 
demonstrated in Figure 4.01, indicated an increase in the strength of PAbMAG1 
reactivity to the immunogen, upon administration of the consecutive boosters. This was 
recorded as increasing absorbance levels between all four successive bleeds with 
terminal bleed showing the highest reactivity across all antigen dilutions. As anticipated 
the pre-bleed exhibited no reactivity to the immunogen and therefore provides baseline 
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Figure 4.01. The reactivity of pre-bleed, 1st bleed, 2nd bleed and terminal bleed 
from the immunised rabbit with MAG1 peptide. Crude rabbit sera at indicated 
dilutions were incubated with MAG1 coating antigen at 8 μg/ml in ELISA system. Each 
bleed raised against MAG1 in the above figure represents a single sample taken from 
the rabbit at different time points over two months post immunisation. Pre-bleed 
represents levels of anti-MAG1 antibodies prior to immunisation with the peptide. 1st 
bleed shows levels of anti-MAG1 antibodies 14 days post-immunisation. 2nd bleed 
shows antibody titres after 28 days and the terminal bleed shows levels of anti-MAG1 
antibodies 42 days post-immunisation. Error bars show standard error of the mean 




4.2.3. Optimisation of anti-MAG1 polyclonal antibody 
In order to optimise the PAbMAG1 for subsequent immunoassays, antiserum from the 
terminal bleed was purified for the IgG fraction using affinity chromatography (Protein 
G column) and the protein concentration was determined. Purified antibody was 
subsequently verified for IgG isotype by anti-isotype ELISA (Figure 4.02). We next 
decided to titrate the PAbMAG1 against MAG1 peptides of different lengths, to 
determine the optimal antigen-antibody binding, and against two negative control 
peptides (NC1GTY3 and 8023) to measure antibody reactivity at different 
concentrations. The assays were performed in both non-biotinylated and biotinylated 
systems to determine the effect of peptide orientation within an ELISA plate on 
antibody accessibility. Data presented in Figure 4.03 and Figure 4.04 shows the 
antibody titres to MAG1 peptides with different number of residues, each peptide 
encompassing the entire or part of the immunodominant epitope sequence (GKELK). 
PAbMAG1 showed low levels of reactivity to short non-biotinylated peptides (3-7 mer) 
which improved with increasing peptide length (Figure 4.03). The efficiency of epitope 
presentation was drastically enhanced when biotin-conjugated peptides were used as 


























Figure 4.02. Verification of the isotype of PAbMAG1 purified terminal bleed with 
class-specific secondary antibodies. Purified IgG fraction from rabbit final serum 
sample collected 42 days post-immunisation with MAG1 peptide was titrated against 
MAG1 coating antigen at 8 μg/ml and probed with anti-isotype secondary Ab (anti-IgM, 
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Figure 4.03. The reactivity of PAbMAG1 with MAG1 peptides of different lengths 
tested in non-biotinylated ELISA. Purified IgG fraction from MAG1-immunised rabbit 
serum was titrated against non-biotinylated MAG1 coating antigen consisting of 
between 3 and 15 residues and negative control peptides at 8 μg/ml. SEM is shown 
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Figure 4.04. The reactivity of purified IgG PAbMAG1 with MAG1 peptides of 
different lengths tested in biotinylated ELISA. Purified IgG fraction from MAG1-
immunised rabbit serum was titrated against biotinylated MAG1 coating antigen 
consisting of between 3 and 15 residues and negative control peptides at 8 μg/ml. SEM 




This was particularly noticeable for short biotinylated peptides where the improvement 
in epitope orientation is reflected in increased OD values compared to their non-
biotinylated counterparts (Figure 4.05). As a result, the best PAbMAG1 reactivity was 
achieved at 2 μg/ml of the MAG1 15-mer biotinylated peptide, which was therefore 
used in subsequent immunoassays. PAbMAG1 showed negligible reactivity with two 
negative control peptides (OD < 0.1) in both systems. Additionally, no cross-reactivity 
was observed with three other MAG peptides in ELISA (Figure 4.06) therefore 
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Figure 4.05. The effect of biotinylation of MAG1 peptides of different lengths on 
PAbMAG1 reactivity in ELISA. Purified IgG fraction from MAG1-immunised rabbit 
serum was incubated with non-biotinylated and biotinylated MAG1 coating antigen 
consisting of between 3 and 15 residues at 8 μg/ml. Bars represent means and SEM 


























Figure 4.06. Cross-reactivity profile of PAbMAG1 with a panel of four MAG 
biotinylated peptides. Purified IgG fraction from MAG1-immunised rabbit serum was 
incubated at 2 μg/ml with biotinylated MAG1, MAG2, MAG3 and MAG4 coating 




4.2.4. Assessment of PAbMAG1 antibody reactivity to IgG1 Fc 
In chapter 3 our bioinformatic analysis highlighted six potential homologous amino acid 
sequence regions between HERV-K10 and IgG1 Fc autoantigen with the GKELK 
(MAG1) Gag matrix segment constituting a potentially strong molecular mimic that 
might be targeted in RA.  Therefore, this finding prompted us to investigate cross-
reactivity profiles of newly developed PAbMAG1 to IgG1 Fc preparations. As 
demonstrated in Figure 4.07 A, PAbMAG1 antibody reacted to both linear (Key 
peptide; mean OD value = 1.8) and conformational epitopes of IgG1 Fc retrieved from 
a patient with heavy chain disease (Per; OD = 0.9), where paraproteins with only heavy 
chain components and no light chains are generated (Malati, 2001), and commercially-
produced Fc (Abcam; OD = 1.45). It also exhibited strong reactivity (OD = 2.6) to a 
purified IgG preparation obtained from RA serum. No cross-reactivity was observed 
with negative control peptides and collagen type II. A control pan-IgG monoclonal 
antibody A57H, which recognises the 383-SNGQPENN-390 peptide sequence on the 
IgG CH3 domain (Nelson et al., 1997) was used to validate reactivity against IgG1 Fc 
proteins and served as negative control against peptide preparations (Figure 4.07 B) 
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Figure 4.07. Cross-reactivity of PAbMAG1 with linear/peptide and 
conformational/protein epitopes of IgG1 Fc and HERV-K10 MAG1 mimics. Anti-
K10 antibody PAbMAG1 at 2 μg/ml (A) and pan-IgG A57H control monoclonal antibody 
at 1 μg/ml (B) were incubated with protein and peptide coating antigens (8 μg/ml) in 
ELISA system. IgG1 Fc preparations were retrieved from a patient with heavy chain 
disease (Fc Per) and commercially-produced (Fc Abcam, Fc key). Purified IgG control 
from an RA patient and negative controls (NC1GTY3, 8023, collagen II) were also 
incorporated in this assay. SEM is shown for 3 experiments. ****, p ≤ 0.0001, ns = not 
significant.   
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4.2.5. Inhibition assay confirming specificity of PAbMAG1 for MAG1 peptide 
We next decided to perform an inhibition ELISA, to ascertain the specificity of 
PAbMAG1 for its respective peptide MAG1 (RIGKELKQAGRKGNI). This analysis also 
validated the in silico investigation confirming that the immunodominant epitope was 
exposed and able to react with specific antisera. Purified PAbMAG1 at its optimum 
concentration of 2 μg/ml was incubated with ten-fold dilutions of MAG1 15-mer peptide 
and negative control peptides before the preparation was transferred to a microtitre 
plate pre-coated with biotinylated MAG1 15-mer peptide. Results demonstrated in 
Figure 4.08 confirm that PAbMAG1 was specific for its respective antigen as an 
increase in the antibody binding to plate-bound MAG1, and thus increasing OD values, 
correlated with decreasing concentrations of pre-incubated MAG1 peptide. This 
confirms successful inhibition of the PAbMAG1 by its target peptide. High antibody 
specificity was reflected in the steep gradient of the curve. Conversely, the absorbance 
values of PAbMAG1 preincubated with non-related negative control peptides 
(NC1GTY3 and 8023) remained high and unchanged suggesting that they did not 
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Figure 4.08. Inhibition of PAbMAG1 achieved with MAG1 peptide demonstrating 
the antibody specificity. PAbMAG1 at 2 μg/ml was pre-incubated with MAG1 peptide 
or NC1GTY3 and 8023 negative control peptide preparations (each at 2, 4, 6 and 8 
μg/ml) for 1 hour prior to the antibody:peptide transfer to an ELISA plate pre-coated 




4.2.6. Assessment of HERV-K10 expression in cultured cells using 
immunocytochemistry and immunofluorescence in vitro assays 
To determine its diagnostic potential, an in vitro analysis of the polyclonal antibody 
generated to HERV-K10 MAG1 peptide (PAbMAG1) was performed using 
immunocytochemistry (ICC) and immunofluorenscence (IF) on a number of cancer cell 
lines including GH, MCF-7, T-47D and KM-H2 (Figures 4.09 to 4.12), which were 
previously used for HERV-K expression studies (Simmons, 2016). GH teratocarcinoma 
cell line was reported to harbour HERV-K Gag particles (Boller et al., 2008) whilst MCF-
7 and T-47D breast cancer cell lines were demonstrated to have elevated levels of 
HERV-K10 transcripts and viral particles (Ejthadi et al., 2005). On the other hand, KM-
H2 Hodgkin’s lymphoma cell line was shown to not express HERV-K Gag transcripts 
(Freimanis et al., 2010). We used anti-human HLA-ABC (MHC I) as a positive control 
antibody to ascertain that the staining procedure was successful. Rabbit IgG isotype 
control antibody and no primary antibody controls were incorporated to measure the 
level of non-specific background signal caused by primary and secondary antibodies, 
respectively. PAbMAG1 was applied as primary antibody at 2 μg/ml as used in the 
previous ELISA assays.  
As expected, GH teratocarcinoma cell line exhibited strong cytoplasmic staining with 
PAbMAG1 in both ICC and IF (Figure 4.09 A and B, respectively) therefore serving as 
a positive control cell line. MCF-7 and T-47D breast cancer cell lines, exhibited 
moderate (MCF-7; Figure 4.10 A and B) and weak (T-47D; Figure 4.11 A and B) 
cytoplasmic immunostaining with PAbMAG1 in both systems. The staining in these 
malignant cells appears diffuse throughout the cytoplasm of the cell, which indicates 
cytoplasmic localisation of the retroviral Gag protein, that is necessary for viral particle 
formation before budding (Löwer et al., 1993). Upon staining with PAbMAG1, such 
patterns were not observed in KM-H2 Hodgkin’s lymphoma cell line (Figure 4.12 A and 
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B), which showed negligible levels of staining, a finding supported by the lack of 
detectable HERV-K transcripts (Freimanis et al., 2010), and was therefore used as a 
negative control cell line. Cytoplasmic immunostaining was noted in all four cell lines 
tested with anti-HLA antibody, whilst no immunostaining was detected for isotype 
control and no primary antibody negative control. Mean fluorescence intensity (MFI) 
was assessed for all four cell lines (Figure 4.13) and validated the in silico investigation 
of accessible epitopes performed in chapter 3, confirming the binding of PAbMAG1 to 



















Figure 4.09. Examples of HERV-K10 Gag immunostaining in representative cytospins of GH teratocarcinoma positive 
control cell line. Cells at 105 were cytospun and stained with PAbMAG1, anti-HLA positive control antibody, isotype negative control 
antibody or secondary antibody only. Images show cytoplasmic labelling of GH teratocarcinoma cells in immunocytochemistry 
observed as brown staining (A; magnification x20) or as green staining (FITC) with blue DAPI-stained nuclei in immunofluorescence 
(B; magnification x40). Data are representative of 3 experiments.  
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Figure 4.10. Examples of HERV-K10 Gag immunostaining in representative cytospins of MCF-7 breast cancer cell lines. Cells 
at 105 were cytospun and stained with PAbMAG1, anti-HLA positive control antibody, isotype negative control antibody or secondary 
antibody only. Images show cytoplasmic labelling of MCF-7 breast cancer cells in immunocytochemistry observed as brown staining 
(A; magnification x20) or as green staining (FITC) with blue DAPI-stained nuclei in immunofluorescence (B; magnification x40). Data 
are representative of 3 experiments. 
B A 























Figure 4.11. Examples of HERV-K10 Gag immunostaining in representative cytospins of T-47D breast cancer cell lines. Cells 
at 105 were cytospun and stained with PAbMAG1, anti-HLA positive control antibody, isotype negative control antibody or secondary 
antibody only. Images show cytoplasmic labelling of T-47D breast cancer cells in immunocytochemistry observed as brown staining 
(A; magnification x20) or as green staining (FITC) with blue DAPI-stained nuclei in immunofluorescence (B; magnification x40). Data 
are representative of 3 experiments. 
B A 










Figure 4.12. Examples of HERV-K10 Gag immunostaining in representative cytospins of KM-H2 Hodgkin lymphoma negative 
control cell line. Cells at 105 were cytospun and stained with PAbMAG1, anti-HLA positive control antibody, isotype negative control 
antibody or secondary antibody only. Images show cytoplasmic labelling of KM-H2 Hodgkin lymphoma cells in immunocytochemistry 
observed as brown staining (A; magnification x20) or as green staining (FITC) with blue DAPI-stained nuclei in immunofluorescence 
(B; magnification x40). Data are representative of 3 experiments. 
B A 









































































   





















Figure 4.13. Mean fluorescence intensity (MFI) of intracellular staining observed 
in four malignant cell lines upon incubation with PAbMAG1 and control 
antibodies. Graph shows MFI values observed for PAbMAG1 (A), anti-HLA antibody 
(B), isotype control (C) and no primary antibody control (D) used in the 
immunofluorescence assays (Fig. 4.09-4.12 B). Cell lines used included HERV-K10-
harbouring GH teratocarcinoma positive control, MCF-7 and T-47D breast cancer and 
KM-H2 Hodgkin lymphoma negative control cell line. Bars represent means and SEM 






4.2.7. Assessment of PAbMAG1 antibody reactivity to IgG1Fc linear epitopes 
using western blotting 
To ascertain the reactivity to potential linear epitopes within a protein structure, the 
PAbMAG1 antibody was evaluated by western blotting. Since peptides such as MAG1 
are not suitable for electrophoresis due to their small molecular weight, PAbMAG1 was 
tested against two IgG1 Fc protein preparations, one from a patient (Per) and the other 
commercially-produced (Abcam). Bovine serum albumin (BSA) served as a negative 
control protein in this system. Protein electrophoretic transfer to nitrocellulose was 
validated by the control monoclonal pan-IgG A57H antibody, which bound to both IgG1 
Fc proteins, in reduced (band 30-35 kDa) and non-reduced (band 60-65 kDa) 
fragments as well as some intact IgG (150kDa) (Figure 4.14). PAbMAG1 exhibited 
strong reactivity, in relation to A57H antibody, against both IgG1 Fc preparations 
(Figure 4.15) across different protein dilutions, and detected protein bands within non-
reduced (60-65 kDa) Fc fragments, validating this antibody for the detection of linear 
IgG1 Fc epitopes. This antibody also bound to Fc epitopes within some intact IgG 







Figure 4.14. Positive reactivity of pan-IgG A57H monoclonal antibody to two IgG1 
Fc preparations. IgG1 Fc from a patient (Per) and from a commercial source (Abcam) 
were analysed by SDS-PAGE and western blotting and probed with A57H antibody at 
1 μg/ml. Immunocomplexes were revealed by enhanced chemiluminescence. Bovine 









Figure 4.15. Positive reactivity of PAbMAG1 to linear epitopes within IgG1 Fc 
preparations. IgG1 Fc from a patient (Per) and from a commercial source (Abcam) 
were analysed by SDS-PAGE and western blotting and probed with PAbMAG1 at 2 
μg/ml. Immunocomplexes were revealed by enhanced chemiluminescence. Bovine 





4.2.8. Assessment of HERV-K10 expression in cultured cells using a flow 
cytometry based in vitro assay 
To further characterise the PAbMAG1 antibody, we wished to determine its 
performance in detection of intracellular HERV-K10 proteins by flow cytometry. To this 
end, we conjugated PAbMAG1 antibody with fluorescein isothiocyanate (FITC) to 
reduce the levels of potential non-specific binding from a secondary antibody and 
verified this procedure with an immunofluorescent staining protocol using four 
malignant cell lines as per Section 4.26 (Figure 4.16). We next assessed the 
expression of HERV-K10 intracellular proteins with PAbMAG1 at its optimum 
concentration of 2 μg/ml within the same cell lines by flow cytometry. We used anti-
human HLA-ABC (MHC I) as a positive control antibody to ascertain that the staining 
procedure was successful. To account for background cell staining we incorporated a 
rabbit IgG FITC-conjugated isotype control and no primary antibody negative control 
to this analysis. As depicted in Figure 4.17, PAbMAG1 antibody performed poorly in 
the K10-harbouring GH cell line, showing virtually no staining and lower mean 
fluorescence intensity (MFI :1439.28) than the isotype (MFI : 16476.19) and no primary 
antibody (MFI : 3272.85) controls, when compared to the HLA positive control (MFI : 
95719.28). This poor performance of PAbMAG1 antibody, resulting most probably from 
assay restriction phenomenon or cell fixation with acetone, was observed across all 
four cell lines (Figure 4.18). To ensure that the lack of staining by PAbMAG1 is not a 
consequence of suboptimal antibody concentration or a prozone effect, we performed 
a titration of PAbMAG1 and isotype control antibodies in the GH positive control cell 
line (Figure 4.19). From these data we concluded that unlike the isotype control 
antibody, PAbMAG1 titrated poorly across all dilutions and therefore does not appear 



















Figure 4.16. HERV-K10 Gag immunostaining of GH, MCF-7, T-47D and KM-H2 
cancer cell lines with fluorochrome-tagged PAbMAG1 antibody. Cells at 105 were 
cytospun and stained with in-house FITC-conjugated PAbMAG1 at 2 μg/ml. 
Fluorescent microscopy images show cytoplasmic labelling of HERV-K10 (green) and 
blue DAPI-stained nuclei in four cell lines including K10-harbouring GH 
teratocarcinoma positive control, MCF-7 and T-47D breast cancer and KM-H2 Hodgkin 
lymphoma negative control cell line. Data are representative of 3 experiments.  
  








Figure 4.17. Assay restriction profile of PAbMAG1 antibody in K10-harbouring 
GH teratocarcinoma cell line determined by flow cytometry. 106 GH cells were 
permeabilised and stained with FITC-tagged PAbMAG1 at 25 μg/ml for intracellular 
HERV-K10. Representative histogram shows mean fluorescence intensity of GH 
staining with PAbMAG1 (orange, 1439.28) and controls including anti-HLA (blue, 
95719.28 ), isotype Ab control (purple, 16476.19) and no primary Ab control (green, 

















Figure 4.18. Assay restriction profile of PAbMAG1 in four cancer cell lines 
determined by flow cytometry. 106 GH, MCF-7, T-47D and KM-H2 cells were 
permeabilised and stained with PAbMAG1 at 25 μg/ml for intracellular HERV-K10 and 
with control antibodies. Representative histograms show PAbMAG1, isotype control 
and anti-HLA control staining for all four malignant cell lines. Data are representative 
of 3 experiments. 








                     
 
                    
 




Figure 4.19. Poor antibody titration of PAbMAG1 in K10-harbouring GH 
teratocarcinoma cell line in flow cytometry. 106 GH cells were permeabilised and 
stained with PAbMAG1 and an IgG isotype control at six dilutions (1/25, 1/50, 1/100, 










Polyclonal antibodies (PAbs) generated in vitro using synthetic peptides are widely 
used in biomedical research since they are relatively simple and inexpensive to 
produce. Moreover, they can recognise an antigen from different orientations, therefore 
the screening and characterisation of PAbs is vital for the development of sensitive 
immunoassay systems. There are currently no commercially available antibody 
reagents to HERV-K10 Gag, which has been implicated as a possible trigger in a 
number of diseases including rheumatoid arthritis (Nelson et al., 2014a). Evidently the 
availability of standardised antibody reagents to this viral region, with determined 
strength of reactivity and potential restriction profiles in certain immunoassays, would 
find useful applications in both a clinical and research context.  
In this chapter, a polyclonal antibody was generated against a highly antigenic 
synthetic peptide epitope MAG1 within the viral matrix, to obtain a tool for HERV-K10 
Gag protein detection in different assay applications. Epitopes are typically categorised 
into two groups, linear epitopes composed of sequential residues and conformational 
epitopes created by protein folding to somewhat resemble the native structure 
(Sivalingam and Shepherd, 2012). The latter are generally used for applications which 
rely on the protein natural structural context such as flow cytometry or therapeutic 
strategies, whereas the former are preferred in protein-denaturing assays such as 
western blotting or immunocytochemistry/ immunofluorescence (Forsström et al., 
2015). Traditional protein immunization protocols involve synthetic peptides which act 
as immunogens (Brown et al., 2011). Therefore, we have used a 15-mer MAG1 linear 
peptide conjugated to KLH carrier, which improves antibody affinity by inducing isotype 
switching and CDR maturation (Patra et al., 2014), to produce a high affinity polyclonal 
antibody (PAbMAG1) to the HERV-K10 Gag region in a rabbit (Figure 4.01). High 
levels of reactivity were observed by ELISA for PAbMAG1 with its specific linear target 
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but not with the other MAG peptides, which confirmed antibody specificity. This finding 
is in agreement with the observations made by Forsstrom et al. (2015) who reported 
that antibodies generated to a unique peptide target exhibit less cross-reactivity than 
those developed using a full-length protein. Since the size of epitopes is highly diverse 
with linear stretches of 3-15 amino acids on average (Kringelum et al., 2013), we 
wished to determine how the number of epitope residues affects the PAbMAG1 binding 
in ELISA. To this end, we synthesised a panel of MAG1 peptides of different lengths 
(3-, 4-, 5-, 7-, 9-, 12-, and 15-mer), each containing some or all immunodominant 
GKELK residues. We observed that the levels of PAbMAG1 reactivity diminished with 
decreasing length of MAG1 peptide (Figure 4.03) with best binding reported for 15-, 
12- and 9-mers and negligible binding for shorter peptides. This finding suggests that 
a minimum set of supporting residues is required for effective antigen-antibody binding. 
As reported by other groups (Stave and Lindpaintner, 2013), it appears that when 
interacting molecules possess complementary structures the strength of their 
interaction is more pronounced. This might be affected by the neighbouring residues 
as certain amino acids such as serine or glycine are more neutral and flexible than 
others (e.g. proline) which might be strongly charged or structurally rigid (Turunen et 
al., 2015; Juarez et al., 2016). Moreover, we observed that the efficiency of epitope 
presentation drastically improved when biotinylated peptides were used as coating 
antigens in complex with neutravidin in the ELISA system (Figure 4.04), when 
compared to their non-biotinylated counterparts. This was particularly noticeable for 
shorter peptides (7-mer and less; Figure 4.05) and suggested that the target epitopes 
were more favourably presented and more accessible on the microtitre plate. In this 
case, structured orientation of a peptide is facilitated by a neutravidin-biotin bridge 
which prevents the peptide from binding to the plastic plate in a random fashion (via 
hydrophobic interactions) (Crocker and Murray, 2003). This is in agreement with 
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observations made by Welch et al. (2017) who reported a two-fold improvement in 
antibody reactivity with the use of biotin linker. Interestingly, PAbMAG1 showed 
increased reactivity to 5-mer MAG1 peptide when compared to 7-mer peptide, which 
suggests that the epitope accessibility may have been sterically compromised in the 
7-mer by non-polar isoleucine and neutral glutamine residues on either side of the 
epitope. 
Finally, our interest in molecular mimicry between HERV-K10 Gag and IgG1 Fc led us 
to also examine immunological cross-reactivity of PAbMAG1 to IgG1 Fc. In using our 
ELISA system, we demonstrated the antibody specificity for MAG1 peptide and IgG1 
Fc epitopes (Figure 4.07), which supports the premise of molecular mimicry between 
the viral and host proteins in RA. Variation in OD values between the protein and 
peptide preparations results most probably from the nature of epitope mimics with 
conformational and linear segments recognised by the antibody (Ponomarenko and 
Van Regenmortel, 2009). Since antibody efficacy in one assay method is not typically 
predictive of its success in another (Brown et al., 2011), PAbMAG1 was tested for 
reactivity in western blotting where it proved positive against accessible epitopes on 
IgG1 Fc. In this technique, proteins are generally rendered linear from conformational 
states (Westwood and Hay, 2001) and hence our antibody PAbMAG1, appeared to 
cross-react with continuous epitopes on IgG1 Fc preparations (Figure 4.16), with 
comparable strength of reactivity to that observed for pan-IgG A57H monoclonal 
antibody (Figure 4.15). 
Immunoreactivity of PAbMAG1 to conformational HERV-K10 targets was also 
assessed in cell preparations using immunocytochemistry (ICC), immunofluorescence 
(IF) and flow cytometry in four cancer cell lines. In ICC and IF, PAbMAG1 exhibited 
reactivity to intracellular viral antigens within the cytoplasm of GH, MCF-7 and T-47D 
cell lines (Figure 4.10 to 4.13), which were previously shown to harbour HERV-K viral 
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products (Ejtehadi et al., 2005; Löwer et al., 1993). The observed cytoplasmic viral 
protein distribution is in agreement with published Gag localisation (Stake & Bann 
2013, Chiang and Chang 2005).   The lack of staining reported in KM-H2 negative 
control cell line (Figure 4.13), was also previously reported (Freimanis et al., 2010). 
PAbMAG1 showed a clear assay restriction profile in flow cytometry and failed to 
recognise intracellular viral targets within all three HERV-K-harbouring cell lines 
(Figures 4.18 to 4.20). This phenomenon may have resulted from the manner in which 
the target antigenic determinants were presented, modified or masked. In flow 
cytometry, target epitopes are presented in their native state therefore antibodies 
generated to a short peptide may be unable to bind to such epitopes as a result of their 
unstructured features (Forsström et al., 2015). In addition, it has been reported that 
certain procedures within a flow cytometry protocol, such as acetone fixation as used 
in this investigation, can perturb the antigen conformation and mask or denature the 
target epitopes thus significantly impairing antibody reactivity (Brown et al., 2011; Bull 
et al., 1999). Consequently, the target epitopes in all four cell lines may not be 
accessible or might be structurally compromised. Moreover, since a 15-mer peptide 
was selected for immunisation, it is possible that the number of determinants on the 
native protein identified by PAbMAG1 was restricted. Evidently, this could have 
affected the antibody performance in this system and resulted in the assay restriction 
phenomenon revealed in our investigation. Interestingly, the polyclonal antibodies to 
MAG1 were effective in ELISA where epitopes are presented in a relatively native 
conformation, as well as in ICC, IF and western blotting against epitopes in various 
states of denaturation (Brown et al., 2011), suggesting that the target epitopes were 
favourably displayed and accessible, which was previously observed for other 
antibodies developed using synthetic peptides (Waldron et al., 2002). Accordingly, 
other groups have reported that antibodies generated to linear targets exhibit more 
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effective binding in immunoassays with either completely or partially denatured 
epitopes (Stave and Lindpaintner, 2013; Forsström et al., 2015). 
Since there is a paucity of anti-HERV-K10 reagents, the novel PAbMAG1 generated 
against Gag protein sequence and assessed for reactivity in a range of immunoassays 
could serve as an effective tool for assessment of K10 Gag protein expression. For 
instance, HERV-K10 Gag proteins are synthesised in testicular tumours, in particular 
in seminoma cells, therefore PAbMAG1 antibodies may be suited for screening of 
tumour biopsies of those patients in ICC and IF (Sauter et al., 1995). Therefore, this 
approach could help to further explore the role of HERVs in this cancer. Moreover, it 
could be used for the detection of Gag protein levels in choriocarcinomas, teratomas 
and other germ cell tumours, which have been shown to possess increased K10 levels 
(Flockerzi et al., 2008). Analysis of tumour tissues for HERV-K10 expression with this 
antibody could also be performed by immunoblotting since Gag polyprotein renders an 
80 kDa product (Sauter et al., 1995). This would considerably add to the repertoire of 
non-invasive screening methods for such cancers. 
In addition, PAbMAG1 could be employed in research applications for the detection of 
cytoplasmic viral particles in K10-producing cell lines such as Tera 1 (Nelson et al., 
2014a) and GH teratocarcinoma cell lines (Patience et al., 1998). Since K10 Gag 
protein has been previously detected in biological samples such as peripheral blood 
from patients with essential thrombocythemia (Morgan and Brodsky, 2004) and in 
synovial fluid from RA patients (Freimanis et al., 2010), PAbMAG1 could be used to 
capture the Gag proteins from such samples in ELISA for the assessment of viral 
expression. Finally, PAbMAG1 could serve to establish the principle for the 
development of a monoclonal anti-K10 Gag reagent of high specificity which could be 
considered as a therapeutic tool for conditions where HERV-K10 may be implicated in 
the disease pathogenesis. It could be used analogously to the bacterial exotoxin-
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neutralising monoclonal antibodies raxibacumab, obiltoxaximab and bezlotoxumab 
(Wang-Lin et al., 2018) as well as the anti-HERV-W monoclonal antibody (GNbAC1) 
used as a potential treatment for MS (Madeira et al., 2016). 
In this chapter, on developing a polyclonal antibody (PAbMAG1) to a synthetic peptide 
of HERV-K10 containing the epitope GKELK, we established antibody reactivity 
profiles in a range of immunoassay systems and demonstrated immunological cross-
reactivity to IgG1 Fc. This observation clearly substantiates the premise of molecular 
mimicry between HERV-K10 and IgG1 Fc, and an association with RF binding epitopes 
in RA (Nelson et al., 2014a; Westwood et al., 2008). Consequently, this work prompted 
us to assess serological reactivity of RA patient sera to the immunodominant epitope 
in the Gag region of HERV-K10 and to investigate potential molecular mimicry with a 




5. SEROLOGICAL INVESTIGATION OF RA PATIENT SAMPLES FOR 
REACTIVITY TO HERV-K10 
 
5.1. Introduction 
The aetiology of RA remains elusive, although a genetic predisposition, together with 
other triggers including viral agents are considered to be contributory factors. More 
recently, human endogenous retrovirus HERV-K10 has been implicated as a potential 
aetiological agent within RA and has been linked to producing viral particles in RA 
synovial tissue (Nelson et al., 2014a; Takeuchi et al., 1995; Stransky et al., 1993). It 
has been suggested that the HERV-K10 Gag region could play a pivotal role as a viral 
trigger of RA or could augment disease pathogenesis through mechanisms such as 
molecular mimicry, epitope spreading and provision of superantigen motifs. The 
premise of molecular mimicry implies structural homology between the microbial agent 
and human proteins (Tugnet et al., 2013; Balada, Vilardell-Tarrés and Ordi-Ros, 2010). 
As a consequence, an immune response to a virus could also induce undesired B and 
T cell reactivity to a host protein. In effect, an inflammatory response with ensuing 
collateral damage would occur. In chapter 3 we used in silico analysis and molecular 
modelling to demonstrate key epitopes of HERV-K10 Gag that may share identical or 
similar epitopes on a key RA autoantigen, IgG1 Fc (Trela, Nelson and Rylance, 2016). 
Moreover, we used a polyclonal antibody to one potential HERV-K10 Gag / IgG1 Fc 
mimic (MAG1) to validate our finding (chapter 4) (Nelson et al., 2014a). A functional 
Gag region is a pre-requisite for viral particle formation. The complete translated Gag 
of HERV-K10 stems from two overlapping reading frames encoding matrix, and capsid 
plus nucleocapsid segments, to produce a precursor protein which is cleaved to 
generate individual protein products. These regions are essential in the assembly of 
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viral particles and exhibit increased levels of transcriptional activity in RA patients 
(Löwer et al., 1993; Ono et al., 1986; Freimanis et al., 2010). The matrix lies directly 
underneath the lipid envelope which mainly provides an outer viral protective coat and 
facilitates the attachment of envelope glycoproteins. Following degradation of the lipid 
envelope, the matrix would be readily exposed to the adaptive and innate immune 
systems. RA is considered to be antigen-driven and thus it is of interest to establish 
whether the class of generated antibody represents a secondary immune response. 
Previous studies from our group have demonstrated a general antibody response (IgM) 
to HERV-K in RA patients as compared to controls, which may suggest a continual 
supply of antigenic / immunogenic viral products to the immune system (Freimanis et 
al., 2010). More recently, we noted significantly higher antibody reactivity to HERV-
K10 Gag in RA as compared to inflammatory, non-inflammatory and healthy controls 
(Nelson et al., 2014a). Consequently, a fragment of the Gag matrix might supply a 
reservoir of antigenic peptides which could initiate and perpetuate a secondary (IgG) 
immune response to this endogenous retrovirus. In this chapter, we therefore set out 
to investigate reactivity of IgG antibodies in RA patients to a highly antigenic matrix 





5.2.1. Validation of reactivity to MAG1 in RA 
We have previously demonstrated the reactivity of purified IgG anti-MAG1 (PAbMAG1) 
antibodies from an immunised rabbit to both HERV-K10 and IgG1 Fc in a number of 
immunoassays. We therefore set out to assess mimicry of viral and host proteins in 
RA by testing the reactivity of IgG antibodies obtained from RA patients, with specificity 
analogous to or equal to that of RFs, to MAG1 antigenic peptide. To this end, we 
purified two RA serum samples for IgG fraction via affinity chromatography and after 
protein quantification, we titrated the purified serum samples against biotinylated 
MAG1 peptide in ELISA. As presented in Figure 5.01, both RA patients exhibited strong 
anti-MAG1 reactivity which was comparable for both samples and suggested that RF 
or RF-like autoantibody in patient sera recognised the K10 viral mimic. Moreover, 
subsequent titration of purified PAbMAG1 against its target MAG1 peptide revealed a 
striking parallelism in titration profiles between serum antibodies from two RA patients 
and PAbMAG1 over a wide range of concentrations suggesting that an identical or 
highly similar epitope on MAG1 was recognised in all three cases. Therefore, our 
finding prompted us to investigate the anti-MAG1 IgG reactivity with a higher number 
of samples in a further six RA patients. We also set out to verify the effect of MAG1 
biotinylation on the reactivity of antibodies from purified RA sera since peptide 
biotinylation imparted beneficial effect on PAbMAG1 reactivity (chapter 4). As 
demonstrated in Figure 5.02, all RA serum samples exhibited very low levels of activity 
to non-biotinylated MAG1 peptide, which was comparable to that for two negative 
control peptides. In this assay, PAbMAG1 exhibited high levels of reactivity to its non-
biotinylated target peptide, as shown in chapter 4, and therefore acted as a positive 
control. We observed marked increase in the reactivity of patient autoantibodies to 
biotinylated MAG1 peptide (Figure 5.03), when compared to its non-biotinylated 
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counterpart, which suggested improved steric epitope orientation in this system and 
was therefore selected for subsequent serological analysis. Unsurprisingly, PAbMAG1 
detected its target peptide in both systems (max. OD = 2), as demonstrated before 
(chapter 4, Figure 4.03 and 4.04) and served as a control antibody.  
Since RA serum samples are clinically assayed for the disease markers in their crude 
form (without affinity purification), we therefore set out to analyse the level of reactivity 
to biotinylated MAG1 peptide from crude preparations of RA sera. The antibody 
reactivity was tested for six RA patients with different RF levels and three healthy 
controls, which were resuspended in our standard blocking buffer (2% BSA / PBS) at 
1:200. We observed poor differentiation between patient serum samples and healthy 
controls (Figure 5.04 A) as well as considerable non-specific reactivity to the negative 
control (NC1GTY3) peptide (Figure 5.04 B). In order to improve the sensitivity of our 
assay, we mitigated the issue of serum matrix effect, arising from a series of matrix 
components in complex biological samples that cause interference, with the use of 
different blocking agent (1% Hammarsten-grade casein / PBS). This blocking buffer is 
devoid of carbohydrate and fatty acids and therefore reduces the chances of cross-
reactivity with serum matrix components as previously shown by Sigdel et al. (2012). 
As demonstrated in Figure 5.05 A and Figure 5.05 B, we found a significant decrease 
in non-specific reactivity across all the serum samples to MAG1 peptide and NC1GTY3 
control, respectively, which confirmed the effectiveness of this blocking agent and was 
therefore used in subsequent serological assays. This is in accordance with previous 
reports demonstrating that serum non-specific binding can be rectified with effective 





Interestingly, upon establishing an effective protocol, we observed increased reactivity 
of RF positive sera from RA patients to MAG1 peptide when compared to RF negative 
sera and healthy controls (Figure 5.05 A). This finding prompted us to investigate in 
greater detail the possible correlation between RF autoantibody levels and anti-MAG1 
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Figure 5.01. Parallelism of titration profiles of IgG from two RA patients and 
PAbMAG1 antibody to biotinylated MAG1 peptide. Purified IgG fraction from RA 
patient serum samples and PAbMAG1 from rabbit sera were titrated against MAG1 
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Figure 5.02. Poor titration profiles of IgG from six patients with RA to non-
biotinylated MAG1 peptide. Purified IgG fraction from RA patient and control serum 
samples were titrated against MAG1 coating antigen (8 μg/ml) in non-biotinylated 
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Figure 5.03. Enhanced titration profiles of IgG from six patients with RA to 
biotinylated MAG1 peptide. Purified IgG fraction from RA patient and control serum 
samples were titrated against MAG1 coating antigen (8 μg/ml) in biotinylated ELISA 
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Figure 5.04. High levels of non-specific binding observed for patient serum 
diluted in BSA blocker. Purified IgG fractions from RF seropositive and RF 
seronegative RA patients and healthy control serum samples were probed against 
MAG1 (A) and NC1GTY3 coating antigens (B) (both at 8 μg/ml) in biotinylated ELISA 
system. Bars represent individual patients and SEM is shown for 3 experiments. RA - 
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Figure 5.05. Low levels of non-specific binding observed for patient serum 
diluted in Hammarsten casein blocker. Purified IgG fractions from RF seropositive 
and RF seronegative RA patients and healthy control serum samples were probed 
against MAG1 (A) and NC1GTY3 coating antigens (B) (both at 8 μg/ml) in biotinylated 
ELISA system. Bars represent individual patients and SEM is shown for 3 experiments. 




5.2.2. Serological analysis of patient cohorts for anti-MAG1 reactivity 
Upon the observation that RA autoantibodies show increased reactivity with MAG1 
viral peptide, it was important to more accurately determine whether IgG serum 
antibodies from RA react with HERV-K10 MAG1 and to compare this reactivity to the 
serological responses of patients with other arthritides and healthy controls. We 
therefore performed a study in a larger RA patient cohort and incorporated several 
control cohorts. Antiserum was obtained from whole venous blood of RA patients (n = 
124) and the reactivity to biotinylated MAG1 15-mer peptide was evaluated and 
compared to control groups including non-inflammatory rheumatic disease 
(osteoarthritis, OA) (n = 10), inflammatory autoimmune arthritis (psoriatic arthritis, PsA) 
(n =13), autoimmune rheumatic disease (systemic lupus erythematosus, SLE) (n = 8) 
and healthy samples (H) (n = 30). These control cohorts, in which HERVs may play a 
causative role or which show similar inflammatory profiles to RA, were employed to 
examine the possibility that the increase in K10 expression was a by-product of 
inflammation. 
Optical density (OD) values for samples tested in each cohort are demonstrated in 
Figure 5.06. We found a disease-specific increase in RA patient reactivity to MAG1 
peptide identified as a significant difference between the mean IgG antibody response 
in those patients as compared to OA (*, p  ≤ 0.05), PsA (**, p  ≤ 0.01), and healthy 
controls (*, p  ≤ 0.05). No significant difference was observed between RA and SLE 
cohorts. All control cohorts exhibited noticeable clustering around the mean value. A 
marked overlap in anti-HERV-K10 antibody reactivity was observed between all 
cohorts, although data stratification (Table 5.01) revealed a large proportion of RA 
samples (45 / 124; 36%) with OD values statistically higher (OD ≥ 1) when compared 
to controls.   
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Figure 5.06. Increased mean serological response to HERV-K10 biotinylated 
matrix peptide MAG1 in patients with RA. Crude serum samples from RA patients 
and control cohorts (1/200) were incubated with MAG1 coating antigen (8 μg/ml) in 
biotinylated ELISA system. Symbols represent individual subjects; bars represent 
means and SEM (in brackets) is shown for 3 experiments. *, p ≤ 0.05, **, p ≤ 0.01, ns 
= not significant. P value calculated by ANOVA was 0.0030. RA: rheumatoid arthritis, 
OA: osteoarthritis, PsA: psoriatic arthritis, SLE: systemic lupus erythematosus, OD: 


























< 0.5 15 12 2 20 3 23 2 25 5 17 
0.5 - 0.99 64 52 8 80 10 77 6 75 21 70 
1 - 1.49 35 28 0 0 0 0 0 0 4 13 
≥ 1.5 10 8 0 0 0 0 0 0 0 0 
TOTAL 124 100% 10 100% 13 100% 8 100% 30 100% 
Table 5.01. Stratification of serum reactivity to MAG1 peptide in RA patients and 
control cohorts. Patient stratification is based on the results acquired for their serum 
reactivity with MAG1 coating antigen (8 μg/ml) in biotinylated ELISA system. 
Distribution of patient samples (n) and percentile of total is reported per OD ranges for 




To determine whether the increased reactivity observed for RA cohort in Figure 5.06 
was linked to RF titre, I evaluated the reactivity of RF+ and RF- serum samples in 
comparison to controls. We noticed a significantly increased reactivity of RF+ patients 
as compared to RF- group (***, p  ≤ 0.001), OA (**, p  ≤ 0.01), PsA (***, p  ≤ 0.001), 
SLE (**, p  ≤ 0.01), and healthy controls (***, p  ≤ 0.001) (Figure 5.07). There was no 
significant difference between the RF- cohort and control groups which indicates that 
RF status might have a direct effect on anti-viral response. Moreover, our data showed 
a weak positive correlation between RF levels and anti-MAG1 reactivity (R2 = 0.02) 

























































Figure 5.07. Increased mean serological response to HERV-K10 biotinylated 
matrix peptide MAG1 in RA patients with positive rheumatoid factor profiles. 
Crude serum samples from seropositive and seronegative RA patients and control 
cohorts (1/200) were incubated with MAG1 coating antigen (8 μg/ml) in biotinylated 
ELISA system. Symbols represent individual subjects; bars represent means and SEM 
is shown for 3 experiments. **, p ≤ 0.01, ***, p ≤ 0.001, ns = not significant. P value 




       























 =  0 .0 2
p  =  0 .1 1 3
 
Figure 5.08. Correlation of RA serological activity to HERV-K10 Gag matrix 
peptide MAG1 with rheumatoid factor levels. RA crude serum reactivity to MAG1 
coating antigen (8 μg/ml) assessed in biotinylated ELISA system for each RA patient 
was correlated with the levels of RF autoantibody detected in their serum using a 




A negative control peptide NC1GTY3 was also used to analyse patient serum samples 
for reactivity to a random non-human HERV epitope and to remove bias from the 
investigation. Patterns of reactivity reported for this peptide were intriguing as some 
patient cohorts, i.e. RA, PsA, SLE and healthy controls, showed lower OD values with 
comparative distribution (x̅ OD = 0.09, 0.095, 0.094 and 0.09, respectively), whilst the 










































O D  N C 1 G T Y 3  ( S E M ) :
R A  0 .0 9 0  ( 0 .0 0 3 )
O A  0 .1 2 6  ( 0 .0 0 7 )
P s A  0 .0 9 5  ( 0 .0 0 9 )
S L E  0 .0 9 4  ( 0 .0 0 6 )
H e a lth y  0 .0 9  ( 0 .0 0 5 )
 
Figure 5.09. Negative serological response to control peptide NC1GTY3 in 
patients with RA and control cohorts. Crude serum samples from RA patients and 
control cohorts (1/200) were incubated with NC1GTY3 negative control coating antigen 
(8 μg/ml) in biotinylated ELISA system. Symbols represent individual subjects; bars 
represent means and SEM (in brackets) is shown for 3 experiments.  
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 5.2.3. Serological reactivity of patient serum antibodies to other HERV-K10 
peptides  
Because RA-derived antibodies in our previous experiments showed increased 
reactivity to MAG1 viral peptide, we wished to determine whether other homologous 
HERV-K10 peptide sequences which harbour RF epitopes would evoke similar 
responses. To achieve this, we assessed RA serum reactivity to MAG2, MAG3 and 
MAG4 biotinylated peptides and compared them with responses from the control 
cohorts.  
We found comparably high disease specific increases in RA patient reactivity to all 
three MAG peptides as compared to control cohorts (Figures 5.10, 5.11 and 5.14). 
With peptides MAG2 and MAG3, there was a significant difference between the mean 
IgG antibody response in RA patients as compared to OA, SLE and healthy controls 
(*, p ≤ 0.05 for all cohorts) and no significant difference with PsA cohort (Figure 5.10 
and Figure 5.11, respectively). All control groups demonstrated marked sample 
clustering around the mean values. Furthermore, we observed a very weak positive 
correlation between RF levels and anti-MAG2 / anti-MAG3 reactivity (R2 = 0.001) 












































O D  M A G 2  ( S E M ) :
R A  0 .7 0  ( 0 .0 3 )
O A  0 .4 5  ( 0 .0 5 )
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S L E  0 .3 9  ( 0 .0 4 )
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Figure 5.10. Increased mean serological response to HERV-K10 biotinylated 
matrix peptide MAG2 in patients with RA. Crude serum samples from RA patients 
and control cohorts (1/200) were incubated with MAG2 coating antigen (8 μg/ml) in 
biotinylated ELISA system. Symbols represent individual subjects; bars represent 
means and SEM (in brackets) is shown for 3 experiments. *, p ≤ 0.05, ns = not 












































O D  M A G 3  ( S E M ) :
R A  0 .7 5  ( 0 .0 4 )
O A  0 .4 4  ( 0 .0 4 )
P s A  0 .5 4  ( 0 .0 3 )
S L E  0 .4 5  ( 0 .0 6 )
H e a lth y  0 .6 0  ( 0 .0 4 )
 
Figure 5.11. Increased mean serological response to HERV-K10 biotinylated 
matrix peptide MAG3 in patients with RA. Crude serum samples from RA patients 
and control cohorts (1/200) were incubated with MAG3 coating antigen (8 μg/ml) in 
biotinylated ELISA system. Symbols represent individual subjects; bars represent 
means and SEM (in brackets) is shown for 3 experiments. *, p ≤ 0.05, ns = not 
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Figure 5.12. Correlation of RA serological activity to HERV-K10 Gag matrix 
peptide MAG2 with rheumatoid factor levels. RA crude serum reactivity to MAG2 
coating antigen (8 μg/ml) assessed in biotinylated ELISA system for each RA patient 
was correlated with the levels of RF autoantibody detected in their serum using a 
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Figure 5.13. Correlation of RA serological activity to HERV-K10 Gag matrix 
peptide MAG3 with rheumatoid factor levels. RA crude serum reactivity to MAG3 
coating antigen (8 μg/ml) assessed in biotinylated ELISA system for each RA patient 
was correlated with the levels of RF autoantibody detected in their serum using a 




We also found that when using the MAG4 peptide (Figure 5.14), RA sera showed the 
highest mean levels of reactivity (OD = 0.82) and a significantly increased response 
when compared to OA, PsA and healthy control groups (*, p ≤ 0.05) but not to SLE 
cohort. A weak positive correlation, comparable to that with MAG1 peptide, was 












































O D  M A G 4  ( S E M ) :
R A  0 .8 2  ( 0 .0 3 )
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Figure 5.14. Increased mean serological response to HERV-K10 biotinylated 
matrix peptide MAG4 in patients with RA. Crude serum samples from RA patients 
and control cohorts (1/200) were incubated with MAG4 coating antigen (8 μg/ml) in 
biotinylated ELISA system. Symbols represent individual subjects; bars represent 
means and SEM (in brackets) is shown for 3 experiments. *, p ≤ 0.05, ns = not 
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Figure 5.15. Correlation of RA serological activity to HERV-K10 Gag matrix 
peptide MAG4 with rheumatoid factor levels. RA crude serum reactivity to MAG4 
coating antigen (8 μg/ml) assessed in biotinylated ELISA system for each RA patient 
was correlated with the levels of RF autoantibody detected in their serum using a 




Levels of RA disease markers may fluctuate in response to disease activity and 
treatment during the course of a clinical protocol (Barra et al., 2013). Since HERV-K10 
reactivity could be affected by RA therapeutic agents and K10 may act as the triggering 
event in RA autoimmunity, we wished to assess anti-K10 reactivity in early arthritis as 
well as at different time intervals. Out of 124 RA patients recruited for this study, 20 
patients were newly diagnosed RA cases (within up to 6 months before serum sample 
collection) exposed to limited treatment, typically consisting of two Disease Modifying 
Anti-Rheumatic Drugs. We therefore compared the mean serum antibody reactivity of 
the 20 RA patients diagnosed in 2017 and the remainder diagnosed pre-2017 to MAG1 
– 4 peptides. In this scenario, we observed increased antibody reactivity of newly 
diagnosed RA patients to all four MAG peptides as compared to the RA patients who 
were diagnosed earlier (Figure 5.16A). Of all peptides tested, only MAG4 showed the 
greatest difference in reactivity between the two patient cohorts which was significant 
(**, p ≤ 0.01) with mean OD values of 1.037 (2017 group) and 0.866 (pre-2017 group). 
No correlation was observed between RF levels of the newly diagnosed RA patients 
and their serum anti-MAG reactivity with any of the peptides (Figure 5.16B i-iv). A 
further 20 patients had their blood sample taken at more than one time point, i.e. at 3, 
6 or / and 9 months, in addition to their initial sample (0 m). Of those 20 patients, 17 
provided their sample 3 months after the first sample of whom 10 exhibited higher 
reactivity to MAG1 peptide when compared to 0 m sample, whilst the remaining 7 
patients showed lower reactivity compared to the initial sample (Figure 5.17). Four 
patients provided their ‘6 m’ sample, half of which exhibited higher reactivity than the 
‘0 m’ sample. A single ‘9 m’ sample which was assessed showed higher anti-MAG1 
reactivity than the initial and the ‘3 m’ samples and lower reactivity when compared to 
the ‘6 m’ sample. Overall, there was no significant trend towards higher reactivity to 
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MAG1 in the months following diagnosis, but the longer-term loss of reactivity between 
the 2017 and pre-2017 cohorts was significant for MAG4 peptide.  
200 
 

































2 0 1 7
P re -2 0 1 7
* *











Figure 5.16. Patients with newly diagnosed (2017) RA demonstrate serological 
reactivity with HERV-K10 peptides MAG1 – 4 that does not correlate with 
rheumatoid factor levels. Crude serum samples collected from RA patients (1/200) 
were incubated with four separate MAG coating antigens (8 μg/ml) in biotinylated 
ELISA system (A). RA crude serum reactivity to MAG antigens assessed for each 
newly diagnosed patient was correlated with the levels of RF autoantibody detected in 
their serum using a commercial quantitative ELISA test (B i-iv). Symbols represent 
individual subjects; bars represent means. **, p ≤ 0.01.  
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Figure 5.17. Serological response to HERV-K10 biotinylated matrix peptide 
MAG1 at different intervals reported for 20 patients with RA. Crude serum samples 
collected from RA patients (1/200) were incubated with MAG1 coating antigen (8 
μg/ml) in biotinylated ELISA system. Initial sample (0), sample obtained at 3 months 
(3), 6 months (6) and 9 months (9) interval.  
202 
 
Since age has been reported to have influence on disease activity in RA (Pawłowska 
et al., 2011) and age-associated decline in IgG responses to HERV-K Env has been 
previously observed (Kim et al., 2016), we evaluated the extent of anti-MAG1 response 
in relation to patients’ age. We found that there was a weak negative correlation with 
age (R2 = -0.15) within the RA cohort with mean age of 61 years at the time of sample 
collection (Figure 5.18). In addition, as hormonal factors appear to contribute to 
autoimmunity (Quintero et al., 2012) and to differentially influence RA development 
(Alpízar-Rodríguez et al., 2016), HERV expression may be affected by those hormonal 
signals (Nelson et al., 2004). Therefore, we assessed the levels of anti-HERV-K10 
reactivity with regard to patient sex and demonstrated weakly raised mean OD values 
in females to MAG1, MAG2 and MAG3 but not to MAG4 peptide, as compared to 
males, however no statistical significance was observed between these two cohorts 
(Figure 5.19).  
In order to analyse the levels of anti-MAG1 reactivity in all 124 RA sera and to identify 
any correlations between the levels of serum reactivity to MAG1 and other MAG 
peptides, a collective heatmap of anti-K10 reactivity was created (Figure 5.20) and 
structured according to anti-MAG1 OD values from low (bright green) to high (red). We 
found that RA antibody reactivity to MAG1 peptide is predominantly concentrated 
around medium to high OD values (OD: 0.5 – 0.99 and 0.1 – 1.49, respectively) with 
significant overlap between peptides i.e. reactivity levels for MAG1 often reflect the 
levels observed for other MAG peptides. There was a small proportion of patient 
samples which exhibit either low reactivity profiles (OD: 0.1 – 0.49; bright green) or 
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Figure 5.18. Negative correlation of RA serological activity to HERV-K10 peptide 
MAG1 with patient’s age. RA crude serum reactivity to MAG1 coating antigen (8 
μg/ml) assessed in biotinylated ELISA system for each RA patient was correlated with 
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Figure 5.19. Marginally enhanced mean serological response to HERV-K10 
peptides MAG1 - 4 in female versus male patients with RA. Crude serum samples 
collected from RA patients (1/200) were incubated with four different MAG coating 
antigens (8 μg/ml) in biotinylated ELISA system. Symbols represent individual 
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Figure 5.20. Heat map of antibody profiles showing the intensity of reactivity to 
four HERV-K10 MAG peptide mimics of IgG1 Fc in individual RA patient serum 
samples. Each column of the heat map represents an antigen-specific antibody 
response to MAG1-4 coating peptides (8 μg/ml) in biotinylated ELISA, while each row 
represents an individual RA patient (n = 124). Samples are sorted by decreasing 
reactivity (OD values) for MAG1. The colour scale shows the relative degree of 
antibody reactivity, from low reactivity (white) to high reactivity (light red). Red indicates 





The immunopathogenesis of rheumatoid arthritis remains elusive, however a viral 
agent, together with genetic background, could confer susceptibility to disease onset. 
The detection and role of human endogenous retroviruses has gained growing interest 
in RA as a result of several serological and molecular studies in clinically active 
individuals (Tugnet et al., 2013; Herve et al., 2002). One of the most biologically active 
forms of endogenous virus, HERV-K10, has proved particularly intriguing in RA 
patients (Ehlhardt et al., 2006; Nelson et al., 2004). We have previously shown that 
this agent, classified within the HML-2 family, may act as a candidate elicitor of 
autoimmune responses in RA through cross-reactivity with host proteins termed 
molecular mimicry. HERV-K10 bares structural homology with some autoantigens in 
RA, however the chief RA autoantigen, IgG1 Fc, has not been previously explored. 
Increased serological response of IgM class antibodies to HERV-K10 Gag matrix 
products, crucial for viral particle formation, was reported for RA patients as compared 
to inflammatory and healthy controls (Freimanis et al., 2010). This finding was 
substantiated by molecular investigation which revealed upregulation of K10 mRNA in 
PBMCs and synovial fibroblasts from RA patients with basal level in controls, 
consistent with the ubiquitous expression of HERV-K10 in the human genome 
(Freimanis et al., 2010; Ejtehadi et al., 2006; Nelson, Freimanis and Roden, 2008). 
Our group has previously observed an increased secondary serological response to a 
single HERV-K10 matrix fragment in a small cohort of RA patients (Nelson et al., 
2014a). Consequently, this finding prompted us to assess the IgG antibody response 
to HERV-K10 Gag in a large RA patient cohort and to investigate additional 
homologous peptide mimics (MAG1 – 4) which harbour RF epitopes, with MAG1 
constituting the main region of interest.  
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Our optimised HERV-K10 ELISA system was used to examine patient serum samples, 
identifying different degrees of reactivity to K10 matrix epitopes in RA patients as 
compared to patients with OA, PsA, SLE, and healthy individuals. We have 
demonstrated significantly increased mean IgG antibody reactivity toward all four K10 
peptides in RA patients as compared to control cohorts with the highest mean observed 
for MAG1 peptide (OD = 0.9) (Fig. 5.06). This finding is in agreement with our in silico 
investigation (chapter 3) which revealed that MAG1 peptide contained the most 
immunodominant epitope with homology to IgG1 Fc autoantigen and RA shared 
epitope motif. In specifically defining anti-IgG reactivity to HERV-K10 in RA, our 
observations support the notion of an antigen driven immune response, which does 
not simply constitute a by-product of inflammation. Clearly a continuous supply of 
endogenous antigen would undoubtedly promote a secondary immune response that 
would facilitate class switching from IgM to IgG. It may also suggest some specificity 
for K10 in RA, although there remain a number of other arthritides that have yet to be 
assessed (e.g. gout, ankylosing spondylitis). We also observed clear variations in 
reactivity within the RA cohort which is consistent with previous serological reports 
regarding HERV expression in other conditions such as SLE showing various response 
among patients (Perl, 2003). The heterogeneity of HERV activity exhibited by RA and, 
to some extent, the control groups with MAG1 – 4 peptides may reflect the distinct 
immune reactions among patients or the presence of specific polymorphisms (variants) 
within HERV-K10 (Moyes, Griffiths and Venables, 2007). Interestingly, HERV 
sequence polymorphism has been suggested as a contributing factor to allelic variation 
in the human genome and thus a possible association of certain haplotypes with 
autoimmunity such as that of HRES-1 (genotype I allele) with SLE (Magistrelli et al., 
1999). Moreover, some insertionally polymorphic HERVs have been integrated into 
only a proportion of individuals e.g. HERV-K(C4) gene is present in approximately 70% 
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of the population (Dangel et al., 1994). This observation implies that rheumatoid 
arthritis does not comprise a single disease entity (Firestein and Mcinnes, 2017) which 
has also been recognised for other autoimmune conditions such as SLE due to the 
variety of clinical manifestations in both diseases (Agmon-Levin et al., 2012).  
Interestingly, we also noticed a significantly increased (p ≤ 0.001) anti-MAG1 reactivity 
of RF+ versus RF- RA patient cohort (Fig. 5.07), with the latter reported to be more 
heterogenous than the seropositive RA (Malmström, Catrina and Klareskog, 2017). 
This finding suggests that RF+ serum antibodies are more cross-reactive with MAG1 
epitopes when compared to RF- sera. Given that HERV-K10 MAG peptides exhibit 
molecular mimicry with epitopes located on IgG1 Fc, which are within rheumatoid factor 
binding region, we next wished to determine whether there was a correlation between 
anti-MAG IgG reactivity and the levels of IgG RF in RA patient serum. We observed a 
weak positive correlation of the antibody reactivity to all four MAG peptides with RF 
levels (Figs. 5.08, 5.12, 5.13, 5.15), the latter reflecting disease reactivity for 
seropositive individuals (Aletaha, Alasti and Smolen, 2015). While the Disease Activity 
Score (DAS) was not available at the time of RA serum collection, it was fascinating to 
note that Reynier et al. (2009) reported a substantial association between HERV-K 
viral load in peripheral blood and the disease activity (as established by the DAS28 
score) in RA during active disease period. Consequently, further studies employing 
DAS should be undertaken to verify this finding for HERV-K10. 
Given the complexity of immunoreactivity, certain levels of RF autoantibodies could be 
generated even in patients diagnosed with seronegative RA by means of standardised 
kits with a cut-off value of antibody levels at < 20 U/ml for RF-negative patients 
(Ajeganova and Huizinga, 2014). Indeed RF has been shown to be false-negative 
around 31% of the time (Walker-Cillo, 2010). Therefore, our findings, which may 
suggest HERV-K10 involvement in a considerable number of predisposed RA patients, 
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such as those recognised within this study, could potentially contribute to the 
development of an additional diagnostic assay for RA.  
In addition, we found that there was a small overlap in the levels of anti-K10 reactivity 
between RA and control cohorts, which may be indicative of the ubiquitous nature of 
HERV-K10 in the general population with 30-50 copies per haploid genome (Nelson et 
al., 2014a). To date there are no extensive population studies concerning the basal 
levels of expression of anti-HERV antibodies in healthy individuals and different 
diseases for direct comparison with our findings. Therefore, our data provides a level 
of base-line activity, particularly in healthy individuals that may be useful to future 
studies in RA and other medical conditions. Overall, despite the abundance of 
antibodies present in patient serum samples, we demonstrated negligible cross-
reactivity of serum IgG to the negative control peptide NC1GTY3, which confirmed the 
specificity of anti-MAG response. Moreover, this validated our bioinformatics 
methodology and the performance of our assays.  
This Ab isotype arises upon numerous somatic hypermutations and thus affinity 
maturation of antigen-binding sites (Doria-Rose and Joyce, 2015), and may reflect the 
tenacity of Ab binding in our anti-HERV-K10 ELISA system. Recalling our earlier data 
in this chapter and chapter 4, we found that non-biotinylated MAG peptides performed 
poorly when exposed to the patient serum samples due to potential epitope masking 
via steric hinderance. Complementary binding was therefore maximised through the 
use of a neutravidin-biotin peptide bridge which improved serum antibody binding to 
MAG peptides. Biotinylation has been shown to enhance analyte binding by more than 
200-fold which is consistent with our observations (Trilling, Beekwilder and Zuilhof, 
2013; Freimanis et al., 2010). 
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We also observed that the levels of anti-MAG reactivity were enhanced in the 20 
patients with early RA, who were only exposed to DMARD therapy, as compared with 
the patients with established disease (Fig. 5.16). This notion was previously reported 
for anti-collagen autoantibodies in RA (Whittingham, Stockman and Rowley, 2017) 
together with the observation that RF autoantibody levels mirrored the disease 
severity. Moreover, substantial fluctuations of anti-K10 antibody activity were detected 
in further 20 patients for whom sequential serum samples of up to 9 months since the 
initial sample were available (Fig. 5.17). These results are consistent with changing RF 
autoantibody levels in patients responding to therapies (Aletaha, Alasti and Smolen, 
2015). When correlating the difference in the mean IgG antibody levels to MAG1 with 
patient’s age we demonstrated a weak negative correlation between this dataset (Fig. 
5.18). In support of this, it has previously been shown that IgG responses to HERV-K 
Env decline with increasing age (Kim et al., 2016). In addition, we have previously 
reported minor fluctuations in anti-K10 antibody levels with age in control patient 
cohorts, which could serve as an index of nominal anti-HERV-K10 response in future 
autoimmunity research (Nelson et al., 2014a). It is interesting to note that HERV-K 
reactivation is consistent with human adult-onset diseases and / or senescence where 
HERVs, normally silenced by DNA methylation, undergo gradual global demethylation 
with age (Balestrieri et al., 2015). Global DNA hypomethylation has been reported in 
cells and tissues derived from patients with RA (Klein, Ospelt and Gay, 2012), where 
typical mean age of onset ranges from 30 to 50 years (Machado-Alba, Ruiz and Medina 
Morales, 2015). Moreover, HERV hypomethylation, which lead to increased viral 
expression, has also been demonstrated in other autoimmune conditions including 
SLE (Wu et al., 2015).  
Further, we determined the impact of gender on the antibody reactivity to all four K10 
epitopes as it is suggested that HERVs may contain hormone responsive element 
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which plays a role in viral expression (Trela, Nelson and Rylance, 2016). We observed 
a slight increase in the mean IgG levels to MAG1 and MAG3 peptides among female 
subjects as compared to male patients (Fig. 5.19), which is in agreement with the 
notion that hormonal factors may influence HERV expression (Nelson et al., 2004). In 
addition, RA prevalence is 2-fold to 3-fold greater among women compared to men, 
which indicates hormonal involvement providing further support for our findings 
(Smolen et al., 2018). Moreover, an increased HERV-K10 mRNA and protein 
expression has also been detected in oestrogen-stimulated cell model systems 
(Ejthadi et al., 2005), which may therefore suggest that oestrogen could increase 
HERV expression leading to RA perpetuation.  
In this chapter, on screening patients’ serum samples, we found significant anti-IgG 
reactivity to all four HERV-K10 MAG peptides in RA patients compared with disease 
control cohorts and healthy subjects. This finding supports the notion of molecular 
mimicry between endogenous retrovirus and IgG1 Fc that could augment high-affinity 
anti-HERV-K10 and autoantibody production in RA. In future experiments, it will be 
important to assess the significance of subtle structural variations within epitopes, 
possibly arising from post-translational modifications, which could contribute to 




6. IMPACT OF HERV-K10 AND AUTOANTIGEN CITRULLINATION ON RA 
SERUM ANTIBODY REACTIVITY 
 
6.1. Introduction 
The autoimmune nature of RA is accentuated by abundant generation of 
autoantibodies with diverse antigenic specificities and varying diagnostic value. One 
such autoantibody, rheumatoid factor (RF) constitutes a hallmark of seropositive RA 
and binds to the IgG1 Fc fragment forming large immune complexes in the synovium 
(Ingegnoli, Castelli and Gualtierotti, 2013). The other major group of autoantibodies 
present in around 60 to 70% of RA patients’ sera constitute antibodies against 
citrullinated proteins / peptides (ACPA) (Fernandes-Cerqueira et al., 2015). 
Citrullination is a form of post-translational modification involving conversion of protein-
bound arginine residue into the non-standard amino acid citrulline in the presence of 
peptidylarginine deiminase enzymes. This process, which is believed to contribute to 
RA pathogenesis, promotes neo-(auto) antigen production to which self-tolerance has 
never been established (Valesini et al., 2015; Badillo-Soto et al., 2016). The targets of 
ACPAs identified thus far in RA synovium constitute a number of structural citrullinated 
proteins such as fibrinogen, which is one of the most abundant autoantigens in RA, as 
well as vimentin, collagen type II, and several viral antigens (Wegner et al., 2010; 
Trouw, Huizinga and Toes, 2013). However, recognition of numerous citrullinated 
autoantigens might suggest that no traditional antigenic determinant is targeted by 
ACPAs and that the culpable autoantigens can indeed change over time instigating 
new reactivities in the ACPA response (Trier et al., 2015). Moreover, Tsuda et al. 
(2015) demonstrated that ACPAs might be induced by molecular mimicry due to 
exposure to multiple citrullinated viral proteins. Therefore, antibodies generated 
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against citrullinated epitopes could sustain the immune response via epitope spreading 
and cross-reactivity with a broad array of citrullinated proteins. Although RF and ACPA 
are autoantibodies to vastly different target proteins in terms of their origin and function, 
it has been suggested that RF may also bind to immune complexes containing an 
antigen composed of citrullinated sequences of arginine-rich cellular proteins (Tan and 
Smolen, 2016). 
We have previously demonstrated immunological cross-reactivity of anti-HERV-K10  
antibodies to the IgG1 Fc region and an increased IgG response in RF+ RA serum to 
multiple K10 epitopes (chapter 5), supporting the premise of molecular mimicry 
between the virus and IgG1 Fc, and an association with RF binding epitopes. 
Moreover, our in silico alignment studies (chapter 3) confirmed that there is a 
considerable degree of homology between human IgG1 Fc and other RA autoantigens, 
which may contribute to cross-reactivity. Because citrullination occurs extensively 
within RA synovium, we set out to assess how this process affected the antigen : 
antibody interactions, and how serum from patients with RA reacted with modified 





6.2.1. RA autoantigen selection and detection of citrullinated targets 
To further explore the premise of autoantigenic mimicry and potential epitope 
spreading in RA we next wished to determine the level of sequence and structural 
homology between HERV K10, IgG1 Fc and other abundant autoantigens in the RA 
joint. In chapter 3 we have observed that K10 epitopes mimic those on IgG1 Fc (Table 
3.06) and that fibrinogen contains numerous highly homologous amino acid sequences 
(of 5 resides and more) with IgG1 Fc (Table 3.04). To determine sequence similarities, 
we therefore aligned these fragments (Table 6.01) and demonstrated two peptide 
sequences on IgG1 Fc, each composed of 5 linear residues (KPREE, DELTK), with 
80% and 60% identity, consecutively, in terms of alignment scores with fibrinogen, and 
further 4- and 6-residue IgG1 Fc sequence (KSRW, HEDPEV) with 75% and 50% 
identity to fibrinogen, respectively. Overall, the respective substitutions (e.g. 
proline/lysine, threonine/asparagine, lysine/asparagine and serine/threonine) of these 
particular peptides scored reasonably in terms of amino acid replacement values (-2 
to +34). We also showed two epitopes on HERV-K10, each composed of 5 amino acids 
(GKELK, IDKSR), with 60% homology to those on fibrinogen and two further K10 
epitopes (PPSR, KVSTKNL) with 50% identity to fibrinogen with reasonable 
replacement score (-14 to +46). In addition, to assess the conformational similarity 
between these viral and host antigens, we converted them into 3D molecular graphic 
models (Figure 6.01).  Minor structural differences in the overall mesh structure of the 
compared antigen pairs were revealed particularly between fibrinogen and IgG1 Fc.  
Moreover, within these data we observed multiple arginine residues between the 
homologous sequences identifying them as targets for citrullination in RA (Table 6.01 
and Figure 6.01, red highlighted resides), which may lead to autoantibody cross-
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reactivity by generating neo-epitopes and epitope spreading (Valesini et al., 2015). It 
is well established that citrullination has several different implications for protein 
conformation such as change in protein folding due to the loss of arginine positive 
charge (Badillo-Soto et al., 2016). To this end we verified the effect of citrullination on 
the three-dimensional structures of these epitopes using in silico molecular 
visualisation, which revealed subtle conformational alterations within tertiary structure 












Table 6.01. Regions of sequence homology established in silico for IgG1 Fc, 
fibrinogen and HERV-K10. Matching homologous amino acid pairs were established 
using publicly available bioinformatics software ExPASy SIM and LALIGN. Numerals 
indicated amino acid position and sequence alignment with reference to protein 
accession numbers: HERV-K10 (AAA88030.1), IgG1 Fc (AF150959.1), fibrinogen β-
chain (P02675) and fibrinogen γ-chain (P02679). Bold characters indicate amino acid 
substitutions and characters highlighted in red identify arginine residues susceptible to 
citrullination. Residues Alignment score shown as number of identical residues and % 
homology. Tudos Replac. (replacement) score for amino acid substitution. Amino acid 
single letter code: A-Alanine, S-Serine, T-Threonine, V-Valine, L-Leucine, D-Asparate, 









Figure 6.01. Molecular models demonstrating structural mimicry between 
immunodominant epitopes of HERV-K10 and RA autoantigens IgG1 Fc and 
fibrinogen. Three dimensional structures of homologous regions between HERV-K10, 
IgG1 Fc and fibrinogen were modelled in PyMOL and UCSF Chimera molecular 
graphics systems and presented in mesh mode together with their amino acid 









Figure 6.02. Molecular models demonstrating structural mimicry between HERV-
K10, IgG1 Fc and fibrinogen in their native and citrullinated form. Three 
dimensional structures of regions of homology of IgG1 Fc versus fibrinogen and HERV-
K10 MAG2 and MAG3 peptides versus fibrinogen were modelled in PyMOL and UCSF 
Chimera molecular graphics systems and modified using a PyTMs citrullination plugin. 
Numerals indicate amino acid starting position. Characters highlighted in red identify 
arginine residues susceptible to modification into citrulline residues (green). Structures 
to the left of the arrows indicate native epitopes and structures to the right of the arrows 
indicate their in silico modified counterparts. Citrullination is represented here with the 
symbol of Peptidyl Arginine Deiminase enzyme, PAD with citrulline residues 
highlighted in green.  
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To identify citrulline-specific probes, which could serve as positive controls for 
citrullination, we therefore assessed the reactivity of three commercial anti-citrulline 
polyclonal antibodies to commercially-sourced citrullinated fibrinogen by ELISA (Figure 
6.03). We observed very limited reactivity of all citrulline-specific antibodies in this 
system (OD < 0.5) when compared to the anti-fibrinogen antibody response (OD = 2.6) 
which could result from the assay restriction phenomenon. Therefore, an antibody-
independent chemical method, using a rhodamine-labelled phenylglyoxal probe that 
specifically detects citrullinated proteins, was employed in western blotting to identify 
any protein-bound citrulline residues (Figure 6.04). We found that commercial 
citrullinated fibrinogen and in-house citrullinated (i.e. using a PAD enzyme cocktail) 
fibrinogen and IgG1 Fc were detected in this system whilst their native (non-
citrullinated) counterparts were not. This assay confirmed that the chemical probe was 
sensitive and specific for citrullinated residues, and that our in-house citrullination 
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Figure 6.03. Poor reactivity of three commercial anti-citrulline polyclonal 
antibodies with citrullinated fibrinogen. Three citrulline-specific antibodies and 
fibrinogen-specific control antibody were incubated with citrullinated fibrinogen 






                                          
Figure 6.04. Verification of citrullination protocol with citrulline-specific probe 
on modified and native fibrinogen and IgG1 Fc. Native fibrinogen and IgG1 Fc were 
citrullinated in-house using a PAD enzyme cocktail (at 1:10 enzyme:protein ratio) or 
commercially (fibrinogen). Proteins were separated via SDS-PAGE electrophoresis 
and probed upon protein transfer onto a nitrocellulose membrane using a citrulline-




6.2.2. Serum reactivity to native and citrullinated autoantigens 
Having established methods to induce and detect citrullination, we next wished to 
address the effect of this process on antibody binding. We considered that this change 
in peptide sequence and structure might have consequences for cross-reactivity in RA, 
and thus we set about investigating antibody responses to these potentially citrullinated 
targets in RA. To ensure that the tertiary structure of our antigens of interest (HERV-
K10 MAG1 – 4, IgG1 Fc and fibrinogen) was not perturbed by our in-house citrullination 
protocol, we used peptide/protein specific polyclonal antibodies for detection of their 
corresponding targets in their native and citrullinated forms. We observed a slight 
decrease in anti-MAG1 antibody reactivity to its citrullinated versus unmodified target 
(difference in OD < 0.2) whereas anti-MAG2, anti-MAG3 and anti-MAG4 antibodies 
showed a significant decrease in reactivity (**, p ≤ 0.01, ***, p ≤ 0.001 and ***, p ≤ 
0.001, respectively) to their citrullinated targets (Figure 6.05). On the other hand, no 
such effect was observed for IgG1 Fc and fibrinogen.  
Since citrullination has been shown to increase protein immunogenicity as a result of 
steric shift (Badillo-Soto et al., 2016), we considered the possibility that this could 
induce cross-reactivity of autoantibodies in RA. To assess this, we screened the 
reactivity of six RA serum samples to native and in-house citrullinated MAG1-4, IgG1 
Fc and fibrinogen by ELISA. We found significantly increased RA antibody responses 
to all citrullinated targets, when compared with their native counterparts (Figure 6.06), 
except for IgG1 Fc which showed no such effect. The difference in immunoreactivity to 
native versus citrullinated targets was particularly noticeable for MAG1, MAG2 and 
MAG3 peptides (****, p ≤ 0.0001, ****, p ≤ 0.0001, ***, p ≤ 0.001, respectively). 
Moreover, high levels of reactivity to the citrullinated antigens were predominantly 
exhibited by autoantibodies in the diseased group as serum antibodies from six healthy 
individuals showed generally low reactivity across all antigens (Figure 6.07). The 
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increased response within RA serum samples to the majority of modified epitopes 
containing citrulline residues suggested that they may be more favourably orientated 
towards RA autoantibodies, possibly due to the change in their charge, than their 
unmodified counterparts. We therefore studied the effect of this post-translational 
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Figure 6.05. Reactivity of peptide- and protein-specific polyclonal antibodies to 
MAG1 – 4, IgG1 Fc and fibrinogen in their native and citrullinated forms. Peptide 
and protein coating antigens (8 μg/ml), pre- and post-treatment with a PAD enzyme 
cocktail, were incubated with their corresponding antibodies in ELISA system. SEM is 
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Figure 6.06. Increased mean serological response of six pooled RA patient 
serum samples to citrullinated versus native forms of MAG1 – 4 peptides, IgG1 
Fc and fibrinogen. Crude pooled sera from RA patients were incubated with peptide 
and protein coating antigens (8 μg/ml), pre- and post-treatment with a PAD enzyme 
cocktail, in ELISA system. Bars represent means and SEM is shown for 3 experiments. 
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Figure 6.07. Low mean serological response of six pooled serum samples from 
healthy individuals to native and citrullinated forms of MAG1 – 4 peptides, IgG1 
Fc and fibrinogen. Crude pooled sera from healthy controls were incubated with 
peptide and protein coating antigens (8 μg/ml), pre- and post-treatment with a PAD 
enzyme cocktail, in ELISA system. Bars represent means and SEM is shown for 3 




6.2.3. Serological response of RF and ACPA antibodies to native and 
citrullinated RA autoantigens 
In chapter 5, we reported increased levels of reactivity of IgG antibody in RA sera to 
viral sequences homologous with the principal RF target (Figure 5.06), IgG1 Fc, which 
showed positive correlation with RF titres (Figure 5.08). This supported the notion of 
an augmented secondary immune response through mechanisms of molecular 
mimicry in RA. Moreover, earlier in this chapter we demonstrated considerable 
sequence and structural homology between the epitopes of HERV-K10 and IgG1 Fc 
with one of the major ACPA targets, fibrinogen, through in silico analysis (Figure 6.01). 
We therefore set out to analyse the cross-reactivity of RF and ACPA antibodies to IgG1 
Fc and fibrinogen autoantigens in their native and citrullinated forms. We first sought 
to stratify RA patients based on RF and ACPA titres to explore if RF interacts with 
citrullinated residues, in the context of no ACPA. Thus, we recruited 42 RA patients 
with clinically pre-determined ACPA and RF status (positive / negative) and quantified 
the titres of both IgG autoantibodies by ELISA (Figures 6.08 and 6.09). Based on these 
data, sera were stratified into 9 samples containing ACPA and RF (ACPA+RF+), 9 with 
ACPA only (ACPA+RF-), 5 with RF only (ACPA-RF+), and 19 with neither autoantibody 
(ACPA-RF-) (Table 6.02). Determination of autoantibody positivity was based on 















Figure 6.08. Rheumatoid factor IgG titres determined for the four RA sera sub-
types. The presence of RF autoantibody titres in patient serum samples was assessed 
through the verification of reactivity against IgG Fc using a commercial sandwich 
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Figure 6.09. Anti-citrullinated protein antibody IgG titres determined for the four 
RA sera sub-types. The presence of ACPA titres in patient serum samples was 
assessed through the verification of reactivity against cyclic citrulline peptide using a 








Table 6.02. Stratification of rheumatoid arthritis patients according to serum 
titres of RF and ACPAs. Patient characteristics amongst the four sera sub-types 
(ACPA+RF+, ACPA+RF-, ACPA-RF+, ACPA-RF-) determined by protein-based 










Number of subjects 9 9 5 19 
Females 7 5 2 16 
Males 2 4 3 3 
Age, mean years (SD) 61.1 (7.4) 64 (7.7) 60.8 (9.9) 63.05 (10.2) 
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Having stratified the patients based on their RF and ACPA profiles, we next wished to 
assess the cross-reactivity of these sera subtypes with citrullinated and native 
fibrinogen by western blotting (Figure 6.10). As expected, sera containing ACPAs 
(ACPA+RF+) reacted strongly with citrullinated fibrinogen (top row). Despite the 
significant sequence and structural mimicry between IgG1 Fc and fibrinogen revealed 
in our in silico analysis, no detectable reactivity was demonstrated for sera containing 
RF alone (ACPA-RF+) with native fibrinogen. However, when fibrinogen was 
citrullinated we observed binding of RF+ sera, even in the absence of detectable 
ACPAs (ACPA-RF+; second top row), suggesting that citrullination facilitates cross-
reactivity of RF with fibrinogen. This effect was RF-dependent, as reactivity with 
citrullinated fibrinogen was abolished in ACPA-RF- sera from RA patients or healthy 
controls. Based on the above findings, we proceeded to confirm these data by ELISA 
using fibrinogen or IgG1 Fc in their native or citrullinated forms as coating antigens. As 
expected, we found that ACPA-RF+ sera reacted with both unmodified and citrullinated 
IgG1 Fc, with marginally enhanced reactivity reported for the latter form (Figure 6.11). 
Whereas, unsurprisingly, ACPA+RF- sera exhibited significantly higher reactivity with 
citrullinated versus native IgG1 Fc (****, p  ≤ 0.0001). Accordingly, no serological 
response with IgG1 Fc was demonstrated by the ACPA-RF- patient cohort or healthy 
controls. We also observed limited reactivity of ACPA+RF- and ACPA-RF+ sera with 
native fibrinogen (Figure 6.12). In agreement with the data from western blotting, 
citrullination facilitated the significant increase in binding of ACPA-RF+ antibody sera 
with non-target fibrinogen. Consistent with this effect being RF-dependent, no 
serological response with citrullinated fibrinogen was observed for the ACPA-RF- 
cohort or healthy controls. Consequently, these findings indicate that RF is able to 
cross-react with the ACPA target fibrinogen, and that this response is critically 
dependent on protein citrullination.  
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Figure 6.10. Cross-reactivity of RF+ serum with citrullinated fibrinogen in the 
absence of ACPAs. Native fibrinogen was citrullinated in-house using a PAD enzyme 
cocktail (at 1:10 enzyme:protein ratio) or commercially (fibrinogen). Native and 
citrullinated fibrinogen was separated via SDS-PAGE electrophoresis and probed upon 
protein transfer onto a nitrocellulose membrane using sera from RA patient cohorts 





                  
Figure 6.11. Citrullination facilitates cross-reactivity of ACPA+ serum with IgG1 
Fc in the absence of RF in ELISA. IgG1 Fc coating antigens (at 8 μg/ml), pre- and 
post-treatment with a PAD enzyme cocktail, were incubated with sera from RA patient 
cohorts with different autoantibody profiles and healthy controls. Black lines represent 
means. Coloured lines indicate statistical comparison between particular datapoints. 






                    
Figure 6.12. Citrullination facilitates cross-reactivity of RF+ serum with 
fibrinogen in the absence of ACPAs in ELISA. Fibrinogen coating antigens (at 8 
μg/ml), pre- and post-treatment with a PAD enzyme cocktail, were incubated with sera 
from RA patient cohorts with different autoantibody profiles and healthy controls. Black 
lines represent means. Coloured lines indicate statistical comparison between 




We have previously identified the homologous sequences 44-HEDPEV / 97-HADPDL 
and 132-DELTK / 128-DELNN between IgG1 Fc and fibrinogen. Since these regions 
do not contain arginine residues, they are not susceptible to citrullination, and therefore 
are not targeted by ACPAs. This implies that when the arginine-containing sequences 
190-KSRW / 399-KTRW and 66-KPREE / 51-KKREE are citrullinated, there remain 
accessible epitopes even in the presence of ACPAs which RF may target. To 
determine potential RF reactivity with arginine-free homologous regions, we 
established sequential ELISAs coated with citrullinated fibrinogen or IgG1 Fc that were 
first incubated with sera containing ACPAs alone, to reveal maximum reactivity of 
ACPA to all available citrulline residues. To saturate any remaining unbound citrulline 
residues and identify potential binding to citrulline-free regions, we then added sera 
containing either ACPA or RF, respectively. Results from this experiment revealed that 
for citrullinated IgG1 Fc (Figure 6.13 A), sequential addition of ACPA+RF- sera 
followed by ACPA-RF+ sera resulted in significantly higher reactivity than was reported 
with RF- sera. Similar effect was observed for citrullinated fibrinogen (Figure 6.13 B). 
Nevertheless, sequential incubation with primary ACPAs and secondary RFs in this 
manner could lead to RF binding with the Fc portion of ACPA autoantibodies, which 
could be responsible for the increase in reactivity reported. To this end, we addressed 
this possibility by repeating these assays using ACPA+RF- sera in the primary step 
that had been digested with pepsin to cleave Fc regions generating ACPA F(ab’)2 
fragments. In these assays, sequential incubation with ACPA F(ab’) 2+ sera and sera 
containing ACPAs alone lead to no significant increase in response, implying that all 
free ACPA target epitopes were saturated in the primary step (Figure 6.13 C and D). 
However, when ACPA-RF+ sera were used in the secondary step we observed a 
significant increase in reactivity for both IgG1 Fc (**, p  ≤ 0.01) and fibrinogen (**, p  ≤ 
0.01). For fibrinogen, these data implied that RF is able to interact with citrullinated 
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fibrinogen even when in competition with ACPAs, by targeting additional non-ACPA 
target epitopes. This may explain the small but detectable increase in reactivity of 




                     
 







Figure 6.13. RF reacts with additional epitopes on citrullinated fibrinogen and 
IgG1 Fc in the presence of ACPAs. Graphs show serological response to citrullinated 
IgG1 Fc (A) or fibrinogen (B) coating antigens (8 μg/ml) when incubated with ACPA+ 
sera (step 1), followed by incubation with the indicated RA patient sera-subtypes (step 
2), determined by sequential ELISA. The same experiments were repeated using 
ACPA+ sera digested with pepsin in step 1 (dACPA+RF-) for citrullinated IgG1 Fc (C) 
or fibrinogen (D). Bars represent means and SEM is shown for 3 experiments. **** p≤ 






Although the pathogenesis of RA has not been completely elucidated, genetic 
predisposition, environmental insults and viral pathogens are considered to be 
contributory factors in the destruction of the joint. This can be mediated through RA 
autoantibodies reactive with distinct antigen targets such as IgG1 Fc (RF Ab) and 
citrullinated proteins (ACPA Ab), which form immune complexes (IC) of a pathological 
nature in the context of impaired clearance mechanisms (Van Steendam et al., 2010). 
Moreover, molecular mimicry and cross-reactivity have the potential to trigger auto-
reactivity in RA leading to epitope spreading and the loss of self-tolerance (Cornaby et 
al., 2015).                                                                                                                           
We have previously demonstrated significant sequence and structural mimicry 
between HERV-K10 viral epitopes and those on the Fc region of IgG (chapter 3; Table 
3.06 & 3.12). This finding was subsequently confirmed in vitro where we observed 
immunological cross-reactivity of anti-K10 antibody with IgG1 Fc (chapter 4; Fig. 4.07) 
and increased serum antibody reactivity profiles among RA patients to HERV-K10 
matrix peptides (chapter 5; Fig. 5.20).  
In this study we used our optimised in silico system to assess potential homology of 
HERV-K10 Gag peptides and IgG1 Fc autoantigen with fibrinogen, which constitutes 
one of the major ACPA targets and is present in the IC of RA joints (Sokolove et al., 
2011). In total, four regions of homology were found for HERV-K10 versus fibrinogen 
(GKEL/CK/E, PP/NS/GR, I/LDKS/KR, K/VVST/GKN/EL/C) and for IgG1 Fc versus 
fibrinogen (KP/KREE, KS/TRW, DELT/NK/N, HE/ADPE/DV/L) which possessed 
between one and three amino acid substitutions (Fig. 6.01). Interestingly, our group 
has previously identified one of these regions in IgG1 Fc (KPREE) to be a potential 
major immunodominant fragment targeted by RF (Nelson et al., 2003). Despite minor 
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sequence variations between the mimics, molecular modelling of the peptides revealed 
very little difference in overall mesh structure which was in agreement with our previous 
report (Tugnet et al., 2013). Among the predicted regions of homology, four paired 
peptide alignments contained arginine residues in the sequences of HERV-K10, IgG1 
Fc and fibrinogen, identifying them as targets for citrullination. Strikingly, we found no 
significant effect of citrullination on the peptide tertiary structure when arginine residues 
were converted into citrulline residues and displayed as molecular models (Fig. 6.02). 
This finding prompted our in vitro studies, which confirmed that citrullination of protein-
bound arginine residues did not perturb the structure of immunoreactive epitopes and 
might in fact lead to neoepitope generation and enhanced antibody response (Kidd et 
al., 2008). Indeed, in our preliminary assay we found that RA serum reacted more 
readily with citrullinated forms of all HERV-K10 peptides, IgG1 Fc and fibrinogen (Fig. 
6.06), while this phenomenon was not reported with serum from healthy individuals 
(Fig. 6.07). Therefore, our observation implied that antigen citrullination in RA might 
broaden the effect of epitope spreading and molecular mimicry between the virus and 
host’s proteins with respect to autoantibody reactivity. This is consistent with the 
findings of Tsuda et al. (2015), who demonstrated extensive cross-reactivity of a 
monoclonal ACPA antibody with a variety of targets such as fungal, plant and viral 
antigens including EBV-derived EBNA1 epitopes, which are homologous with several 
RA autoantigens. Moreover, it supports the notion that RA patient’s autoantibody 
repertoire undergoes epitope spreading between citrullinated antigens as reported by 
Turunen et al. (2015), who demonstrated antibody binding to both citrulline and 
homocitrulline-containing type I and II collagen carboxyterminal telopeptides in RA 
serum.  
Owing to the difference in antibody responses observed in our study towards native 
and citrullinated forms of HERV-K10 and the two established RA autoantigens, IgG1 
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Fc and fibrinogen, we wondered whether the arginine-rich regions of homology 
between these autoantigens would allow for cross-reactivity of RF with citrullinated 
ACPA target proteins. To test whether reactivity of patient sera with citrullinated 
fibrinogen could be specifically attributed to RF, we aimed to isolate RF+ sera from RA 
patients that had no detectable ACPAs. This approach allowed us to demonstrate the 
binding of RF+ sera to citrullinated but not native fibrinogen (Fig. 6.12), even in the 
absence of detectable ACPAs, which implies that citrullination facilitates cross-
reactivity of RF with fibrinogen. This reactivity was reported for both linear and 
conformational citrullinate-modified epitopes of fibrinogen and relied on the presence 
of RFs in RA serum as we did not find any response in sera from ACPA-RF- patients. 
Therefore, our finding provides direct evidence that RF is cross-reactive with fibrinogen 
and that this response relies on citrullination. Others have also reported preferential 
antibody responses to citrullinated sequences with altered peptide binding affinity 
(James et al., 2010), which may explain why we found more limited reactivity of RF+ 
RA sera with native fibrinogen, despite its mimicry with IgG1 Fc. Moreover, we also 
demonstrated that RF is able to interact with citrullinated fibrinogen even when in 
competition with ACPAs, by targeting additional non-ACPA target epitopes (Fig. 6.13 
D). As anticipated ACPA+RF- sera exhibited strong reactivity with fibrinogen in its 
citrullinated form only, which confirmed that modified fibrinogen is indeed a target of 
ACPAs in RA (Tsuda et al., 2015; Steiner Gunter, 2006) and that the RF response was 
specific. Consequently, levels of reactivity to both forms of fibrinogen were redundant 
in seronegative patients and comparable to those observed for healthy individuals.  
Clearly, given the complex nature of autoimmune reactions and the heterogeneity of 
human sera, certain amount of autoantibodies could be present even in RA serum 
samples assessed to be ‘seronegative’ by means of commercially optimised 
autoantibody assays (Ajeganova and Huizinga, 2014). As reported by Fernandes-
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Cerqueira et al. (2015) in their study only between 4 and 8% of CCP-negative patients 
showed reactivity against citrullinated fibrinogen peptides. To our knowledge, no such 
observations were made for RF assay. Since our study focused on established 
(secondary) immune response we determined serum IgG-RF levels by means of a 
standardised assay, however it cannot be excluded that IgM-RF and/or IgA-RF 
interfere with IgG-RF binding. In the case of ACPA, autoantibody levels are detected 
using synthetic cyclic citrullinated peptides (CCPs) of unknown sequence (Ossipova et 
al., 2014), for which biological relevance has not been elucidated. Nevertheless, 
affinity-purified anti-CCP antibodies have been demonstrated to be in fact a collection 
of different ACPAs and are able to recognise citrullinated fibrinogen (Ioan-Facsinay et 
al., 2011). Moreover, since CCPs do not correspond to any human peptide sequence 
(Ossipova et al., 2014), it may explain the lack of reactivity of ACPA-RF+ sera in the 
anti-CCP test despite the citrullinated target being present. Although it is plausible that 
RA autoantibody levels may change over time, Barra et al. (2011) reported that there 
was a minimal change in RF and ACPA positivity up to five years of follow-up whilst 
Ursum et al. (2010) and Mjaavatten et al. (2011) demonstrated that RF and ACPA 
levels are stable within the first year after RA onset.  
Interestingly, we also observed increased reactivity of sera containing ACPAs alone 
with conformational epitopes on citrullinated IgG1 Fc but not on native IgG1 Fc (Fig. 
6.11). Although ACPAs are recognised as partly cross-reactive antibodies binding 
other citrullinated proteins such as vimentin or α-enolase (Valesini et al., 2015), there 
are no previous reports in the literature of their reactivity to IgG1 Fc. IgG has been 
recently reported to undergo citrullination in RA synovium and therefore could 
constitute an ACPA target (Badillo-Soto et al., 2016). Recognition of numerous 
citrullinated autoantigens might suggest that no traditional antigenic determinant is 
targeted by ACPAs and that the culpable autoantigens can indeed change over time 
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instigating new reactivities in the ACPA responses (Trier et al., 2015). Therefore, 
antibodies generated against citrullinated epitopes could sustain the immune response 
via epitope spreading and cross-reactivity with broad array of citrullinated proteins of 
endogenous and exogenous origin. In addition, we observed an enhanced response 
of ACPA-RF+ serum antibodies to citrullinated versus unmodified IgG1 Fc, which is 
consistent with other reports demonstrating that citrullination can improve protein 
immunogenicity as a result of steric shift and effect on relaxation dynamics of 
citrullinated proteins (Badillo-Soto et al., 2016). Moreover, Pratesi et al. (2013) reported 
that citrullinated peptides fit better in the antigen binding grooves than the 
corresponding arginine containing sequences and that RA-associated HLA 
DRB1*0401 (shared epitope) has a higher affinity for citrulline-modified peptides than 
for their native counterparts. Accordingly, we found no reactivity with citrullinated IgG1 
Fc in the absence of ACPAs in RF- serum samples.  
Over the past decade, a model for the initiation of RA pathogenesis has been proposed 
which implies that ACPAs react with citrullinated autoantigens, forming ICs containing 
Fc fragments that stimulate the generation of RF (Tan and Smolen, 2016). According 
to this model, RF relies on ACPAs and should be expressed after the ACPA reactivity 
is initiated. However, this model does not consider other RA autoantibodies, in 
particular RF seropositivity in ACPA- patients. Extending the model to include immune 
complexes containing viral and other non-citrullinated antigens reverses this order, 
with RF generated in response to molecular mimics, which lead to tolerance 
breakdown to other autoantigens, inflammation, release of PAD enzymes, 
hypercitrullination and onset of the ACPA response. In this model, ACPAs are 
therefore produced as an indirect result of the RF response. Soluble complexes 
containing RFs have been previously suggested to facilitate ACPA access to RA joint 
or to intensify ACPA effector functions (Ioan-Facsinay et al., 2011; Laurent et al., 
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2015). RFs have also been reported to increase the capacity of ACPA-ICs to promote 
macrophage cytokine generation (Sokolove et al., 2014). There are numerous reports 
which investigate the generation of autoantibodies in the years before the onset of 
symptoms in RA, and it is certain that both RF and ACPAs can precede clinical 
manifestations of the disease (Masi, Aldag and Sipes, 2001; Nielen et al., 2004; Brink 
et al., 2013). Nevertheless, there are conflicting reports regarding RF/ACPA time of 
occurrence before the disease onset (Song and Kang, 2010a; Rantapää-Dahlqvist et 
al., 2003; Nielen et al., 2004), which may be due to different sensitivities and 
specificities of the assays used to detect these autoantibodies (Barra et al., 2011; 
Hoovels et al., 2018). Moreover, limited longitudinal analyses address IgG RF and 
ACPA together (Brink et al., 2016). Although, there is no direct evidence as to whether 
either antibody precedes the other, implying that both of the above scenarios likely 
transpire to some degree, several reports suggested that RF may give rise to 
subsequent ACPA response in RA, particularly in patients with shared epitope allele 
and in smokers (Hutchinson et al., 2016; Murphy, Mattey and Hutchinson, 2017). 
In this chapter, we have demonstrated that citrullination results in enhanced antibody 
responses to viral and host’s antigens which were shown to contain multiple arginine-
rich regions of sequence and structural homology. This observation supports the 
premise of molecular mimicry and neoantigen production in RA that perpetuate the 
autoimmune response due to epitope spreading. We also reported that protein 
citrullination resulted in significant cross-reactivity of RF autoantibodies with a common 
ACPA target, fibrinogen. Importantly, this finding suggests the possibility that RF could 
act directly as an ACPA precursor, making it a potential therapeutic target to limit the 




7. FINAL DISCUSSION AND FUTURE PERSPECTIVES 
 
In this thesis we have explored molecular mimicry mechanisms between endogenous 
proteins of viral and host origin underlying the immune response in RA. These have 
significant implications for our understanding of how antigen-driven reactivity to viral 
epitopes can trigger disease pathogenesis, and perpetuate the autoimmune reactions 
observed in rheumatoid arthritis (RA). 
As highlighted in chapter 1, RA is characterised by breakdown in immunological 
tolerance to self-antigens in B- and T-cell populations, which is detectable years prior 
to the onset of symptoms. This may be a consequence of several mechanisms 
including molecular mimicry, epitope spreading and bystander activation of 
autoaggressive immune cells by microbial agents, which by priming the cells might 
provide a ‘fertile field’ but no apparent disease (Cusick, Libbey and Fujinami, 2012). 
Together with genetic predisposition, further exposure to environmental insults could 
trigger self-reactive responses and result in autoimmune conditions. Due to the 
limitations of existing animal models, this process is still unclear. Understanding 
endogenous pathognomonic mechanisms which lead to auto-reactivity might shed 
some light on RA development and contribute to reestablishment and maintenance of 
tolerance to self. This thesis aimed to investigate the role of endogenous retrovirus 
K10 in RA autoimmunity by taking advantage of in silico and in vitro approaches which 
have been previously used to establish a relationship between HERVs and 
autoimmunity in other disorders such as MS and type 1 diabetes (Curtin et al., 2018; 
do Olival et al., 2013). 
In previous chapters we have suggested that the sequence and structural homology 
between the human endogenous retrovirus (HERV) K10 Gag matrix and IgG1 Fc, the 
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principal target of rheumatoid factor autoantibodies in RA, might play a significant role 
in disease pathogenesis. HERVs, which constitute 8% of the human genome as a 
result of DNA-invading ancestral infections passed in the germline through successive 
generations (Yu, Zhao and Zhu, 2013; Krzysztalowska-Wawrzyniak et al., 2011), have 
been implicated in autoimmune diseases such as multiple sclerosis (Ramasamy, 
Joseph and Whittall, 2017) and systemic lupus erythematosus (Nelson et al., 2014b). 
Endogenous retroviruses have also been repeatedly suggested as aetiological factors 
of autoimmune rheumatic conditions and antibodies to HERVs have been detected in 
patients with RA (Freimanis et al., 2010). The work presented in this thesis suggests 
that HERV-K10 Gag may contribute to the aetiology and pathogenesis of rheumatoid 
arthritis, via molecular mimicry mechanisms, which could have significant implications 
for our understanding of the role of HERVs in other autoimmune diseases. 
As a component of the human genetic material, HERV-derived polypeptides should be 
regarded as autoantigens and tolerated by immune cells. Nevertheless, if not 
expressed in the thymus during tolerance acquisition, they could be treated as 
neoepitopes upon reactivation and may therefore represent an early element in the 
chain of events that leads to tolerance breakdown to other self-antigens (Gröger and 
Cynis, 2018; Balada, Ordi-Ros and Vilardell-Tarrés, 2009; Herve et al., 2002). In this 
light, the first question that was posed in this thesis was related to the homology 
between the immunodominant peptides on HERV-K10 matrix and those on IgG1 Fc 
autoantigen, targeted by rheumatoid factor antibody. This revealed six linear B cell 
epitopes on HERV-K10, coinciding with our T cell epitope predictions, with four 
epitopes (MAG1-4) corresponding to established RF binding regions. This could 
suggest that K10, which was reported to produce viral particles and products in RA 
joint (Löwer et al., 1993; Stransky et al., 1993), had the potential to evoke autoimmune 
antibody responses observed in RA patients. On the other hand, the structure-
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dependent nature of antigen:antibody binding could affect the performance of current 
predictive approaches for B-cell epitopes, which are typically mapped for linear motifs 
using in silico sequence analysis. In addition, our current understanding of protein 
immunogenicity and B-cell epitope characteristics is limited, which can lead to 
suboptimal results and erroneous predictions (Kringelum et al., 2013). In comparison 
to its parallel field of T-cell epitope prediction, mapping of B-cell epitopes is less 
traceable and in need of standardisation (El-Manzalawy and Honavar, 2010). 
However, with the use of multiple platforms, the performance of in silico methods have 
been reported to provide the preliminary groundwork for subsequent in vitro 
investigations of HERV mimics in autoimmunity (Freimanis et al., 2010; do Olival et al., 
2013; Nelson et al., 2014a).  
Accordingly, upon identification of highly antigenic epitopes on HERV-K10 (MAG1-4), 
which exhibited significant homology with IgG1 Fc autoantigen in RA, serological 
methods were employed in chapters 4 and 5 to investigate the association of K10 with 
the disease. Due to the paucity of antibody reagents to HERV-K10, we generated an 
anti-MAG1 polyclonal rabbit antibody and validated it for specificity, selectivity and 
reproducibility in several immunoassays including ELISA, western blotting, 
immunocytochemistry and flow cytometry. This probe enabled us to demonstrate 
significant cross-reactivity with IgG1 Fc which prompted subsequent serological 
studies with patient serum samples. Evidently, a panel of standardised antibody 
reagents to this viral region, would find useful applications in the development of 
diagnostic immunoassays and research work. It would be of interest to generate and 
standardise a monoclonal reagent of stringent specificity to this epitope which could 
provide novel approaches to investigating and treating potential K10-induced 
conditions, comparable to the technology recently introduced in MS with anti-HERV-W 
monoclonal antibody (GNbAC1) (Curtin et al., 2016). Moreover, co-detection of anti-
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HERV-K10 antibodies together with the current RF and anti-CCP tests could provide 
additional clinical value in the diagnosis of RA patients and contribute to RA profiling. 
The ability to directly assess anti-HERV-K10 specificity in a high-throughput test could 
facilitate the identification of RA subtypes, and therefore the HERV pathogenic 
involvement together with the disease prognosis and response to treatment. Like in 
the case of anti-HERV-W GNbAC1 antibody in MS, anti-HERV-K10 antibody of unique 
specificity could be employed to diminish or prevent the K10-mediated immune 
responses to self.  
Our serological investigation revealed a significantly elevated mean IgG antibody 
reactivity to all synthesised HERV-K10 peptides MAG1 – 4 in patients with RA as 
compared to patients with OA, PsA, SLE and healthy individuals. These data support 
the notion of molecular mimicry between K10 virus and IgG1 Fc, and an association 
with RF binding epitopes. Moreover, as suggested in chapter 5 and by Herve and 
colleagues (Herve et al., 2002), the observed mature immune response to multiple K10 
epitopes is a collectively sustained antigen-driven response, which could contribute to 
epitope spreading to other autoantigens. This may have a bearing on the titre and 
affinity of RF, therefore further analyses of the kinetics of interactions between K10 
peptides and RF autoantibodies in patients with RA using surface plasmon resonance 
technology should prove interesting.  
Furthermore, pathological changes and the site of inflammation in RA are mainly 
reported within the affected joints, therefore it would be of interest to broaden the 
investigation by assessing the extent of anti-HERV-K10 reactivity in RA synovial fluid. 
It has been previously reported that serum autoantibody levels may decrease with time 
as they are progressively sequestered within the cartilage following continuous 
synovial damage (Whittingham, Stockman and Rowley, 2017). Our findings in a cohort 
of 20 RA patients, who donated their serum samples at several time points, were 
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inconclusive in this respect. Therefore, changes in anti-MAG1 levels should be 
explored in longitudinal studies of a larger cohort of matched serum and synovial fluid 
samples to identify any differences or similarities between circulating and synovium-
localised viral antibodies and their potential correlation with RA disease activity scores.  
The processes that lead to the breakdown of immune tolerance, progression to active 
RA and joint destruction are highly dynamic and are likely to be co-dependent. 
Understanding the interaction of these mechanisms is vital as it may facilitate suitable 
diagnostic and prognostic opportunities. In fact, clarifying the links between HERV-K10 
and the breach of tolerance may have implications relating to both RA aetiology and 
therapeutic strategies. Indeed, based on findings from this investigation, it could be 
possible that the initial trigger of autoimmune reactions, most likely occurring in the 
secondary lymphoid tissues, is mediated by structural homology between the K10 
epitopes and host antigens such as IgG1 Fc which can lead to the production of RF 
autoantibodies. These antibodies could become cross-reactive, first with unmodified 
homologous autoantigens (e.g. fibrinogen) and subsequently with their citrullinated 
counterparts as a result of epitope spreading upon hypercitrullination. This may 
promote preferential binding of RFs with citrulline-containing protein targets even in 
the apparent absence of ACPA antibodies (chapter 6). RF could then lead to the 
initiation and propagation of ACPA responses (Fig. 7.01). Therapeutic targeting of RF 
and anti-HERV-K10 response may therefore represent a route to limiting RA-
associated pathology. As soluble blocking peptides have been previously shown to 
reduce antibody-mediated damage in MS and cardiomyopathy without generating 
harmful immune complexes (Fridkis-Hareli, 2013; Münch et al., 2012), the inhibitory 
effect of MAG peptide mimics on RA autoantibodies could be explored.  
Collectively, these findings suggest that HERV-K10 epitopes through molecular 
mimicry with self-antigens could result in breakdown of immune tolerance, leading to 
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increased immune reactivity to the virus and predisposing to autoimmunity in RA. The 
effect of these mimics on the autoantibody response might in part explain the variation 
of the phenotype of RA. Moreover, it is conceivable that the mimicry between viral and 
self-proteins occurs at a ‘disease-related’ epitope. Without this, autoimmune 
responses may be triggered but no pathology transpires. The heterogenous nature of 
anti-MAG response observed from our data suggests that HERV-K10 epitopes might 
be immunogenic only in a specific subset of RA patients, who are genetically 
predisposed and have been exposed to the right environmental factors. This is also in 
agreement with the previously reported HERV-K polymorphism in the human 
population and the premise of specific disease-associated unfixed viral loci among 
individuals (Marchi et al., 2014), which could contribute to the observed differences in 
anti-K10 responses. Therefore, our findings imply that RA does not constitute a 





Figure 7.01. A model for the initiation of rheumatoid pathology in RA synovium 
proposed in the current study. Molecular mimicry between HERV-K10 and host 
IgG1 Fc proteins triggers the anti-HERV-K10 response and the production of RF 
autoantibodies. Subsequent formation of immune complexes leads to inflammation, 
influx of peptidyl arginine deiminase (PAD) enzymes, hypercitrullination of other 
autoantigens (e.g. fibrinogen) and epitope spreading. This promotes cross-reactivity of 
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